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Chapter 1
 
General Introduction
Thesis Aim and Outline
“The tails of lizards and of serpents, if they be cut off, will grow again”
(Aristotle, History of Animals, book II, chap. 17, 508b 4-7)
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General introduction
GENERAL INTRODuCTION
The Stem Cell and its Potential
The regeneration of body parts is surely not a new concept to mankind. The recognition of the 
regenerative capabilities of an organism dates back to 330 BC, when Aristotle observed that 
a living lizard could grow back the lost tip of its tail. Since then, attempts at understanding 
the regenerative capabilities of human being have progressed in a slow pace. In the new mil-
lennium, biology and biotechnology are increasingly being recognized as a serious competitor 
of biochemistry, aiming to offer “biological solutions to biological problems.” As a result, the 
interest in the area of stem cells has virtually exploded in the last decade. Edmund B. Wilson 
first mentioned the term “stem cell” in his book, The Cell in Development and Inheritance, 
in 1896. Stem cells are pluripotent cells with the unique ability to self-renew and differentiate 
into one or more specialized cell types, playing a crucial role in homeostasis and tissue repair. 
Following an injury, a stem cell self-renews, undergoing cell division to ultimately give rise to 
one daughter stem cell and one progenitor cell. Stem cells can be classified as (a) multipotent 
adult stem cells (ASCs) in the developed body (b) pluripotent embryonic stem cells (ESCs) 
harvested from a blastocyst and (c) induced pluripotent stem cells (iPSCs), which are somatic 
cells genetically reprogrammed to an embryonic stem cell state. 
Stem cell therapy (or transplantation) is the use of stem and progenitor cells to replace defec-
tive cell populations, profiting from the plasticity and migratory capacity of stem cells. 
 After systemic or local transplantation, stem cells are able to migrate and differentiate at 
pathologic sites in the body to produce a therapeutic effect. Thus, cell-based therapies are val-
ued as a promising innovative strategy to tackle diseases of various organs systems. Ultimately, 
personalized cell therapies for treating and curing human diseases are the ultimate goal of most 
stem cell-based research.
The first known human application dates back to 1959, when Edward Thomas aimed at a 
hematological reconstitution with isologous bone marrow in lethally irradiated patients with 
acute leukemia (101).
Since then, numerous animal studies have been carried out with moderate to major successes, 
focusing on diseases of various organ systems (7,60,89). For patients with bone marrow failure 
or leukemia autologous stem cell transplantation is an already established therapy strategy. 
Other more experimental applications include disorders of various origins: neurodegenerative 
(e.g. multiple sclerosis (51)), neurotrauma (cerebral (120) or spinal cord injury (22)), cardio-
vascular (myocardial infarction (12,66,66,85)) and musculoskeletal disorders, cancer (mela-
noma (110)), arthritis, diabetes (83,104), and peripheral vascular disease. 
To illustrate, the US public clinical trials database, http://www.clinicaltrials.gov, shows 1377 
completed and 1337 ongoing clinical trials using stem cells for a variety of diseases (accessed 
22/04/2015, unknown status excluded).
 
 
Challenges in Stem Cell Therapy
Based on the progress that has been obtained in small and large animal studies in the last 
decade, cellular transplantation was embraced as the Holy Grail in tissue regeneration, ac-
celerating clinical translational applications. Despite the fact that the novelty of cell trans-
plantation was ambitiously translated to the clinical arena, it failed to produce overwhelming 
clinical success stories. Clearly, humans are not just big mice. While some clinical studies 
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indeed showed a positive effect (59), they were increasingly contrasted by studies failing to 
prove such a beneficial clinical effect, an issue probably even underreported (25,35,70). These 
ambiguous results are not entirely surprising, realizing that stem cells face a daunting task dur-
ing transplantation. The often hostile environment of ischemia, necrosis and/or inflammation 
that reigns within transplant accepting tissue, has a tremendous impact on stem cell function, 
potentially hampering the viability, differentiation and integration of the grafted cells into the 
host tissue (88). In addition, the spectrum of available types of stem cells is broad, each with 
its own biological phenotype and behavior. Currently, many cell types are being considered 
for cell-based therapy; here the challenge lies in determining which types are most suitable in 
trying to fulfill criteria regarding therapeutic efficacy, ease of access and practical use. Estab-
lishing the efficacy of different routes of administration of the cells is another point of research 
attention. Direct implantation, intravenous and even selective intraarterial (intracoronary in 
casu cardiac applications) administration lead each to a different biodistribution of cells.  Stem 
cell function itself, however, is not the only or perhaps not even the most important parameter 
to monitor. Recent observations gained insights in transient paracrine actions of stem cells, 
aside from the regenerative ability. Trophic factors were reported to be released by stem cells, 
eliciting responses from resident cells (11,41). The efficacy of any cell therapy thus depends on 
the interaction of many different factors such as disease etiology, cell type, delivery route, cell 
retention/engraftment, activation of resident cells, and functional integration. 
Efficacy, however, is not the only hurdle. With the rapid progress of research in this field, in-
creased sociopolitical awareness raised concerns on the safety and ethics of stem cells. Moral 
objections were made to the creation of human embryos from which embryonic stem cells 
(ESCs) are derived. Opponents of stem cell research that uses human embryos, claimed that 
it must be accorded fundamental human rights from the moment of its conception (10). To 
them, removal of the ESCc at the blastocyst stage (around the third to fifth day of embryo-
genesis) resulting in embryonic death qualifies as homicide (10,79). These ethical worries are 
avoided by the use of adult stem cells (ASCs). ASCs are found throughout the body in differen-
tiated organs. Several types are recognized, i.a. mesenchymal stem cells (MSCs), hematopoietic 
stem cells, neural stem cells, endothelial stem cells. Mesenchymal stem cells (MSCs), a type 
of ASC, are defined by their fibroblast-like morphology, adherence to plastic, and capacity for 
differentiation. MSCs are most often derived from bone marrow but can also be isolated from 
adipose tissue. In multiple in vitro studies their potential for cell therapy was shown. Since 
ASCs are adult cells that are often autologously acquired, the requirement to create an embryo 
is obviated. Unfortunately, compared with ESCs, the ability of ASCs to differentiate is less 
elaborate: being pluripotent (not multipotent) cells their differentiation is restricted to subsets 
of a certain lineage (in case of MSCs to osteogenic, chondrogenic, and adipogenic cells). 
Takahashi and Yamanaka announced in 2006 that the ectopic expression of four genes (Sox2, 
Oct4, Klf-4 and c-Myc) can reprogram differentiated adult skin cells to transform into plu-
ripotent cells (97). These ‘artificial’ ESCs were coined ‘induced pluripotent stem cells’ (iPSCs, 
hiPSCs in humans). As the generation of these iPSCs would no longer require the use of em-
bryos, many ethicists pronounced this discovery to have solved the ethical issues. Moreover, 
the autologous origin would bypass any issues with immunogenicity. Intriguingly, aside from 
the therapeutic potential, iPSCs were revealed to harbor diagnostic potential as well. iPSCs 
derived form a spinal muscular atrophy patient may mimic the neurodegenerative process 
characteristic of this genetically inherited disease in vitro (34), facilitating an ‘in-dish’ live 
study of disease. On the other side, critics claimed iPSCs to not behave enough like human 
embryonic stem cells and retain some “epigenetic memories” of their original somatic cells 
possibly interfering with differentiation. Even others were worried by the amount of required 
manipulation to cause unwanted mutations (52). 
12
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With regard to safety, it is crucial to be informed about any potential adverse effects or direct 
toxic effects of stem cells in vitro prior to any clinical translation. Many studies have shown the 
stem cells to remain their pluripotency and to be safe. The main concern is to control wayward 
stem cells, as risks of neoplastic transformation are in wait, inherent to the stem cell ability to 
unlimited proliferation. Indeed stem cells were shown to be able to induce teratomas or dif-
ferentiate into malignant tumors of a single cell type (74,77).
Nonetheless, poorly understood is the interplay of the transplanted cells with the local, locore-
gional and even systemic environment, of which most actions remain hidden from researchers’ 
observations (‘black box’). Stem cell therapy thus heralds a complex process in which the stem cell 
fate is unclear. Eventually it was acknowledged that the translational step was perhaps too ambi-
tious at the time and that a modest step back to benchside was warranted. To elucidate the stem 
cell fate, the ‘gold standard’ of histology is a widely accepted and valuable tool in preclinical re-
search, but in the clinical setting it is of limited use. It only provides a snap-shot at a certain time-
point, inherently triggering the endstage of the experiment, rendering an in vivo, real-time, lon-
gitudinal and noninvasive follow-up impossible. Local diagnostic biopsy is theoretically possible 
but an invasive procedure and thus preferentially to be avoided in the delicate posttransplantation 
area. Facilitated by ongoing improvements and design of novel techniques, the field of imaging 
sciences at some point converged towards regenerative medicine, fueling joined efforts to add 
pieces to the stem cell puzzle: to track the cells in vivo making use of clinical imaging modalities.
 
 
Cell Imaging: seeing Stem Cells at Work in vivo
Ergo, ‘seeing the stem cells at work in vivo’ (94) is the goal to which increasing research efforts 
in this field have leveraged. Cell imaging has been defined as “the visualization of specific cells 
in an intact animal” thus concerning the imaging of entire cells whereas molecular imaging 
seeks to visualize molecules and sub-cellular components within individual cells (69). As an 
alternative to histology, (pre)clinical imaging techniques, such as magnetic resonance imaging 
(MRI), computed tomography (CT), positron emission tomography (PET), ultrasound (US), 
single photon emission computed tomography (SPECT) or optical imaging (OI) offer new 
dimensions for cell therapy monitoring. Not only do they provide anatomical information al-
lowing detection of morphological changes, they also facilitate an analysis of functional prop-
erties, owing to novel techniques, such as assessment of the left ventricle function after stem 
cell transplantation for heart failure (84) (i.e. functional MRI) or of perfusion characteristics 
(using contrast media). Traditionally, the radiological assessment remains macrocellular by 
nature. At the other end of the imaging spectrum, clinical nuclear imaging techniques (PET, 
SPECT) target sub-cellular molecular processes by function, using any anatomical informa-
tion solely as a frame to locate the process. However, none of these techniques is able to visual-
ize the transplanted cells without prior ‘labeling’ or ‘tagging’ of the transplanted cells. 
In between is the novel domain of ‘cell imaging’. In cell imaging cells are labeled or tagged with 
a suitable contrast agent in vitro prior to cell transplantation, commonly achieved by exposing 
the cells to the labeling agent in culture (20,73). Through endocytosis the labeling agent is 
then incorporated in the intracellular compartments, allowing the labeled cells to be imaged 
in real-time noninvasively as cell clusters in vivo, or even as single cells (21). Alternatively, cells 
of interest can be labeled with suitable contrast agents in vivo.
 While it was already in the early nineties that the feasibility of cell tracking in vivo was reported 
(20,73), it was not until 2005 that the first clinical trial applying cell tracking of labeled cells 
in vivo took place (110). In between, numerous additional studies confirmed the feasibility of 
cell labeling and cell tracking both in vitro and in vivo by different imaging modalities without 
significant toxicity while preserving the regenerative stem cell capacities (16,20,21,28,31,48). 
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As a prerequisite of a favorable cell therapy outcome, stem cell transplants must first of all take 
the hurdle of survival in the transplantation area, later followed by an exhibition of their regen-
erative properties: migration (homing), engraftment, differentiation and integration into tissue. 
Reported high cell death rates post-transplantation, resulting from result of multiple mechanical, 
cellular and host factors, raised concerns, as stem cell survival was assumed to be the first and 
most important prerequisite for successful transplantation. Several studies have demonstrated 
that only 10–30% of transplanted stem cells survive within a few days of transplantation, further 
decreasing to 5–15% over 10–12 week (32,57,72). Unsurprisingly, researchers immediately took 
this to heart directing their efforts at improving stem cell viability (87,117). Undoubtedly, to be 
able to actually ‘see’ cell transplant viability in vivo by current clinical imaging techniques (a topic 
covered in this thesis) would certain contribute to our understanding of the premature stem cell 
death. The combined application of the stem cell as a viable ‘drug agent’ and at the same time 
as a ‘diagnostic contrast agent’ implicates a convergence of two ‘ics’: the ‘therapeutics’ and the 
‘diagnostics’, commonly known as ‘(nano)theranostics’ in the field of nanomedicine and gene 
therapy. With regard to cell size, ‘microtheranostics’ is probably better suited.
Enthused by these novel developments, radiology departments around the globe, acknowledg-
ing the potential of (stem) cell imaging, started setting up specialized ‘molecular or cell imag-
ing centers’ to contribute to this novel field of research. From a (clinical) radiologist’s perspec-
tive, finally new doors had opened to assess disease and therapy more upstream at the cell level 
rather than the ordinary assessment of macrocellular morphology and anatomy. 
 
 
Imaging Modalities for Cell Imaging
The arsenal of imaging modalities is quite extended, ranging from tissue-based contrast im-
aging modalities like MRI, CT and US to photon-based imaging modalities such as PET, 
SPECT and optical imaging (OI, consisting of bioluminescence (BLI) and fluorescence imag-
ing). Each imaging modality has a variety of tracers, labels or contrast agents and each imaging 
technique has its own advantages and disadvantages for cell tracking studies. A thorough selec-
tion of the most suitable imaging modality with accompanying tracer needs to be made. For 
stem cell tracking purposes the modality should be translational too, allowing use in humans. 
In spite of research that showed the feasibility of labeling MSCs with gold nanoparticles al-
lowing detection by computed tomography (CT) (13) and the fact that CT is a noninvasive 
imaging modality, it has never played a major role in cell imaging due to radiation aspects, the 
lack of sensitivity and low contrast-to-noise, especially for soft tissue parts. 
Among the noninvasive imaging modalities, ultrasound (US) remains a commonly utilized 
modality for high-resolution evaluation of especially superficial soft-tissue. Among its advan-
tages are its non-invasiveness, low cost, portability, the ability of dynamic imaging, the real-
time interactivity and lack of ionizing radiation. The expansion of this imaging modality for 
stem cell delivery and tracking is, unfortunately, limited by its depth-dependent spatial resolu-
tion, the inability of ultrasound waves to penetrate hard tissue (e.g. bone) and the difficulty of 
attaching a long-lived ultrasound-visible label.
Unlike tissue-contrast based imaging, the photon emission-based imaging modalities (i.e. 
PET, SPECT and OI) generate images by detecting the release of light or other forms of elec-
tromagnetic radiation. In bioluminescence imaging (BLI), light emitted from cells containing 
the luciferase enzyme is detected. Although it has proven beneficial in preclinical research, it 
is not suitable for use in humans as it (i) suffers from light scattering, limiting its use to small 
animals only and (ii) requires both genetic transformation and (iii) the invasive administra-
tion of luciferin substrate (81). The first limitation precludes the use of fluorescent imaging, 
an imaging modality that uses fluorophores as exogenous contrast agents, in humans as well.
14
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In PET and SPECT signal capture is not based on light but on detection of high-energy γ-rays. 
PET and SPECT are not limited by signal penetration depths in tissue (94). In PET, decay of a 
radiotracer causes a positron to be emitted. Upon encounter of an electron a positron-electron 
“coincident” event results in an annihilation pair that emits two gamma ray photons in the 
opposite direction. SPECT involves detection of γ-rays too, but in a slightly different way. In 
SPECT imaging the gamma radiation is measured in two-dimensional projections that are re-
constructed into a tomographic image, without a “coincident” event. This difference accounts 
for the higher sensitivity obtained from PET versus SPECT scans. However, SPECT and 
PET are not without limitations; (i) PET imaging in small animals requires (micro)pinhole 
apertures or micro-PET small-animal scanners to achieve high resolutions (200 μm and/or 1 
mm3) required for small animal imaging. Moreover, (S)PE(C)T tracers (ii) undergo uptake 
in normal tissues (e.g., the heart with [18F-FDG] F18-fluoro-deoxyglucose) hampering the 
specificity, (iii) cause nonnegligible tissue photon attenuation, (iv) raise concerns regarding 
radiation damage to cells, (v) suffer from a generally short half-life and (vi) need to be present 
in adequately high cellular concentration to meet detection thresholds (24,94).
Studies aimed at clinical translatability, have therefore mainly focused on MRI. The main ad-
vantages of MRI over other techniques are (i) its excellent 3-dimensional anatomical imaging 
capabilities at high resolution (ii) together with functional imaging capabilities, (iii) the lack 
of ionizing radiation and (iv) the possibility of small animal imaging with clinical scanners re-
quiring mere modification of surface coils.  MRI is therefore regarded as the imaging technique 
of choice for clinically applicable cell tracking.
Cell Labels for MRI 
Compared with other imaging modalities, MRI provides an unprecedented anatomical reso-
lution. However, its success in cell imaging suffers because of its intrinsic insensitivity (4). 
To overcome this relative weakness, efforts have focused on increasing the sensitivity of the 
contrast agent (CA) itself, or on an amplification of the intracellular accumulation using e.g. 
nanocarriers such as micelles (1,46,103), or liposomes (33,49,71). 
Two types of MRI cell ‘labels’ are recognized: intrinsically active labels, producing signal with-
out extrinsic intervention (direct labeling), and activatable (‘switchable’) cell labels such as 
reporter gene based contrast agents (indirect labeling) (5,29,65). Indirect labeling carries im-
portant advantages regarding the in vivo monitoring of cell fate and function but while widely 
used in animal models, this approach is currently far from clinical translation and beyond the 
scope of this thesis. Specific reviews on that topic are available elsewhere (17,107). 
For cell transplants to be imaged by MRI, they must be distinguished from natural back-
ground noise signal. The ideal cell label or tracer is one which, after sufficient intracellular 
build-up, allows prolonged and stable retention enabling longitudinal imaging, is readily avail-
able at acceptable costs, is taken up by cells easily and efficiently, does not suffer from leakage 
prematurely, has a sufficiently low detection threshold differentiating it from the background 
and carries insignificant biological toxic and side effects, on genetic and phenotypic level. 
Imaging agents for MRI-based cell tracking can be subdivided into the following categories: 
T2 contrast agents (superparamagnetic contrast agents, SPIOs), T1 contrast agents (paramag-
netic contrast agents, typically containing gadolinium or manganese), CEST agents and non-
proton contrast agents (typically containing fluorine). Each of these categories of contrast 
agents have specific properties with associated advantages and limitations (Table I). In many 
cases these agents have been used in the form of nanoparticles in order to increase their bio-
compatibility, delivery efficiency and/or signaling properties.
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General introduction
T2 Contrast Agents 
Superparamagnetic iron oxide (SPIO) particles typically consist of a crystalline iron oxide 
(Fe3O4 or Fe2O3) core coated with a hydrophilic shell of dextran, citrate, polymers or lipids. 
The iron oxide crystals have a strong magnetic moment, causing a disturbance of the local 
magnetic field by which they affect the T2 relaxation of surrounding water protons resulting 
in local signal loss in MR images.  SPIO particles have a stronger effect on MR relaxivity than 
paramagnetic agents (47).
Already in the early nineties studies using these SPIO agents for labeling of a variety of cells dem-
onstrated safety of the use of SPIOs for intra-cellular labeling and the consequent tracking of the 
labeled cells by MRI (20,73). Rapid clinical implementation of commercially available FDA-ap-
proved (ferumoxides and ferucarbotran) SPIO particles followed (30,37). Main incentives for the 
interest in SPIO particles are their unparalleled detection sensitivities (see Table II) as MRI labels.
However, the use of these agents in (pre)clinical studies revealed some practical and technical 
limitations: (i) SPIO-labeled stem cells still generate a signal void despite cell death, ham-
pering the cell viability specificity (9,15), (ii) quantifying engraftment becomes unreliable 
because of the considerable residual signals generated by the persistence of iron-laden tissue 
macrophages after cell death (76,78,100), (iii) even in absence of residual signals the quantifi-
cation of T2 and T2* relaxation times is difficult as it depends on intravoxel distribution (56), 
accelerated SPIO dilution occurs in highly proliferating cells as a result of iron metabolism in 
the physiological cellular pathways (113,114).
Unfortunately, these SPIOs have ceased to be manufactured for economic reasons (27) limit-
ing the use of SPIOs for new and ongoing research.  Despite this, efforts are made to generate 
new, optimized SPIO particles for cell labeling and imaging (19,58,64).
 
 
19F-based nanoparticles
Conventional MRI labeling techniques are based on the excitation of 1H nuclei.  Athough 
31P, 23Na and 13C can be excited by MR as well, their abundance in the human body restricts 
their use for cell imaging. Due to the natural absence of 19F nuclei in the body, 19F labeled 
cells are endorsed with a with high specificity (82). However, 19F imaging does require some 
dedicated hardware on a MRI system, which is usually not routinely available in most MRI 
centers.
For cell labeling, studies have mainly focused on the use on perfluorocarbons (PFC’s) (92). A 
main advantage of PFC’s is that each molecule contains a high number of 19F nuclei, increas-
ing the signaling capacity per molecule. In order to promote biocompatibility and cell loading 
efficiency, formulations of PFC’s used for cell labeling and imaging generally consist of coated 
nano-emulsions or polymer-based nanoparticles (45,91,93). A nano-emulsion based formula-
tion of PFC’s was also used in the very recently published first report on 19F-based cell imaging 
in humans (2). In this study, dendritic cells (DC’s) were labeled with a PFC nano-emulsion 
formulation, with the purpose of visualizing the DC’s after intradermal administration as 
part of a phase-I trial. While this study demonstrated the clinical feasibility of 19F-based cell 
tracking, the current main concern of 19F-based cell imaging, i.e. limited sensitivity, was also 
highlighted. The lowest amount of cell to be detected was between 4x105 and 6.25x105 cells/
voxel. In comparison, in the first reported human application of iron-oxide-based cell imag-
ing a significantly lower detection sensitivity of of 2x103 cells/voxel was demonstrated (111). 
Nonetheless, the results were encouraging and will certainly further inspire already ongoing 
efforts to develop improved 19F-based cell imaging techniques. These involve efforts to increase 
cellular uptake by probe modifications or the use of transfection agents that promote cellular 
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uptake of particles (3,90,112), probe modifications that increase the signaling capacity per 
molecule (23,109) and hard- and software developments (6).
 
 
T1 Contrast Agents
Manganese
Similar to Gadolinium (see further), manganese is also a T1 contrast agent, shortening the 
relaxation time of surrounding water protons. Because of the concerns regarding the cellular 
toxicity of Gd ions, manganese has been studied as an alternative positive contrast agent for 
cell labeling. Manganese is a natural cellular component and functions, for instance, as a co-
factor for enzymes and receptors. Manganese as a contrast agent has been used in the form of 
the FDA-approved manganese chloride. Initial studies on the use of manganese-based agents 
for cell labeling and imaging also used MgCl2 (40). Moreover, because of the fact that man-
ganese is transported by calcium channels, MnCl2 has been proposed as a cell labeling agent 
by which a direct read out of the viability of cells would be possible (116). Because of the low 
relaxivity properties of MgCl2, nanoparticle formulations of manganese have been explored as 
T1 agents for cell labeling. This involves manganese oxide particles with variations in coating 
with the goal to improve biocompatibility, stability and or relaxivity (61,115). Most recently 
silica coated MnO particles were shown to have excellent relaxivity properties, also at magnetic 
field strengths higher than 3.0T. This allowed for highly sensitive positive contrast detection of 
MnO-labeled cells, in the order of several thousand cells (Table 2). Unfortunately, however, in 
various reports significant effects of MnO particles on cell functionality have also been reported, 
such as reduced cell survival (95,116) and impaired multi-potent differentiation capacity 
(53,75). These findings may significantly reduce interest for clinical translation of such ap-
proaches.
 
 
Gadolinium
Gadolinium (Gd3+) chelates are the most commonly used contrast agents in clinical MRI and 
are generally characterized as T1 or positive contrast agents. The seven unpaired electrons of 
the Gd3+ ion create a magnetic moment that shortens the T1 relaxation time of surrounding 
water protons typically resulting in signal enhancement on MR images. 
Interaction of Gd-bound chelates with H2O protons decreases the water T1 and T2 relaxation 
times. The interactions occurring between Gd and H2O protons on the molecular level are 
twofold (122). ‘Inner sphere relaxation’ refers to the formation of a dipole-dipole interaction 
between a water molecule and the primary sphere of the paramagnetic Gd3+ ion (with seven 
unpaired electrons). In this interaction, a chemical exchange occurs resulting in an enhanced 
relaxation of the water protons. Thus, the relaxation will be enhanced by an increased frac-
tion of water molecules that can interact with Gd and by a shorter residence time of the water 
molecule with Gd (allowing Gd to interact with additional water molecules). ‘Outer sphere 
relaxation’ is a more complex concept. It is the result of the relative rotational and translational 
diffusion of water molecules and the paramagnetic ion. Basically stated, the relaxivity influence 
of the paramagnetic ion enhances when an increased number of water molecules can approach 
the paramagnetic ion and/or the further the paramagnetic ion can move through space and/or 
the closer the water protons can approach the paramagnetic ion. 
The possibility of obtaining positive contrast from labeled cells instead of negative contrast 
as obtained with T2 contrast agents has been considered a major advantage, and stimulated 
the use of Gd-based nanoparticles for cell labeling. Remarkably, several studies reported a re-
18
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duced longitudinal r1 relaxivity following cellular internalization of Gd in vitro, due to limited 
water exchange consequent to CA entrapment in cytoplasmic or subcellular compartments 
(14,18,38,54,55,62,86,98,99).
Despite the fact that various studies showed limited or no adverse effects of the Gd-based 
labeling agents on the functionality of labeled cells at relevant labeling concentrations 
(26,80,105,106), major concerns regarding the toxicity of the long term presence of ionic Gd 
exist (18,68,118) , which may limit introduction of such agents into the clinic. Gadolinium 
contrast agents have been associated with the occurrence of nefrogenic systemic fibrosis in 
patients with impaired kidney functions (44), and a negative effect on disease pathology of 
implanted neural stem cells labeled with the Gd-based contrast agent GRID (Gadolinium-
Rhodamine Dextran) was reported in a rat stroke model (68).
As chelated Gd-based agents are too small molecules to be endocytosed by cells passively and 
because of sensitivity issues, strategies have been employed to encapsulate the Gd-chelates 
inside nanocarriers (e.g. liposomes, micelles) to attain significant amplification. Particulate Gd 
contrast agents were shown to be far more effective than regular Gd chelates in terms of the 
amount of Gd initially incorporated and the retention of Gd in the cell over time (43,80,106). 
Various particulate formulations of Gd-based cell tracking agents have been developed over the 
past few years including liposomal (8,39,50,55) and micellar (1,46,103) nanoparticles, poly-
mer coated Gd-oxide particles (26,108), and carbon nanostructures (105) in order to increase 
cellular loading with Gd or to increase the signaling capacity by increasing the T1-relaxivity. 
Remarkably, several studies reported a reduced longitudinal r1 relaxivity following cellular 
internalization of Gd in vitro, due to limited water exchange consequent to CA entrapment in 
cytoplasmic or subcellular compartments (14,18,38,54,55,62,86,98,99). As this thesis centers 
on the use of liposomes as vehicles to carry Gd-chelates we will provide a short introduction 
on liposomes.
Gadolinium-liposomes
Liposomes are nanoparticles consisting of a bilayer of (phospho)lipids, much like cellular bilay-
ers. The bilayer consists of lipid constituents with hydrophobic head groups and hydrophilic tail 
groups. Various methods exist to fabricate liposomes. The most followed procedure is to dry an 
organic solution containing a mix of desired (phosho)lipids in a rotary evaporator under in vacuo 
conditions thus forming a thin lipid planar bilayer film. Hydration and sonication of this planar 
lipid film causes budding vesicles to enclose the hydration agent, resulting from phospholipids 
tail groups facing the inner area of the bilayer and the polar head groups facing the aqueous 
content. Multilamellar spheres are thus spontaneously formed, typically in a size range of 40-
180 nm (121). The size can further be fine-tuned by passage through physical membrane pores 
of known size (extrusion). The versatility is demonstrated by the fact that both the constituents 
in the aqueous core and surface properties can be modulated. For example, the versatility is ap-
parent from their use as an approved ‘theranostic’ anti-cancer drug (DoxiI®), carrying contrast 
agent (‘diagnostics’) and drugs (‘therapeutics’) at the same time within a single liposome (36,63). 
Extensive studies proved the liposomes to be biocompatible and safe (102).
Gd-liposomes are formed by using a Gd contrast agent solution as the hydrating agent or by 
incorporation of Gd-lipids in the bilayer. Furthermore, the use of cationic synthetic lipids in 
the bilayer augments the uptake and endocytosis by anionic cell membranes. Gd-liposomes 
have been employed for a variety of applications in the form of either an intravenous contrast 
agent or a cell label. Their use as a ‘stand-alone’ intravenous contrast agents was demonstrated 
in multiple studies. For example, liposome encapsulated Gd-DTPA was demonstrated to de-
tect early osteoarthritic changes in the knee (42) and shown to function as a longcirculating 
agent for MR angiography (MRA) (8). Alternatively, the incorporation of the Gd-lipid Gd-
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General introduction
diethylenetriamine- pentaacetic acid (bis)stearylamide (Gd-DTPA-BSA) in liposomal bilayer 
together with phosphatidylserine (PS) resulted in apoptosis mimickers, facilitating the imag-
ing of atherosclerotic plaques (67). Gd-DTPA-BSA was further used in liposomes containing 
the cyclic RGD-peptide to enable internalization by means of the αvβ3 integrin receptor in 
HUVEC cells in vitro (55). The work in this thesis focuses on the use of liposome encapsulated 
Gd.
 
To conclude, cell imaging is a promising strategy to answer vital questions regarding stem cell 
function. Cell imaging can contribute to elucidate specific aspect from the cell therapy ‘black 
box’, such as cell engraftment, cell viability, cell proliferation and differentiation, the immu-
nogenicity and al tumorigenicity. These characteristics are paramount and form the root of 
success or failure of stem cell therapy. 
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THESIS AIM AND OuTLINE
In the past decades men has seen an upcoming use of stem cells to repair incurably diseased 
tissue. The exact and detailed role and fate of stem cells in host tissue after transplantation is 
yet to be unraveled though. Being able to ‘see’ the cells at work in vivo would definitely con-
tribute to our understanding of their interaction with host tissue. This could be accomplished 
by clinical imaging techniques. 
This thesis therefore addresses the feasibility of labeling mesenchymal stem cells (MSCs) with 
cell labels (mainly Gd-liposomes) by passive endocytosis, to facilitate ‘tracking’ of these labeled 
cells in vivo by two imaging techniques (magnetic resonance imaging (MRI) and biolumines-
cence imaging ((BLI)). 
When we started our work in this research field in 2008, superparamagnetic iron oxide par-
ticles (SPIOs, a T2 contrast agent) were by far the most popular cell label for MRI-based cell 
tracking at that time. Nevertheless, SPIOs were not without drawbacks:
1. They cause signal loss, potentially to be confused with signal loss from (patho)physiologi-
cal conditions such as hemorrhage, blood flow or air-pockets. 
2. SPIOs are difficult if not impossible to perform T2 quantification on. 
3. SPIOs appeared to generate non-cell associated contrast in case of transplanted cell death, 
resulting from macrophage engulfment, severely hampering their specificity. 
4. T2 contrast agents are best visualized by T2-weighted sequences, which have an inher-
ently lower signal-to-noise ratio than T1-weighted images. 
Therefore this thesis is centered on the use of Gd-liposomes (a T1 contrast agent), which we 
hypothesized to be able to overcome these limitations since:
1. they cause hyperintensity on T1-weighted images, a feature quite rare for biological tis-
sues, allowing good background discrimination.
2. T1 quantification techniques are much more straightforward
3. they are much more smaller and hypothesized to escape macrophage reuptake following 
cell death
4. they are imaged on T1-weighted images with a generally high SNR.
Gd-liposomes thus being a novelty in cell labeling which weren’t characterized fully, we started 
in chapter 2 by assessing the labeling efficiency of MSCs. We measured the cell incorporated 
Gd content as a result of both labeling time and lipid dose variations. Possible direct toxic ef-
fects of the Gd-liposomes causing cell death and possible interference with the differentiation 
and proliferation ability of MSCs were studied. With time-resolved confocal fluorescence laser 
scanning microscopy (CLSM), we studied the intracellullar clustering of Gd-liposomes and 
their fate over time, owing to the incorporation of fluorescent dyes in both the lipid membrane 
(rhodamine) and the intraliposomal space (calcein). The in vitro contrast behavior of Gd-
liposomes was assessed by MR Imaging of a dilution range of labeled MSCs.  An in vivo pilot 
experiment on ‘cell viability visualization’ was carried out, transplanting viable and nonviable 
MSCs into rodent soft tissue. 
Histology was performed to detect cell and liposomal presence. 
In chapter 3 we further explored the effects of Gd compartmentalization on MRI signal in 
vitro, again by quantification of T1 and T2 relaxation times. To this extent we compared stock 
gadolinium (Gd-DO3A-Butrol) with both intact and ruptured liposomes and with both intact 
(viable) and lysed (nonviable) Gd-liposome labeled MSCs. We further studied the properties 
of Gd-liposomal formulations, such as liposomal size, suspension concentration and intrali-
posomal [Gd], in relation to MRI signal intensity. Measurements of the actual Gd content by 
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Inductively Coupled Plasma-Optical Emission Spectroscopy (ICP-OES) allowed us to put our 
findings in perspective with existing theories on intravoxel water distribution and diffusion, 
using a mathematical approach.
Because of intriguing findings in the pilot experiment and the need for clinical imaging meth-
ods to assess stem cell viability post-transplantation we extended the in vivo experiment in 
chapter 4 in four dimensions: we (i) compared Gd-liposome labeled cells to SPIO-labeled 
cells, (ii) performed measurements of T1, T2 and T2* relaxation times of labeled cell clusters, 
(iii) performed a longitudinal follow-up for 15 days and lastly (iv) genetically enriched the cells 
with the bioluminescent reporter gene luciferase, resulting in dual labeled cells, Gd-liposome-
labeled Fluc-MSCs and SPIO-labeled Fluc-MSCs. Our primary aim was to correlate changes 
in T1, T2, T2* relaxation times to actual cell transplant viability. Based on known literature, 
we expected for both contrast labels to see relaxation time differences between viable and non-
viable MSCs, associated with (de)compartmentalization. Our secondary aim was to compare 
sensitivity (the detection limit) and specificity (truly cell-associated signal generation) of both 
contrast labels. This was all correlated with bioluminescence imaging (BLI), which is based on 
the principle of detection of light emitted by viable cells only, allowing a reliable validation of 
cell viability, sensitivity and specificity. Information on contrast label presence was obtained by 
histological staining and ex vivo methods, for SPIO and Gd-liposomes respectively.
Being the leading cause of death globally, cardiovascular disease (specifically myocardial infarc-
tion), drew our attention as a suitable disease model to study stem cell tracking. The ultimate 
goal of regenerating nonviable infarcted myocardial tissue by stem cell therapy was chased 
by many researchers at that moment. Beyond the unresolved safety and ethical issues, crucial 
questions: “What is the best route for cell delivery?” “What kind and how many cells?” and 
“When to inject?” remained. Thus, in chapter 5 we aimed to give an overview of the latest 
proceedings and state-of-the-art of the various imaging techniques (MRI, PET, SPECT/CT, 
bioluminescence and fluorescence) for cardiac stem cell tracking. We presented the strengths 
and limitations of each approach, with a particular focus on clinical applicability.
In chapter 6, we used a quantitative MRI approach to investigate the changes in T2 relaxation 
time associated with proliferation, viability and death of SPIO-labeled Fluc-MSCs transplant-
ed to the heart in vivo. The luciferase insert provided for validation of the actual cell viability. 
Reproducibility studies were performed in normal rats, imaged in different sessions, to assess 
the robustness of T2 quantification by a single cardiac phase cardiac triggered double inver-
sion black blood 2D fast spin echo (BBFSE) sequence. Healthy rats underwent thoracotomy 
to receive intramyocardial transplantations of either viable or nonviable cells. Cell fate was 
monitored over a period of 15 days by BLI and MRI.
In chapter 7 we further explored the quantification spectrum by aiming to assess the T1 
relaxation time of healthy and myocardial (diseased) tissue in phantom studies and in rats 
in vivo. T1 quantification is clinically widely used for assessment of the extent of nonviable 
myocardium (on delayed enhancement images) and therefore suitable to monitor the effect of 
stem cell therapy delivered to the heart. For translational purposes it is imperative to have T1 
quantification sequences that perform equally on fast beating (rats) and relatively slow-beating 
hearts (humans).
The Modified Look-Locker inversion recovery method (MOLLI), requiring an acquisition 
window of about 190 ms, is applicable for T1 quantification in humans (who have an RR 
interval of ± 1000 ms.), but not in rat hearts (with an RR interval is only 100-200 ms). The 
variable flip angle method for T1 quantification is a possible alternative but requires long scan 
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durations. In this chapter the published CINE inversion recovery acquisition on humans, 
modified to fit fast heart rates too (mCINE-IR), was applied on rats for the first time, enabling 
the possibility of translational studies with an identical sequence. Simulations were used to 
study signal evolution and heart rate dependency. 
The results of this thesis are further discussed and summarized in chapter 8.
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Abstract
In the current study cell labeling was performed with water soluble Gadolinium-DTPA con-
taining liposomes, to allow for cell tracking by MRI. Liposomes were used to assure a highly 
concentrated intracellular buildup of Gd, aiming to overcome the relatively low MRI sensitiv-
ity of Gd (as compared to T2 contrast agents). Liposomes were positively charged (cationic) to 
facilitate uptake by binding to anionic charges in the cell membrane of bone marrow-derived 
mesenchymal stem cells (MSCs). We assessed the cellular Gd load for varying labeling times 
(1h, 4h and 24h) and liposome concentrations (125, 250, 500, 1000 μM lipid), closely moni-
toring effects on cell viability, proliferation rate and differentiation ability. Labeling was both 
time- and dose-dependent. Labeling for 4h was most efficient regarding the combination of 
processing time and final cellular Gd uptake. Labeling for 4h with low-dose concentration 
(125 μM lipid, corresponding to 52±3 μM Gd) yielded an intracellular load of 30±2.5 pg Gd 
cell-1, without any effects on cell viability, proliferation and cell differentiation. Gd-liposomes, 
co-labeled with fluorescent dyes, exhibited a prolonged cellular retention, with an endosomal 
distribution pattern. In vitro assay over 20 days demonstrated a drop in the average Gd load 
per cell, as a result of mitosis. However, there was no significant change in the sum of the Gd 
load in all daughter cells at endpoint (20 d.), indicating an excellent cellular retention of Gd. 
MSCs labeled with Gd-liposomes were imaged with MRI at both 1.5T and 3.0T, resulting in 
excellent visualization both in vitro and in vivo. Prolonged in vivo imaging of 500,000 Gd-
labeled cells was possible for at least two weeks (3.0T).  
In conclusion, Gd-loaded cationic liposomes (125 μM lipid) are an excellent candidate to label 
cells, without detrimental effects on cell viability, proliferation and differentiation and can be 
visualized by MRI.
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Introduction
In vivo cell tracking is a growing field of research since it is considered to be a crucial 
technology for the development and implementation of cell therapy. Cell therapy in itself 
holds great promise for a variety of diseases and disorders such as cancer, cardiovascular disease, 
neurodegenerative diseases, and musculoskeletal disorders by providing unique opportunities 
for tissue regeneration and targeted therapy or drug delivery (7-10). In both pre-clinical and 
clinical studies, therapeutic benefit of cell therapy for all these aspects has been demonstrated 
(11-16). However, the success has been limited and variable and the understanding of the 
processes by which stem cell therapy results in therapeutic benefit are also poorly understood. 
Therefore, the ability to track the fate of transplanted cells in vivo, has been the focus of 
increasing numbers of research efforts.
Currently, MR imaging is considered the modality of choice for in vivo cell tracking in 
patients and large animals due to its high spatial resolution. In order to visualize cells by 
MRI, incorporation of MRI contrast agents (CAs) by the cells of interest is required. Two 
main classes of CAs are being used for this purpose, paramagnetic substances (T1 shortening 
CAs) like gadolinium (Gd)-chelates (17,18) and superparamagnetic particles (T2 shortening 
CAs) which are mainly iron-oxide based (19-22). Generally, the latter allow for more sensitive 
imaging, easier incorporation into the cell and harbor less intrinsic toxicity (23). This has 
led to a vast amount of studies using a variety of iron-oxide particles and labeling procedures 
(6,18,24-33). These studies showed that for virtually every cell type, sufficient iron-oxide can 
be incorporated in the cell allowing for sensitive detection, even at single cell level, without 
apparent toxic effects (6,18). 
However, the use of T2 CAs in cell tracking carries several disadvantages regarding image 
interpretation. Firstly, T2 CAs cause a signal loss which may be confused with (patho)
physiological conditions such as hemorrhage, blood flow or air-pockets (34-36) or with areas 
containing an endogenous high iron content, such as the liver, the spleen or tumors like 
melanomas. Secondly, due to susceptibility artifacts, the size of a cell cluster will be heavily 
overestimated on MRI. This will severely hamper interpretation of surrounding anatomical 
structures in a cell graft. Thirdly, iron-oxide particles are susceptible to reuptake by macrophages 
in vivo (37,38), which is especially relevant during direct cell implantation, because of the 
concurrent high cell death rates. Finally, T2 CAs are best visualized by T2 weighted sequences, 
which have an inherently lower signal-to-noise ratio than T1 weighted images. 
More recently, Gd-chelates have been receiving increasing interest as an intra-cellular imaging 
probe (39-43). One of the main advantages of Gd-chelates over T2 CAs is their predominant 
positive contrast effect due to T1-shortening. Furthermore, as a result of its low molecular 
weight, the Gd-chelate can escape macrophage reuptake after cellular release due to e.g. 
cell death. This is a highly important advantage in the in vivo setting as it contributes to 
a high specificity of the MRI signal, aiding the assessment of overall cell viability after cell 
transplantion. 
In this report the use of the clinically approved Gd-DTPA in cell labeling was studied. As Gd 
has an inherently relatively low MR sensitivity, cationic liposomes were used to concentrate the 
Gd, allowing a high intracellular build up (44). The rationale behind making them cationic, 
was to improve uptake by binding to anionic charges in the cell membrane. Liposomes have 
already widely been used for both diagnostic (23,27,41) and therapeutic purposes (45-47) or 
combinations thereof (48) and are a well-known vehicle in DNA-transfection studies (49-51). 
The most exciting feature is their versatility. Both the constituents in the aqueous core and 
surface properties can be modulated, allowing e.g. a combination of a diagnostic tracer with a 
therapeutic one (‘theragnostics’). In order to facilitate a successful clinical translation of Gd-
liposomes as a MRI-tracer in cell-tracking, efforts have to be made to assess the effects on cell 
behavior and viability and to overcome sensitivity issues by improving labeling efficiencies. 
38
Labeling and MRI-tracking of MSCs with Gd-liposomes
These issues have been hardly addressed so far. In this study these issues were addressed using 
bone-marrow derived mesenchymal stem cells.
Material and Methods
Liposome preparation
Gd-DTPA was incorporated in cationic liposomes using the lipid-film hydration technique. 
A 100 μmol mixture of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; Lipoid GmbH, 
Ludwigshafen, Germany), cholesterol (Sigma-Aldrich, St. Louis, MO, USA), 1,2-dioleoyl-
3-trimethylammonium-propane (chloride salt) (DOTAP; Avanti Polar lipids, Alabaster, AL, 
USA) in the molar ratio 47:33:20 was dissolved in chloroform/methanol 2:1 (v/v) and evapo-
rated in vacuo using a rotary evaporator (Büchi Rotavapor R-210, Büchi Labortechnik, Flawil, 
Switzerland). The lipid film was subsequently hydrated in either HEPES buffered saline (20 
mM HEPES, 135mM NaCl, pH adjusted to 7.4) or Gd-DTPA (Magnevist; Bayer Schering 
Pharma AG, Berlin, Germany) to create control liposomes and paramagnetic liposomes, re-
spectively. 
Liposome solutions were extruded at 45ºC through a high-pressure Lipex thermoline extruder 
(Northern Lipids Inc, Vancouver, Canada) by sequential passing through Nuclepore polycar-
bonate membrane filters (Whatman, Newton, MA, USA) with pore diameters of 200 nm, 
100 nm and 50 nm. Per filter type, 5 extrusion steps were applied. The resulting solution was 
ultracentrifuged twice (Beckman Coulter, Fullerton, CA, USA) at 300,000 G (4 °C). Super-
natant was discarded. The resulting liposome pellet was typically resuspended in 2 ml HEPES.
 
 
Characterization of Liposomes
The average diameter and size distribution of the liposomes in the final formulation were 
determined by dynamic light scattering (DLS) using a Zetasizer Nano (Malvern Instruments, 
Worcestershire, UK). The mean resultant size of different batches of Gd-DTPA liposomes as 
determined by DLS was 111-123 nm with a polydispersity index (PDI) of 0.04-0.09, whereas 
HEPES control liposomes were slightly larger with sizes 114-129 nm (PDI 0.06-0.12). The 
zeta potential was 43±7.0 mV. Relative Gd content was determined by Inductively Coupled 
Plasma-Optical Emission Spectroscopy (ICP-OES) and was 66±4 μg Gd/μmol total lipid. Li-
posomal phosphate content was assessed by spectrophotometric analysis according to Rouser 
(52). 
 
Cell Culture and Cell Labeling
Rat mesenchymal stem cells (MSCs; Millipore, Billerica, MA, USA) of passage 3 or 4 were 
used for all experiments at 70% subconfluency. MSCs were cultured in a humidified CO2 
incubator (Heraeus, Hanau, Germany) at 37°C and 5% CO2 in Dulbecco's modified Eagle 
medium (Invitrogen; Carlsbad, CA, USA) supplemented with 2% FBS (Lonza; Basel, Switzer-
land), 2% penicillin/streptomycin (Invitrogen), 2% L-glutamine (Invitrogen), 1% MEM es-
sential vitamin mixture (Lonza), 1% NEAA (Sigma-Aldrich) and 0.5% glutamax (Invitrogen). 
Unless stated otherwise, cells were grown in 75-cm2 flat-bottom flasks (Corning, NY, USA). 
Cell labeling was performed on basis of lipid concentration. Lipid concentration in various 
experiments was 125, 250, 500 or 1000 μM, corresponding to 52±3, 104±6, 209±13 and 
420±25 μM Gd respectively. Control cells were incubated with HEPES-containing liposomes. 
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Labeling was performed for 4h, unless otherwise stated. Cells were detached using accutase 
(Millipore) and underwent three washing steps in prewarmed phosphate-buffered saline (PBS). 
Following harvesting, cells were centrifuged at 300 G for 5 minutes to acquire a cell pellet. 
 
Uptake efficiency and Gd Content Measurement
To assess the uptake efficiency as a function of labeling time (i.e. 1h, 4h, 24h) and lipid dosage 
(i.e. 0, 125, 250, 500 and 1000 μM total lipid) 4 x 105 MSCs were seeded in 25-cm2 flasks 
and labeled with Gd-liposomes at the indicated doses for the indicated times, resulting in 15 
groups. The entire experiment was performed in triplicate.
Following incubation, cells were washed, harvested and centrifuged. Supernatant was then 
carefully aspirated and the obtained cell pellet was suspended in PBS allowing cells to be 
counted in a hemocytometer. After a second centrifugation step the cell pellet was suspended 
in 4 ml. Triton X-100 2% (St. Louis, MO). This solution was heated up at 55 °C in a ther-
moshaker and mixed for 30 min. at 6G to induce cellular and liposomal lysis. Three aliquots of 
20μl Gd-liposomes were treated with Triton and vortexed as well. Both the total amount of in-
ternalized Gd and liposomal Gd were then measured using inductively coupled plasma-optical 
emission spectroscopy (ICP-OES; Optima 4300DV, Perkin Elmer, Norwalk, CT) operating at 
a wavelength of 342 nm.  Cellular uptake efficiency was calculated as:
 
liposomal
pellet
uptake Gd
Gd
Eff = [1.]
 
where Gdpellet is defined as the total amount of Gd in the harvested cell pellet and Gdliposomal the 
amount of Gd in liposomes added to the culture medium. Counting the cells in the harvested 
pellet (Ncells), the mean cellular Gd concentration was derived from
 
cells
pellet
cellular N
Gd
Gd = [2.]
 
In Vitro Toxicity Assay
Unless stated otherwise, all assays were performed with separate groups undergoing labeling 
with increasing dosages of Gd-DTPA liposomes (ie 0, 125, 250, 500 and 1000 μM lipid).  All 
experiments were performed in triplicate. 
Putative dose-dependent cytotoxicity of Gd-liposomes was studied with MTT-assays in a 96-
well plate. Additional experiments were included to study a possible specific cytotoxic effect 
of the Gd-DTPA component, comparing effects on cells labeled with either Gd-liposomes 
or with control liposomes containing HEPES buffer only. The MTT-assay is based on the 
reduction of yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) to 
purple formazan by living cells (53). In both experiments MSCs from the same batch were cul-
tured (1.0 x 104 MSCs per well) overnight in 100 μl culture medium in quintuplets, followed 
by 4h labeling at 70% subconfluency. At end of labeling, cells were washed three times with 
PBS with care in order not to destruct the monolayer. Twenty-four hours after start of labeling 
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MTT substrate (5 μg/μl) was filtered through a 0.2μm filter membrane followed by addition 
of 50 μl to each well. Plates were then incubated for 3h at 37°C, followed by centrifugation. 
Medium was carefully aspirated and 100 μl DMSO was added to each well to lyse the cells 
and dissolve the insoluble formazan product. Absorbance was recorded after 30 min at 490 nm 
using a 96 well-plate reader (Victor2, Perkin Elmer, Norwalk, CT, USA). For internal valida-
tion of the MTT-assay, the correlation between cell amount and absorbance was assessed by 
inclusion of a serial dilution of unlabeled cells, ranging from 4.0 x 102 to 2.5  x 104 cells per 
well.
proliferation and Gd-retention assay
Long-term effects on proliferation were studied on cells which had been labeled for 4h with 
the previous mentioned dosages of Gd-DTPA liposomes. MSCs were counted in a hemocy-
tometer on days 4, 7, 11, 15 and 20. Non-viable MSCs were included in the cell count as 
well, to avoid any bias from possible differences in cell death rates. At each time-point cultur-
ing was consistently continued with 7.5 x 105 MSCs only, maintaining a practical workflow. 
Simultaneously, MSCs were collected and spun down at 300 m/s2 for 5 min in triplicates. 
Total harvested Gd load of these samples was measured by ICP-OES in order to assess possible 
extracellular leakage of Gd. 
Figure 1.  Cellular uptake of Gadolinium (Gd). Mes-
enchymal stem cells (MSCs) were incubated for 1h, 4h 
or 24h with 125, 250, 500 or 1000 μM Gd-liposomes. 
A dose-dependent increase in Gd uptake with increasing 
load of Gd in the incubation medium can be recognized. 
Note the significantly higher intracellular Gd load after 
4h compared to both 1h and 24h (A); No major sig-
nificant difference between 4h and 24h was observed in 
total harvested Gd (B) as well as uptake efficiency (C). 
The experiment was performed in triplicates. Data are 
displayed as means +/- SD
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Differentiation assay
Effects of labeling with Gd-DTPA liposomes on the multi-lineage capacity of MSCs was de-
termined. For this purpose 6 x 104 MSCs were seeded per well in 24-well plates and allowed to 
form a confluent monolayer. Adipogenesis was stimulated for 20 days using both adipogenesis 
induction and maintenance medium (Millipore, Billerica, MA, USA) in three cycles, whereas 
osteogenesis was promoted for 13 days with osteogenesis induction medium (Millipore, Bil-
lerica, MA, USA). Finally, Oil Red O and Alizarin Red staining were performed in separate 
plates to detect adipocytes and osteocytes, respectively.
Confocal Laser Scanning Microscopy
To study the integrity of liposomes following endocytosis, 0.1 mol% of rhodamine-PE (Avanti 
Polar lipids) was added during liposome preparation, serving as a fluorescent bilayer marker. The 
water-soluble, membrane-impermeable dye calcein (Sigma-Aldrich) was added to the hydration 
solution at a concentration of 12μM, at which concentration its fluorescence is maximal (54). 
MSCs were labeled for 4h, washed three times with PBS and imaged for 62h using a LSM 510 
META confocal microscope (Zeiss, Oberkochen, Germany) in a closed humidified chamber at 
37°C and 5% CO2. Hoechst 33258 was used as a nuclear stain. Detailed examination was done 
using a 40x oil-immersion objective lens (NA 1.3). Scans were made in multitrack mode with 
a 405 nm diode laser for Hoechst 33258 excitation (420-480 nm BP filter), a 488 nm Argon 
laser for calcein (505-530 nm BP filter) and a 543 nm Helium-Neon laser for rhodamine (560-
615 nm BP filter). MetaFluor software (Molecular Devices, Downingtown, PA, USA) was used 
for instrument control and image acquisition. Images were analyzed using Zeiss LSM Image 
Browser 4.2.0. Considering the broad bandwidths and asymmetrical spectral profiles of both 
calcein and rhodamine, bandpassfilters were set rationally to prevent cross-talk of fluorescence 
signal from both fluorophores. Nevertheless, additional control experiments were performed to 
confirm the absence of cross-talk, using single fluorophore labeled liposomes containing either 
calcein or rhodamine. All experiments were recorded with the same laser settings.
MR imaging
Data acquisition was performed on a 1.5T (in vitro only) and on a 3.0T (in vitro and in vivo) 
clinical MRI scanner (Signa Excite; GE Medical Systems, Milwaukee IL, USA) using unmodi-
fied gradients and custom made surface coils with an inner diameter of 2 cm.
To study the MRI behavior of Gd-liposomes labeled MSCs in vitro, a stock solution of 1.84 x 
105 labeled MSCs in 0.3% liquid agar (BD, Sparks, MD, USA) was prepared. Care was taken 
to acquire a homogeneous suspension without formation of air bubbles. By serial dilution 8 
concentrations in the range of 1.84 x 105 - 1.45 x 103 cells μl-1 agar were prepared and filled 
out in a 384-wells plate. Surrounding wells were filled with water to prevent air-induced sus-
ceptibility artifacts. To produce T1-weighted images, the plates were imaged using a 2D spin-
echo sequence with echo time (TE)= 10 ms and repetition time (TR)= 500 ms, a resolution of 
40x40 μm2 (FOV 2x2 cm, matrix 512x512), one acquisition and a slice thickness of 1.4 mm. 
The plates were scanned at room temperature (20 ºC). 
For in vivo imaging a suspension of 0.5 x 106 MSCs in 20 μl PBS was injected subcutaneously 
or intramuscularly in the hind limb of Wistar rats (Harlan, Horst, the Netherlands). As a 
control, non-viable cells were injected as well. Cells were killed by repeated freeze-thawing (in 
liquid nitrogen). Viability was then checked by trypane blue assay.
For scanning, rats were anesthetized by i.p. injection of sufentanil and medethomidine both 
at 300 μg/kg body weight. Animals were scanned repeatedly over a two-week period at days 0, 
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5 and 14. A 3D SPGR sequence (with fat suppression) was applied, with TE=3.0 ms, TR=30 
ms and α=30º, at a resolution of 125x125 μm2 and a slice thickness of 400 μm. This resulted 
in an acquisition time of 20 min. Animals were housed under standard conditions of light 
and accommodation, and were fed a standard laboratory diet ad libitum. All experiments with 
animals were performed with prior approval of the institutional animal care committee. After 
the 14 days follow up period animals were euthanized.
Histology
For histological purposes, cells were labeled with liposomes containing rhodamine-PE (Avan-
ti Polar lipids) and in some instances also with the nuclear dye Hoechst (Sigma-Aldrich). 
Hoechst was thus used to label cells with prior to intramuscular injection, not as a counter-
stain. Animals were sacrificed at day 1 or 5 after injection. Muscular tissue at the injection site 
was then carefully dissected out, cryopreserved in OCT Tissue-TEK (Sakura Europe, Alphen 
aan den Rijn, the Netherlands) and cryosectioned at 10 μm slices. 
Statistical analysis
All values are presented as mean±SD from triplicates and expressed in relation to unlabeled 
cells. Statistical significance between selected groups in both the viability and proliferation 
assay were determined with one-way ANOVA; for viability a Bonferroni post-hoc test was 
applied for selected pairs (Graphpad InStat 3.06; Graphpad Software Inc., San Diego, CA, 
USA). The degree of significance is given when appropriate (*p < 0.05; **p < 0.01; ***p < 
0.001). 
 
Results
Cellular Gd uptake
A concentration-dependent increase in intracellular Gd load was observed with increasing Gd 
liposome concentration in the incubation medium (Fig. 1A). This trend was less obvious at 1h 
exposure time. Intracellular Gd-load was highest (70±4 pg Gd cell-1) by labeling with 1000μM 
lipid (420±25 μM Gd) for 4h. 
According to Eq. (1), for each labeling period, maximal uptake efficiency was achieved using 
125μM total lipid (Fig. 1B). Uptake efficiency was not significantly improved by prolonged 
incubation (> 4h). This is most likely caused by intracellular Gd dilution due to cell division, 
outweighing the de novo uptake of abundant Gd by daughter cells. Washout of Gd is consid-
ered less likely, as there was no striking difference in total harvested cell-associated Gd after 
4h and 24h incubation time (Fig. 1C). As a result, considering time-efficiency, further experi-
ments focusing on cell behavior were conducted using the 4h labeling protocol.
 
In vitro toxicity and proliferation assays
MTT assays demonstrated a dose-dependent cytotoxic effect of labeling with both unloaded 
and Gd-loaded liposomes (Fig. 2A). As a validation of the technique, a double dilution series 
of unlabeled cells showed a nice linear relation with the measured absorbance (Fig. 2B). No 
significant effect on cell viability was observed at low dose liposome incubation (125 μM lipid) 
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Figure 2. Viability by MTT-assay as a function of Gd and lipid concentration.  Labeling time of 4h. Note the dose-
dependent negative effect on cell survival at high lipid concentration (normalization to unlabeled control cells) (A). For 
each specific lipid dose, no significant difference (p > 0.05) in viability was found between the two liposome types. Linear 
relation between absorbance and unlabeled cell amount (B). Data are displayed as means +/- SD
Figure 3. Proliferation assay of MSCs. The proliferation rate of labeled cells did not differ significantly (p > 0.05) from 
unlabeled control cells (A). Total harvested Gd load at each passage step is shown in (B). With ongoing proliferation, 
cellular Gd load decreased accordingly (C). Data in (A) and (B) are displayed as means +/- SD. Data in Fig 3C was calcu-
lated by dividing data points in B by corresponding data points in A (total harvested Gd load/ no. of cells)
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for both liposome types (p > 0.05). However, higher concentrations (≥ 250 μM lipid) affected 
viability slightly negative (p < 0.001) in a dose-dependent manner. This trend was observed 
for both unloaded and Gd-loaded liposomes. No statistically significant difference was found 
in viability of cells labeled with identical concentrations of either of the two liposome types, 
throughout the entire examined concentration range (p > 0.05).
 
 
proliferation and Gd-retention assay
Assessment of proliferation was done by cell count over a period of 20 days (Fig 3). As derived 
from the viability assay, variations in cell death exist for different liposome concentrations. 
Therefore, both viable and non-viable MSCs were counted to exclude an influence on prolif-
eration caused by differences in viability. Hence it may be assumed that the growth rates reflect 
merely cellular mitosis. None of the investigated doses exhibited a significant reduction in 
proliferation rate (p > 0.05), compared to control unlabeled cells. 
At various time-points samples were taken for assessment of the total cellular Gd load.  Due to 
mitosis, average Gd load per cell diminished rapidly (Fig. 3C). Data in Fig 3C was calculated 
by dividing data points in B by corresponding data points in A (total harvested Gd load/ no. 
of cells). No significant drop in the total Gd load occurred at 125 μM lipid (52±3 μM Gd) and 
250 μM lipid (104±6 μM Gd) (fig. 3B). However, a small but significant (p<0.05) decrease 
was observed with 500 μM lipid (209±13 μM Gd) in the incubation medium. The decrease 
with this lipid dose may be explained by a lower harvested Gd amount, due to the relatively 
higher cell death (Fig. 2A). Even though care was taken to collect both viable and non-viable 
MSCs, it is possible that a reasonable amount of Gd from disintegrated non-viable cells was 
collected inadequately during centrifugation.
 
Figure 4. Cell differentiation 
assay. In vitro differentiation 
of MSCs is not inhibited by 
Gd-DTPA liposome labeling 
(shown are images of the high-
est incubation dose, 1000μM 
lipid). Differentiation into adi-
pocytes (Oil Red O stain) was 
unimpaired for both control 
MSCs (A) and MSCs labeled 
with 1000 μM lipid (B). Dif-
ferentiation into osteocytes 
was unimpaired as well for 
both control cells (C) and cells 
labeled with 1000 μM lipid 
(D). White arrows in A and B 
point to a lipid vacuole. MSCs 
labeled with doses < 1000 μM 
lipid exhibited similar differ-
entiation phenotypes (data not 
shown).
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Adipogenesis, osteogenesi
An important issue in imaging of 
stem cell transplantation is the 
preservation of differentiation abil-
ity upon incorporation of a tracer. 
Adipogenic and osteogenic differ-
entiation were induced with in vi-
tro cell cultures. Oil red O staining 
revealed that MSC labeled with all 
tested Gd-liposome concentrations 
(125-1000 μM lipid) underwent 
adipogenic differentiation with ef-
ficiencies similar to unlabeled cells. 
Oil vacuoles could be detected 
in nearly all Gd-liposome labeled 
MSCs, being phenotypically indis-
tinguishable from unlabeled MSCs. 
In addition, Alizarin Red staining 
showed a sustained osteogenic dif-
ferentiation potential of Gd-labeled 
MSCs (Fig. 4).
Confocal Laser Scanning 
Microscopy
After labeling with 125 μM lipid 
(52±3 μM Gd) for 4h, viable MSCs 
were imaged for 56h. Liposomes 
showed an intracellular accumula-
tion, which was perinuclear in dis-
tribution. During the entire time 
range no obvious nuclear uptake was 
perceived. Based on the punctate 
appearance of both the liposomal 
membrane-associated rhodamine 
(red) and the core-encapsulated 
calcein (green), liposomes most likely resided in endosomes rather than having a diffuse cyto-
solic distribution (Fig. 5A). No extracellular leakage of fluorescence was recorded during the 
experiment. Although in a labeled state, MSCs were demonstrated to undergo mitotis with a 
roughly equal distribution of liposomes among daughter cells (Fig. 5B).
Absence of crosstalk was confirmed in experiments using control liposomes, containing either 
rhodamine-PE or calcein only (data not shown).
 
MR imaging
In vitro concentrations of Gd-liposome labeled MSCs in the range of 1.45 x 103 - 1.84 x 105 
cells μl-1 agar were imaged to assess the signal intensity as a function of labeled cell concen-
tration. On T1-weighted spin echo (SE)-images, the least cell concentration which could be 
discerned visually from surrounding water was assessed at 2.9 x 103 and 5.8 x 103 cells μl-1 agar 
Figure 5. Confocal fluorescence. Time-resolved confocal laser scan-
ning microscope (CLSM) images of MSCs labeled with Gd-lipo-
somes (4 h), containing rhodamine in the bilayer and intraliposomal 
calcein. Images are bright field, with overlay from confocal fluores-
cence. Elapsed time after cell labeling is indicated. Colocalization of 
rhodamine (red) and calcein (green) fluorescence indicates towards 
intact liposomes, whereas the dotted appearance indicates an endo-
somal distribution. Note the absence of extracellular fluorescence 
leakage. Mitosis was unimpaired, with a roughly even distribution of 
liposomes over daughter cells (B). Indicated time represents elapsed 
time after start of mitosis. Scale bar is shown in the images.
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at 3.0T and 1.5T, respectively (Fig. 6A, B).  
Strikingly, 1.84 x 105 cells μl-1 agar gave rise to a signal loss at 1.5T. This was even more pro-
found at 3.0T (Fig. 6B). This is probably due to a major T2-shortening in very concentrated 
samples (55,56). 
Interestingly, the in vivo injected cell cluster in the hind limb exhibited a dualistic behavior. 
Injected cells were initially perceived as signal loss, slowly gaining in intensity over days (Fig. 
6C).
Non-viable cells were injected in vivo as well, as a control. Viability was checked prior to injec-
tion, showing 98% of cells to be non-viable. Non-viable cells showed a remarkable hyperen-
hancement, immediately after injection. (Fig.7). 
Figure 6. MR-imaging. T1-weighted images of MSCs labeled with 125μM Gd-liposomes for 4h. The same cells were 
scanned at both 1.5T (A) and 3.0T (B). Wells filled with cells are demarcated by the white box. Cell concentrations on 
the top row, from left to right: 1.84*105, 9.28*104, 4.64*104 and 2.32*104 MSCs μl-1 agar. Lower row, from left to right: 
1.16*104, 5.80*103, 2.90*103 and 1.45*103 MSCs μl-1 agar. Longitudinal tracking of viable Gd-liposome labeled MSCs 
(white arrow) in the rat hind leg (3D T1W imaging) imaged at days (C) 1, (D) 5, (E) 7 and (F) 14 after transplantation. 
Both scale bars in A and C represent 10 mm. Scale bar in A applies to B as well. Scale bar in C applies to C-F.
Figure 7. MR-imaging. GRE image (TR 8 ms., TE 
ms., α=30º ) of both viable and non-viable Gd-labeled 
MSCs injected in the lower back muscle, imaged 1 
hour after injection. Viable MSCs are visible as hy-
poenhancement with a hyperintense rim (large arrow), 
whereas non-viable MSCs exhibit a hyperenhancement 
(small arrow). Scale bar, 10 mm.
C
ha
pt
er
 2
47
Histology
On cryosections, cells could be retrieved at least at day 1 and day 5 after transplantation. Red 
fluorescence from the rhodamine-liposomes was visible in a perinuclear pattern at both day 1 
(Fig. 8A) and was still perceived at day 5 (Fig. 8D).
 
Discussion
The achievement of a high intracellular load of CA is an important condition to localize or 
track cells in cellular imaging. This holds true especially for MRI, since its sensitivity is gener-
ally lower with respect to other imaging modalities such as single-photon emission computed 
tomography (SPECT) or bioluminescence (57). Gd-DTPA is a widely used MR contrast agent 
which is approved by the U.S. Food and Drug Administration. Being hydrophilic, Gd-DTPA 
is not taken up spontaneously by cells. This limitation was challenged in this study, by in-
corporation of Gd-DTPA in cationic liposomes allowing an efficient uptake by cells through 
binding to anionic charges in the cell membrane.
A dose-dependent decrease in cell viability was observed with Gd-liposome doses increasing 
from 250 μM lipid, reaching a maximal decrease in viability of around 20% with 1000 μM 
lipid, the highest dose in this study. The decreased cell viability was also observed with empty, 
non Gd-containing liposomes, leading to the conclusion that the observed minor toxicity is 
caused by the cationic liposomes. With a different liposome formulation, in a recent study 
(41) no statistically significant reduction in labeled cell viability was reported for a lipid con-
centration up to 5mM, using Gd-DTPA-BSA liposomes. This difference is probably due to 
the lipid composition used in our formulations consisting of the cationic lipid DOTAP which 
role is to strongly enhance cellular interaction, but apparently also exerts some toxicity. Toxic-
Figure 8. Histological detection of cells labeled with rhodamine containing liposomes. Intramuscular injected cells 
at day 1 (A-C) and day 5 (D-F) post-transplantation. Red fluorescence from the rhodamine-liposomes is clearly visible 
(A, D). The blue nuclear dye Hoechst, which was added to the cells in culture prior to injection, shows the injected cells 
at both day 1 (B) and day 5 (E). Overlay images (C, F). The insets in frame D, E and F show a 10x magnification of the 
area indicated by the dashed rectangle. Scale bar in A applies to A-F.
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ity of Gd-DTPA can be excluded, as Gd-liposomes did not cause any significant additional 
decrease in cell viability, compared to liposomes without Gd. Although DOTAP has been used 
extensively in DNA-transfection studies, reports on damage to cellular physiology exist (58), 
lacking however a clear assessment of dose toxicity (59). Interestingly, our experiments demon-
strated the existence of a dose-dependent toxicity using > 125 μM lipid. The dose-dependent 
toxicity seems to be of minor relevance in cell labeling, considering the excellent Gd uptake at 
125 μM lipid with an outstanding MR-visualization. In addition, a long term biological effect 
of the toxicity remains questionable, considering the absence of fluorescent Gd-liposomes in 
the cell nucleus, reducing the chance of interference with the cell DNA and thus long-term 
genetic damage. Furthermore, both proliferation and differentiation ability were not impaired 
by Gd-liposome labeling.
The apparent absence of Gd-chelate toxicity is in line with earlier studies (40), in which gado-
linium 1,4,7-tris(carboxymethyl)-10-(2’-hydroxypropyl)-1,4,7,10-tetraazacyclododecane (Gd-
HPDO3A) and Gd@C82fullerenol were used. To a certain extent, this tones down the initial 
safety concerns on the hypothesized dechelation of Gd-DTPA upon incorporation in endo-
somes, feared to result in potentially hazardous Gd3+ ions (60). Additionally, the putative mani-
festation of nephrogenic systemic fibrosis (NSF) following transplantation of Gd-labeled cells is 
considered an important drawback in future clinical studies. NSF however, has been reported to 
occur merely in patients with an impaired kidney function (61). Consequently, this complication 
should be easily avoidable if these selected patient groups are excluded in future clinical studies.
The in vitro uptake of Gd-liposomes was both time- and dose dependent. Regarding dose-
dependency, some parallels can be drawn between present results and previous reports by 
different authors. For example, labeling with cationic liposomes for 2 hours yielded an uptake 
of 12.5 pg Gd cell-1 (uptake efficiency 31%) (23), comparable to our findings. Another anal-
ogy concerns the cellular Gd uptake, which was linearly proportional to the concentration of 
Gd-liposomes in the medium. A similar relation was described using Gd-HPDO3A (42) and 
Gadofluorine M (62). 
Of note, labeling for 4h with 125 μM lipid (52±3 μM Gd) yielded an intracellular load of 
29±2 pg cell-1, without any detrimental effects on cell viability, cell proliferation and cell dif-
Table 1 Reported intracellular gadolinium (Gd)-loads following labeling with Gd-compounds.
Reference Gd load  
(pg cell-1)
Incubation 
time (h)
Labeling method Compound Cell viability 
(%)
(16) 12.5 2 cationic 
liposomes
Gd-DTPA 
(Magnevist)
80.6±11.4
(4) 0.12 10 protamine sulfate Gd@C82 
(fullerenol)
100
(53) 13.1 16 pinocytosis / 
electroporation
Gd-HPDO3A 
(Prohance)
*
This report, 2010 29±2 4 cationic 
liposomes, 125 
μM lipid
Gd-DTPA 
(Magnevist)
99±1.37
This report, 2010 70±4 4 cationic 
liposomes, 1000 
μM lipid
Gd-DTPA 
(Magnevist)
83±1.5
*not reported
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ferentiation. This amount is considerably higher (2-97x) than most intra-cellular Gd loads 
reported in other studies, as listed in Table 1. Even higher Gd loads (70±4 pg cell-1) were 
achieved with 1000μM lipid (420±6 μM Gd), with some implications for cell viability how-
ever (-17±1.5%). An uptake of such a magnitude may be attributed to the abundant uptake of 
cationic liposomal lipids (DOTAP) through binding to anionic charges in the cell membrane. 
The advantages of electrochemical interaction in cell labeling have been reported before (63). 
Gd-liposome labeled MSCs maintained the multi-lineage ability, shown by the differentiation 
into both adipocytes and osteocytes.   
Intracellular distribution is a fairly important issue to be aware of in MRI-cell tracking, affect-
ing the relaxivity of both T1 (43) and T2 (64) contrast agents. Live cell confocal fluorescence 
revealed an initial endosomal distribution of the liposomes. A similar distribution pattern was 
reported for Gd-liposomes (41) and Gd-HPDO3A (43). By confocal fluorescence, no extracel-
lular leakage or obvious extracellular membrane-attached liposomes were detected. This was 
further confirmed by ICP-OES measurements, revealing virtually no loss of Gd over at least 20 
days with doses ≤ 250 μM lipid.  This is of importance in cell tracking by MRI, considering the 
effect of compartmentalization on relaxivity. The use of Gd-liposomes will limit the occurrence 
of false-positive labeled cells, contributing to a more reliable quantification of transplanted cell 
fate. This is a clear advantage over iron-oxide particles, being notorious for clustering on the 
extracellular membrane (65), causing some ambiguities in relaxivity. Longitudinal confocal 
microscopy further confirmed the results from the MTT- and proliferation assay, demonstrat-
ing the preserved viability and mitosis of Gd-labeled cells over time. 
As mentioned before, a major incentive for the use of intra-cellular Gd is the signal gain, as 
opposed to the signal loss rendered by iron-oxide particles. Interestingly, Gd-labeled cells were 
able to cause a signal loss both in vitro and in vivo. A signal loss in vivo was also reported in 
a study using a Gd-based, bi-functional agent called GRID (66). In that study, injection of 
GRID-labeled cells into the rat brain resulted in a hypo-intense tract surrounded by hyper-in-
tense rim. This phenomenon was explained as a difference in cell density in the two areas. The 
strong T2-shortening effect of highly concentrated T1 CAs has been reported before (55,56). 
In our study this effect manifested in vitro at 1.84 x 105 cells μl-1 and in vivo at 2.5 x 104 cells 
μl-1, a tenfold difference. This difference implies that more factors are in play, for example 
differences in water diffusivity or the compartmentalization of Gd. The difference in signal 
behavior in vitro and in vivo is complex and in vitro results can not be extrapolated directly to 
the in vivo situation. For example, in vitro the cellular Gd concentration decreased according 
to proliferation (fig 3C), a known limitation of external labeling. The proliferation ability of 
cells in vivo however will hardly be the same. It is also possible that after injection the density 
of a labeled cell cluster increases, concurrently increasing the Gd load per voxel, causing differ-
ences in signal behaviour between in vitro or in vivo applications.
The increase over time in signal intensity in vivo has been reported before (67) and may be due 
to cell division leading to a net lower Gd concentration per cell or cell death with extracellular 
loss of Gd. The latter was confirmed by the injection of non-viable Gd-labeled cell controls 
(in which the membrane was ruptured), which caused a hyperenhancement (Fig 7). Compart-
mentalization of Gd affects T1 contrast by hindering the accessibility to surrounding water 
(53). Cell death with membrane rupture therefore improves the diffusion of water to Gd, 
leading to an increased R1 relaxation rate, causing a bright signal on MRI. In future studies, 
additional quantification techniques like e.g. bioluminescence could be used to further relate 
the MRI signal in detail to underlying biological events such as viability and proliferation.
Gd-liposomes can be considered a promising candidate to shift the emphasis in future cell 
labeling studies from T2 to T1 CAs. As the uptake of Gd-liposomes does not rely on receptor-
mediated uptake, Gd-liposomes might prove a valuable labeling technique for multiple cell 
lines. They can overcome many of the disadvantages associated with T2 contrast agents. This 
might substantiate the use of Gd-liposomes in MRI-guided medicine.
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Conclusions
Labeling of mesenchymal stem cells with cationic Gd-liposomes for 4h resulted in high cellular 
Gd uptake. It represents an efficient labeling method, as prolonged incubation up to 24 h. did 
not further improve Gd uptake. Labeling with low concentrations of Gd-liposomes showed no 
effects on viability, proliferation rate and differentiation, while resulting in sufficient cellular 
Gd-uptake and MRI visualization both in vitro and in vivo. Gd-liposomes were located intra-
cellular in endosomes, with excellent retention of Gd for at least 20 days. No obvious leakage 
of the Gd label from the cells was noted. Gd-labeled cells were clearly visualized on a 3.0 T 
clinical scanner. With the proposed labeling method, Gd-liposomes prove to be an excellent 
candidate for MRI cell tracking.
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Abstract
Purpose: Cationic liposomes carrying high concentrations of Gd can be used as an efficient 
cell labeling agent. In a compartmentalized state, Gd can cause signal loss (relaxivity quench-
ing). The effect of liposomal [Gd], liposomal size and compartmentalization state on relaxivity 
quenching was assessed.
Methods and Materials: Dependency of SI on intraliposomal [Gd] was assessed comparing 
three different [Gd] (0.3, 0.6 and 1.0M Gd) in both small (80nm) and large (120 nm) cationic 
liposomes. In addition, five compartmentalization states were compared: free Gd, intact Gd-li-
posomes, ruptured Gd-liposomes, Gd-liposomes in intact cells and Gd-liposomes in ruptured 
cells (simulating cell death). Gd also causes R2 effects, which is often overlooked. Therefore 
both R1 and R2 relaxation rate of a dilution range were measured by T1- and T2-mapping on a 
7T dedicated animal MR scanner.
Results: Less is more. As the unidirectional water efflux rate (outbound across the liposome 
membrane, κle ) is proportional to the surface/volume ratio, smaller liposomes yielded a con-
sistently higher R1 than larger liposomes. For equal voxel [Gd] less concentrated liposomes 
(0.3M Gd) yielded higher R1/ R2 ratio because of the higher liposomal water fraction (vl ). 
Gd exhibits a dualistic behavior: from hypointensity to hyperintensity to hypointensity, with 
decreasing [Gd]. Regarding compartmentalization less membrane barriers means a higher R1/ 
R2 ratio.
Conclusion: Gd-liposomes exhibit a versatile contrast behaviour, dependent on the compart-
mentalization state, liposomal size, intraliposomal [Gd] and liposome number. Both R1 and R2 
effects contribute to this. The versatility allows one to tailor the optimal liposomal formulation 
to desired goals in cell labeling and tracking. 
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Introduction
Cellular imaging is the key for non-invasive assessment of cell transplantation therapies. In this 
rapidly evolving field many aspects of the in vivo kinetics of transplanted cells still need to be 
understood. Magnetic resonance imaging (MRI) provides excellent opportunities in this par-
ticular field thanks to its versatile properties. Combining the right ligand with a MR sensitive 
contrast agent, magnetic resonance imaging is capable of exposing a wide range of previously 
visually occult in-vivo molecular or cellular processes to the naked eye. 
The two types of MRI contrast agents (CAs) currently most widely used are T1 agents (Gado-
linium (Gd)  and to a lesser extent manganese (Mn)) or T2 agents (iron oxide particles). Much 
(pre)clinical experience has been gained in the past decades with Gd-based contrast agents, 
such as Gd-DTPA (Magnevist, Schering, Germany) and Gd-DO3A-Butrol (Gadovist, Scher-
ing). Their use as a cell labeling agent has however been limited, presumably because of the 
lower sensitivity obtained when compared to iron oxide particles. Nonetheless, cationic lipo-
somes loaded with high concentrations of Gd can be used as an efficient cell labeling agent for 
sensitive cellular MRI imaging (1). Gd-based contrast agents have been used successfully in 
several other studies as well (2-7). As Gd mainly shortens T1 relaxation times (and to a lesser 
extent T2 relaxation times), its classical application consists of the generation of signal gain 
(hyper intense or positive contrast) on T1-weighted images. Strikingly, in a compartmental-
ized (intracellular) state, Gd can cause signal loss (hypointense or negative contrast), known as 
‘relaxivity quenching’ (3,7,8). Although initially thought of as a drawback (9), a recent study 
by us showed that contrast changes as a result of (de)quenching can be advantageous, allowing 
for a visual and quantitative distinction between viable and non-viable Gd-liposome labeled 
cells by MRI (10). Relaxivity quenching thus might harbor more potential for cellular labeling 
than currently known. This at the time novel finding of dynamic contrast behaviour in vivo, 
encouraged us to study Gd signal quenching in more detail. Relaxivity of Gd is mainly affected 
by four parameters: the number of water molecules in the inner coordination sphere of the 
complex, the proton exchange rate in this inner sphere (depending on the water concentration 
of the relevant compartments and the compartmentalization), the rotational correlation times 
(related to the size of the molecule) and the electron spin relaxation rates. 
As encapsulation of Gd (inside liposomes and/or inside cells) affects the water exchange rate 
and availability, a better understanding of relaxivity (de)quenching could contribute to an 
enhanced image interpretation with regard to cell division, cell density and Gd-liposome load. 
No doubt, this would further open up possibilities in image-guided monitoring of cell trans-
plantation. Although most studies concerning Gd report merely T1 longitudinal times, in the 
same study we observed that Gd compartmentalization (in liposomes) increased r2 relaxivity 
(compared to ‘free’ Gd). Both T1 and T2 relaxation times of Gd-lipsomes and Gd-liposome la-
beled cells were assessed, as signal intensity is dependent on both. Realizing that high payloads 
of CAs are involved in cell labeling, we focus on the high intraliposomal [Gd] concentrations 
(0.3 M - 1.0 M Gd), which, to our knowledge, haven’t been studied before.
Material and Methods
Liposome preparation
As described before (1), liposomes were prepared to serve as a vehicle to transfer Gd to cells. 
In brief, Gd-DO3A-Butrol (Gadovist; Bayer Schering Pharma, Berlin, Germany) was incor-
porated in cationic liposomes using the lipid-film hydration technique followed by filtration 
through polycarbonate filters (Whatman, Newton, MA, USA).
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Cell labeling and preparation
Fluc-MSCs of passage 4 were used for all experiments. Dulbecco's modified Eagle medium (In-
vitrogen; Carlsbad, CA, USA) enriched with additives was used as culture medium. In short, 
Fluc-MSCs were labeled with 125 μM Gd-liposomes for 4h, harvested by trypsinization, washed 
3 times in PBS and centrifuged at 300 G for 5 minutes to discard of unincorporated contrast 
agent (1).  After centrifugation and cell counting, Fluc-MSCs cells were resuspended to their 
final concentration in Ficoll 1.07 g/mL (in vitro experiments) or PBS (in vivo experiments). 
experiment 1: Liposomal size and Gd load
To assess possible effects of liposomal size and liposomal Gd concentration on T1 and T2 relax-
ation time, varying liposomal formulations were prepared. Liposomes were encapsulated with 
Gd-DO3A-butrol (Gadovist 1.0 M) in three different intraliposomal Gd concentrations: 1.0 
M Gd (undiluted), 0.6 M Gd and 0.3 M Gd (diluted in HEPES). From each batch, both large 
and small liposomes were created. Large liposomes were produced by 5 times filtration through 
200 nm polycarbonate membrane filters followed by 5 times filtration through 100 nm filters. 
Smaller liposomes were created by 5 additional passes through 50 nm filters, followed by ul-
tracentrifugation to separate non-encapsulated from encapsulated Gd. Six different liposomal 
formulations were acquired finally: 1.0 M Gd with size 127 nm (1.0 ML) and PDI 0.076, 1.0 
M Gd with size 83 nm and PDI 0.054 (1.0 MS), 0.6 Gd with size 119 nm and PDI 0.045 (0.6 
ML), 60% Gd with size 93 nm and PDI 0.069 (0.6 MS), 30% Gd with size 124 nm and PDI 
0.071 (0.3 ML), 30% Gd with size 91 nm and PDI 0.066 (0.3 MS). The subscript abbrevia-
tions L and S refer to the size of the liposomal vesicles with L indicating large and S indicating 
small. The average diameter and size distribution of the liposomes in the final formulation was 
determined by dynamic light scattering (DLS) using a Zetasizer Nano (Malvern Instruments, 
Worcestershire, UK). Liposomal phosphate content was assessed by spectrophotometric analy-
sis according to Rouser (11). As quenching occurs at high concentrations of Gd, we aimed 
to produce very concentrated Gd-liposomes. To this end the resulting liposome pellet of each 
batch was resuspended in 400 μl HEPES. A serial dilution of each suspension was then pre-
pared and filled out in a 384 Well plate, followed by MRI scanning.
 
experiment 2: Gd compartmentalization
To assess the effects of Gd compartmentalization on T1 and T2 relaxation time, 5 Gd com-
partmentalization states were compared: viable Gd-liposome labeled MSCs, lysed (non-viable) 
Gd-liposome labeled MSCs, intact Gd-liposomes, lysed Gd-liposomes and free Gd-DO3A-
Butrol. Both lysed cells and lysed liposomes were obtained by repeated freeze thawing in liquid 
nitrogen. Cell death was assessed by Trypane Blue assay, whereas liposomal breakdown was 
assessed by DLS. 
In all in vitro experiments stock batches were prepared in Ficoll, preventing cell sedimentation 
during imaging (12), and a serial dilution was then filled out in a 384 well plate. T1 and T2 
relaxation times of the top as well as the bottom slice were measured, to make sure sedimenta-
tion did not occur. Surrounding wells were filled with water to prevent susceptibility artefacts 
from air and very concentrated samples. 
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MRI data acquisition and analysis
MRI data were acquired at room temperature on a 7T dedicated animal scanner (Discovery 
MR901; GE Medical Systems, Milwaukee IL, USA and Agilent Technologies, Santa Clara, 
CA, USA) with unmodified gradients and custom made surface coils (inner diameter of 5 
cm). Spin echo (SE) sequences with multiple TR (100-2800 ms; TE10 ms) and multiple TE 
(10-100 ms; TR 600 ms) were used to obtain T1 longitudinal relaxation times and T2 trans-
verse relaxation times, respectively. Sequences were acquired with a field of view (FOV) = 5.0 
x 5.0 cm2, matrix = 160 x 160, slice thickness = 1.4 mm and NEX = 2. Using Matlab (version 
R2007b) T1 and T2 times were calculated. Relaxation times were calculated as follows:
refx
x TT
R
1
1
1
11 -=Δ [1.]
In which T1x and T1ref represent the T1 of the Gd-containing sample of interest and the T1 of 
the surrounding wells containing the suspension solution (HEPES or Ficoll), respectively. 
The same formula was applied to derive the ΔR2 using T2, respectively. T1ref and T2ref in vitro 
were assessed to be 3100±120 ms and 167±18 ms., respectively. A voxel-by-voxel linear least 
squares fit of the natural logarithm of the signal amplitude versus at least 6 echo times (TE) 
was performed to construct R2 maps. For R1 maps at least 6 repetition times (TR) were used. 
 
Gd content measurement
The Gd concentration in either liposomes or cells was measured by Inductively Coupled 
Plasma-Optical Emission Spectroscopy (ICP-OES; Optima 4300DV, Perkin Elmer, Norwalk, 
CT) operating at a wavelength of 342 nm. Aliquots containing either liposomes or cells were 
suspended in 4 ml. Triton X-100 2% (St. Louis, MO), heated up at 55 °C and mixed for 30 
min. at 6 g to induce cellular and liposomal lysis. For internal validation, stock Gd-DO3A-
Butrol was included in the measurements as well. This allowed an inter-group comparison of 
T1 and T2 relaxation times, as a function of Gd concentration.
 
Statistical analysis
All values are presented as mean±SD from triplicates and expressed in relation to unlabeled 
cells. 
 
Results and discussion
experiment 1: The effect of liposomal size and Gd load on signal quenching
T1 and T2 relaxation times of a dilution range of the Gd-liposome suspensions (1.0 ML Gd, 1.0 
MS Gd, 0.6 ML Gd, 0.6 MS Gd, 0.3 ML Gd, 0.3 MS Gd) were acquired. Assessment of the actual 
Gd concentration by ICP-OES (Table 1), allowed an inter-group comparison of the ΔR1 and 
ΔR2, as a function of Gd concentration. For some of the most concentrated samples the T1 
longitudinal relaxation could not be measured, because it was impossible to fit a curve through 
these data points; these data points were therefore omitted. 
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Our data showed that all undiluted samples caused prominent signal hypointensities, except 
for 0.3 MS Gd-lipos. 0.3 MS liposomes have the highest R1 relaxivity (i.e. the slope of a linear 
curve fit through the Δ R1 data points). Furthermore, the R1 effects are more pronounced for 
liposomes with a lower intraliposomal Gd concentration or of a smaller size and for more con-
centrated liposome suspensions (containing a larger liposome number). Next, the r1 relaxivity of 
all Gd-liposome suspensions is lower as compared to uncompartmentalized Gd-DO3A-Butrol.
To understand these data we need to take a look at the factors that control r1 relaxivity, both on 
the molecular (Gd-chelate) and liposomal level. As known, interaction of Gd-bound chelates 
with water protons decreases the water T1 and T2 relaxation times. The interactions occurring 
between Gd and H2O protons on the molecular level are twofold (13). ‘Inner sphere relax-
ation’ refers to the formation of a dipole-dipole interaction between a water molecule and the 
primary sphere of the paramagnetic Gd3+ ion (with seven unpaired electrons). In this interac-
tion, a chemical exchange occurs resulting in an enhanced relaxation of the water protons. 
Thus, the relaxation will be enhanced by an increased fraction of water molecules that can in-
teract with Gd and by a shorter residence time of the water molecule with Gd (allowing Gd to 
interact with additional water molecules). ‘Outer sphere relaxation’ is a more complex concept. 
It is the result of the relative rotational and translational diffusion of water molecules and the 
paramagnetic ion. Basically stated, the relaxivity influence of the paramagnetic ion enhances 
when an increased number of water molecules can approach the paramagnetic ion and/or the 
further the paramagnetic ion can move through space and/or the closer the water protons 
can approach the paramagnetic ion. The liposomal suspension represents a two-compartment 
system, the intraliposomal and the extraliposomal compartment separated by the liposomal 
membrane. Gd is contained in the intraliposomal compartment. Diffusion of water across 
the liposomal membrane thus extends the influence of Gd into the non-contrast containing 
compartment. The apparent (measured) voxel signal intensity is dependent on the relaxation 
rate and the cross-compartmental water exchange rates. As long as the H2O exchange rate is 
fast enough on the time scale of T1, protons excited in one compartment can relax in another 
compartment (14). The longitudinal relaxation is then in fast-exchange.  The exchange rates 
can be derived mathematically. For a single liposome with radius r, with a volume expressed as 
V= 4/3πr3 and surface area as A= 4πr2, the unidirectional water efflux rate constant (the recip-
rocal average liposomal water lifetime) across its membrane can be expressed as (15):
l
d
l
l
dl
l
le
r
P
V
AP 31 ===
τ
к [2.]
Pdl , representing the diffusional permeability of the liposomal membrane, was derived by 
interpolation from the NMRD profiles of similar cholesterol containing liposomes (10-3cm-1) 
(16). The occurring exchange is dependent on both the influx (κel ) and efflux water exchange 
rates (κle ) and the water volume fraction of the liposomal (vl ) and extraliposomal (ve ) com-
partment. The unidirectional water influx rate across the liposomal membrane can thus be 
expressed as:
e
l
leel
ν
ν
кк = [3.]
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In fast-exchange, the apparent voxel relaxation rate will be a weighted average of the relaxation 
rate of each compartment - independent of the exchange rate -, assuming a monoexponential 
signal recovery (17). This occurs as long as the sum of the exchange rates (κel + κle ) is much 
higher than the difference between the compartmental relaxation rates (the relaxographic 
‘shutter speed’) (17,18):
|11| elleel RR ->>+кк [4.]
However, if the exchange rate turns to a much smaller value than the difference between the 
compartmental relaxation rates:
|11| elleel RR -<<+кк [5.]
the system turns from fast-exchange to a slow-exchange state (17). In case of slow exchange, 
distinct compartmental relaxation times exists, which are dependent on exchange. Liposome 
encapsulated Gd represents such a slow-exchange state because of the barrier the liposomal mem-
brane imposes on diffusion, causing the exchange rate of H2O to be slower than the T1 proton re-
laxation time. This hinders an even distribution of the T1 relaxation time across the entire voxel.
 
R1 effects
A dilution range of the Gd-liposomes was imaged (Fig. 1). Higher Gd concentrations did not 
automatically produce higher signal intensities. Instead, all undiluted samples caused promi-
nent signal hypointensities, even on T1W images, except for 0.3 MS Gd-liposomes. With in-
creasing dilution the signal intensity rises steeply to a certain maximum, followed by a slow 
decrease in SI. Visually, signal intensity is highest for a fivefold diluted 0.3 Ms liposome solu-
tion (3.9 mM Gd in suspension), as confirmed by the calculated signal intensity (Fig. 6).
The Δ R1 relaxation rate was plotted against the liposomal Gd concentration ([Gdl ]) for each 
of the six formulations (Fig. 2). The R1 effects of the intraliposomal Gd concentration, the 
liposomal size and number will be discussed in detail next. 
R1 effects: intraliposomal Gd concentration 
At comparable liposomal sizes, 0.3 M Gd-liposomes possess a higher r1 relaxivity than 0.6 M 
Gd formulations, whereas the latter possess higher r1 than 1.0 M Gd formulations. This in-
verted relation might seem paradoxical at first glance. However, it can be clarified by the H2O 
availability in proximity to Gd. Previously mentioned, liposome encapsulated Gd represents 
a slow-exchange state. Fig. 2 indeed confirms that the r1 relaxivity of all Gd-liposome suspen-
sions is lower as compared to uncompartmentalized Gd-DO3A-Butrol. In a slow-exchange 
state the volume distribution of H2O over the two compartments matters, more specifically the 
ratio of the liposomal (vl ) and extraliposomal (ve ) volume water fractions, vl /ve (Eq. [2]). The 
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higher r1 relaxivity of 0.3 M Gd-liposomes is attributable to a larger liposomal water volume 
fraction (vl ), for which, in turn, two reasons may be mentioned. Firstly, compared to suspen-
sions with higher [Gdl ], a suspension of Gd-liposomes with a lower [Gdl ] contains less Gd 
molecules per single liposome and thus more liposomes at equal [Gdv ]. More liposomes means 
an increase in vl and a decrease in ve, increasing vl /ve. For example, 3.33 times more liposomes 
are inside a suspension of 0.3 M than in a suspension of 1.0 M Gd-liposomes. Secondly, 0.3 
M Gd-liposomes are created from 1.0 M Gd-DO3A-Butrol (containing 69 volume % H2O) 
diluted with HEPES buffer which contains a higher volume percentage of H2O (82 volume % 
H2O), additionally increasing vl by a factor 1.13 (69%*0.3+82%*0.7). This totals a net vl in-
crease of a factor 3.77 (=3.33*1.31). Thus 0.3 M Gd-liposomes clearly profit from an increased 
number of intraliposomal water molecules in the vicinity of Gd-molecules. The vl /ve ratio was 
calculated by measuring the [Gd] in suspension by ICP (from which we derived [Gdv ]), using 
the following equations. Liposomal Gd mass (MGd l ) can be derived by the product of [Gdl ] 
(in g/l) and the single liposomal volume (vl ):
lllGd VGdM ][= [6.]
Fig 1 Size and concentration-dependent contrast effects of Gd-liposomes
Experiment 1. T1-weighted image (TE 10 ms, TR 400 ms) of a 384 Wells plate containing a 1:1 serial dilution of vari-
ous Gd-liposomes preparations. Gd-liposomes with different intraliposomal [Gd] decreasing in concentration from left 
to right were scanned. From top to bottom: 0.3 MS Gd, 0.3 ML Gd, 0.6 MS Gd, 0.6 ML Gd, 1.0 MS Gd and 1.0 ML Gd 
liposomes. The subscript S and L refer to small and large Gd-liposomes, respectively (refer to text for sizes). Note the severe 
signal intensity loss from highly concentrated samples.
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For 1.0 M Gd-DO3A-Butrol the [Gd] is 157.25 g/l (as Gd has a molar mass of 157.25 g/
mol). The number of liposomes (Nl ) in suspension follows by dividing the total Gd mass in the 
suspension (after liposomal lysis) (MGd tot ) by the single liposomal Gd mass (MGd l ):
lGd
totGd
l M
M
N = [7.]
Given that the volume % H2O in undiluted Gd-DO3A-butrol equals 69% and the volume % 
H2O in HEPES buffer equals 82%, the sum of intraliposomal H2O volume of all liposomes 
together ( OH
totlV
2 ) can be calculated:
)}1(82.069.0{2 GdGdllOHtotl VVVNV -+= [8.]
in which vGd represents the intraliposomal Gd-DO3A-butrol volume fraction (e.g. 0.6 for 
0.6M Gd-lipsomes). The liposomal H2O volume fraction (vl ) can then be derived as follows:
)(2
2
22
2
totls
OH
totl
OH
totl
OH
bulk
OH
totl
OH
totl
l VVV
V
VV
V
V
-+
=
+
= [9.]
where OHbulkV
2 is the total extraliposomal (bulk) volume, Vs is the liposome suspension volume 
and totlV the total liposomal volume (=Nl*Vl ). This being an equation of which all parameters 
are known, vl was derived. As the total water volume fraction (ve+vl ) equals 1, vl was inputted 
in the following equation to calculate the water volume fraction ratio of the two compart-
ments:
l
l
e
l
V
V
V
V
-
=
1 [10.]
Plotting the water volume fraction ratio vl /ve as a function of [Gdv ] shows the vl /ve indeed to 
be largest for the 0.3M Gd-liposomes, followed by 0.6M and 1.0 M Gd-liposomes, consecu-
tively (Fig. 3). The increased vl /ve ratio increases the water influx exchange rate (κel ). With an 
unchanged efflux rate (κle ), the sum of exchange rates thus increases, resulting in enhanced T1 
relaxation effects (Eq. [3]). 
In addition, 0.3 M Gd-liposomes exhibit a relaxographic ‘shutter-speed’ | R1l – R1e| of 1.1 mM
-1 
s-1, which is 3.8 times lower for than 1.0 M Gd-liposomes. Thus the combined effect of the 
decreased relaxographic ‘shutter-speed’ | R1l – R1e| and increased vl /ve ratio drive the 0.3 M Gd-
liposomes more towards a fast exchange state. The approximation of the rate constants is visible 
from Fig 4, where the rate constants are plotted as a function of [Gdv ]. The overall effect is an 
increased higher ‘net’ voxel r1 relaxivity for 0.3M than either 0.6M or 1.0 M Gd-liposomes.
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Fig 2 Experiment 1. Line-chart depicting Δ R1 (A) and ΔR2 (B) relaxation rates as a function of voxel Gd concentration 
([Gdv ]) for a range of Gd-liposomes with three different intraliposomal [Gd] ([Gdl ]), 1.0 M, 0.6 M and 0.3 M Gd. Data 
are presented as mean ± SD (n=3 different samples, SD refers to intersample SD).
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R1 effects: voxel Gd concentration [Gdv ] or liposome number
The T1 mapping data (Fig. 2) shows the Δ R1 relaxation rates for all [Gdl ] to increase with an 
increasing liposome number (i.e. a higher voxel Gd concentration, [Gdv ]), irrespective of the 
tested range of [Gdl ]). Again, as mentioned above, an increasing number of liposomes increas-
es the ratio vl /ve, thereby increasing the influx rate (κel ) (Eq. [3]). As the liposomal Gd load 
[Gdl ] remains constant with in a serial dilution, | el R1R1 - | remains constant too; this propa-
gates the system towards fast-exchange, being in agreement with findings by other authors 
(18). Furthermore, the R1 curves bend off with increasing voxel [Gd] (Fig. 2), indicating some 
kind of saturation. The cause for this could lie in the molar ratio H2O/Gd, which dramatically 
decreases with increasing liposome number (Fig. 5). In the voxel [Gd] range 0-40 mM a 65 
fold decrease in the molar ratio H2O/Gd occurs, severely lowering the chance of interaction. 
The maximal intraliposomal H2O water volume fraction for all undiluted Gd-liposome for-
mulations (0.3M-1.0M) is in the range of 0.1-0.25, so the majority of H2O molecules are in 
the extraliposomal free space. 
 
R1 effects: liposomal size
Smaller liposomes consistently exhibited a higher r1 relaxivity than their larger counterparts 
(Fig. 2). The explanation for this is straightforward. As a result of the larger surface to volume 
ratio, smaller liposomes have a higher efflux rate (κle ) (Eq. [2]). This augments the sums of 
exchange rates, contributing to faster exchange. 
 
Fig 3 Experiment 1. The ratio of the intraliposomal water volume fraction (vl ) and the extraliposomal bulk water fraction 
(ve ) was plotted against voxel Gd concentration ([Gdv ]). The vl /ve ratio is largest for the 0.3M Gd-liposomes, followed 
by 0.6M and 1.0 M Gd-liposomes, consecutively.
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R2 effects 
In many studies on compartmentalized Gd contrast agents to date, the effect on R2 relaxation 
rate was not considered. However, Gd-based contrast agents have a biphasic effect on SI de-
pendent on the concentration and can introduce a T2 effect (severe signal loss) at high concen-
trations, even on T1-weighted pulse sequences.
In our study R2 relaxation rates increased according to the liposomal Gd load [Gdl ], i.e. the 
higher the intraliposomal Gd load the higher the r2 relaxivity (i.e. the slope of a linear curve fit 
through the ΔR2 data points) (Fig. 2). For all Gd-liposomes, r2 relaxivity was higher than for 
Fig 4 Experiment 1. Rate constants (s-1) of Gd-liposomes with an intraliposomal [Gdl ] of 1.0 M (left), 0.6 M (middle) 
and 0.3 M (right) as a function of the voxel [Gd], [Gdv ]. Undashed lines ( 
___ ) represent the relaxographic ‘shutter-
speed’ | R1l – R1e|, which is equal for small and large liposomes with the same [Gdl  ]. The sum of exchange rates (κle+ κel ) of 
small liposomes is drawn with dotted lines (····), whereas the sum of exchange rates (κle+ κel ) for large liposomes is drawn 
with dashed lines (----). Note the approximation of the rate constants with decreasing intraliposomal [Gdl]. The ap-
proximation of the rate constant | R1l – R1e| and the sum of exchange rates (κle+ κel ) is maximal for 0.3 M Gd-liposomes.
Fig 5 Experiment 1. The molar ratio H20/Gd of an arbitrary Gd-liposome suspension is plotted as a function of the 
voxel Gd concentration ([Gdv ]). The molar ratio H2O/Gd decreases exponentially with an increasing [Gdv ], which 
may account for the lower interaction chance of H2O with Gd atoms, and be part of the ‘R1 saturation’ occurring with 
increasing [Gdv ] (see Fig. 2).
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free Gd. This is explained by the liposomal clustering of the Gd-atoms causing a heterogeneous 
distribution across the voxel, increasing the local magnetic susceptibility differences, which in 
turn lead to intravoxel dephasing, an effect which is further magnified by an increasing [Gdv 
]. In general the r2 relaxivity increased with increasing [Gdl ] (Fig. 2). For similar [Gdl ], the 
r2 relaxivity was higher for larger liposomes. The basis mechanism underlying this might be 
the increased clustering of proton spins in larger liposomes, thereby enhancing spin-spin re-
laxation (which induces loss of phase coherence). Furthermore, it may be caused by the larger 
number of smaller liposomes per voxel at similar [Gdv ], resulting in a less heterogenous distri-
bution of spin moments across the voxel. These findings are important, as the signal intensity 
or perceived final contrast is dictated by both R1 and R2 effects. In addition, being aware of 
the intravoxel dephasing effect allows to choose the optimal MRI sequence, according to the 
desired outcome. Spin-echo (SE) sequences can reverse this effect by a 180 degree inversion 
pulse, a gradient-echo sequence can’t.
 
Combined R1 and R2 effects: signal intensity
Differences in concentration of compartmentalized Gd can generate contrast effects across 
the entire range from hypo- to hyperintensity (Fig. 1). Considering this versatility of Gd-lipo-
somes, it is essential to be informed about the dose response of the signal intensity (SI). Having 
shown that compartmentalization affects T1 as well as T2 relaxation times, both parameters 
need to be taken into account. Signal intensity for a spin-echo sequence is described by (19):
Fig 6 Experiment 1. Simulated dose response of Gd-liposomes with varying intraliposomal Gd-concentration. Typical 
SE sequence (TR 500, TE 10 ms) as a function of the voxel Gd concentration, [Gdv ]. Initially T1 relaxation dominates 
but as the CA concentration becomes sufficiently high T1-saturation as well as counter-acting T2 relaxation becomes 
dominant resulting in signal loss at higher concentrations. There is significant signal intensity quenching for all Gd-lipo-
somes along the entire testes concentration range, compared to free Gd-DO3A-Butrol. The highest SI of all liposomes 
is achieved by 0.3 M small Gd-liposomes (91 nm), closely followed by larger liposomes (124 nm) with the same [Gdl ].
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A simulated dose response curve of the tested Gd-liposomes in a typical SE sequence (TR 500, 
TE 10 ms) was generated for all Gd-liposomes (Fig. 6). Initially T1-relaxation dominates but 
as the CA concentration becomes sufficiently high T1-saturation as well as counter-acting T2-
relaxation becomes dominant resulting in signal loss at higher concentrations. There is signifi-
cant signal intensity quenching for all Gd-liposomes, compared to free Gd-DO3A-butrol. 
Compared to free Gd-DO3A-butrol the biexponential curves for Gd-liposomes are shifted to 
the right, attaining their maximal SI at higher voxel [Gd]. Of all liposomes, 0.3 M small Gd-
liposomes (91 nm) achieve the highest SI, closely followed by larger liposomes (124 nm) with 
the same [Gdl ]. As previously explained, the R1 effects underlying this are the combined effect 
of the decreased relaxographic ‘shutter-speed‘ |
el R1R1 - |, the increased sum of exchange rates (κle+κel ) (due to the increased ratio vl /ve resulting from an increased liposome number) and 
lower R2 effects because of lower field inhomogeneities. 
Understanding these effects allows one to titrate the optimal intraliposomal ([Gdl ]) and voxel 
Gd concentration ([Gdv ]) according to the needs and desired application for a specific MRI 
sequence.
 
Experiment 2: The effect of compartmentalization state on signal quenching
To assess the effect of the extent of compartmentalization, 5 different compartmentalization 
states of Gd were compared in vitro: viable Gd-liposome labeled MSCs, lysed (non-viable) Gd-
liposome labeled MSCs, intact Gd-liposomes, lysed Gd-liposomes and free Gd-DO3A-butrol. 
Taking in consideration the high voxel [Gd] ([Gdv ]) for stock liposomes, a large number of 
cells was required (>10E7), to allow for inter-group comparisons to be made. The range of 
[Gdv ] is therefore smaller than for experiment 1 (Fig. 7). 
 
R1 effects 
Gd compartmentalization in either a liposomal or a cellular-liposomal form reduces r1 longi-
tudinal relaxivity as compared to free Gd-DO3A-butrol (Fig 7). In parallel, the r1 relaxivity 
in the lysed groups (lysed cells or lysed liposomes) was larger than the r1 of the intact groups 
(intact cells or intact liposomes). The main reason for this lies in the fact that after lysis of the 
cell and/or liposome membrane an important barrier between bulk H2O molecules and Gd is 
abrogated, allowing free interaction. The r1 relaxivity for the lysed groups though still remains 
slightly lower than for free Gd-DO3A-butrol. A presumable cause could be found in the fact 
that the solution contains an additional amount of liposomal and cellular debris, resulting in 
a net lower H2O fraction, compared to free Gd-DO3A-butrol. In addition, the debris could 
pose a remaining barrier for H2O molecules in their diffusional pathways. 
R2 effects 
Compartmentalization of Gd, in both liposomes and cells, increases the r2 relaxivity (Fig. 7), 
compared to free Gd-DO3A-butrol. This is in accordance with the findings in experiment 
1. Again, this can be explained by the heterogeneous distribution of Gd across the voxel in 
compartmentalized form, increasing the local magnetic susceptibility differences leading to 
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intravoxel dephasing. The r2 relaxivity for Gd-liposomes in viable (intact) cells was larger than 
for intact liposomes. Presumably, the clustering of Gd-liposomes inside cells leads to a more 
heterogeneous suspension than a suspension containing mere Gd-liposomes, in which the 
liposomes can diffuse.  
 
Fig 7 Experiment 2. Line-chart depicting the effect of compartmentalization on ΔR1 (A) and ΔR2 (B) relaxation rate 
as a function of voxel Gd concentration ([Gdv ]) of several different Gd-suspensions (1.0 M): viable Gd-liposome la-
beled MSCs, non-viable Gd-liposome labeled MSCs, intact Gd-liposomes, ruptured Gd-liposomes and free Gd-DO3A- 
Butrol. Data are presented as mean ± SD (n=3 different samples, SD refers to intersample SD).
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Combined R1 and R2 effects: signal intensity
Similar to experiment 1, a simulated dose-dependent signal intensity curve of the 5 compart-
mentalization groups of Gd-liposomes was generated for a typical SE sequence (TR 500, TE 
10 ms) (Fig. 8). Naturally, free Gd-DO3A-butrol performs best with regard to the maximum 
SI, closely followed by lysed Gd-liposomes. Lysed Gd-liposomes outperform lysed Gd-lipo-
somes labeled cells in SI, obviously because of a slightly larger R1 effect.  A lysed state performs 
better in reaching a high SI (for both liposomes and cells) than an intact state, because of the 
combination of an increased R1 and a decreased R2 effect. 
Conclusions
Internalization of Gd liposomes has proven to be an efficient way to load cells with Gado-
linium (1,10,20). However, Gd can exhibit a dynamic contrast behaviour, eliciting a contrast 
effect anywhere in the range from hypo- to hyperintensity. This can be used advantageously 
as a qualitative measure of cell viability (47). As Gd can induce quenching effects as a result 
of either compartmentalization, liposome size, intraliposomal Gd concentration or R2 effects, 
we studied the relation between these parameters and signal intensity. Since the main effort 
in MRI-based cell tracking with Gd is to augment the sensitivity (21) e.g. by achieving a high 
Fig 8 Experiment 2. Simulated dose response of Gd-liposomes in various compartmentalization states. Typical SE se-
quence (TR 500, TE 10 ms) as a function of the voxel Gd concentration, [Gdv ]. Similar to Fig. 2, T2-relaxation results 
in signal loss at higher concentrations. There is significant signal intensity quenching for all compartmentalization states, 
compared to free Gd-DO3A-Butrol.
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payload of Gd per cell or a high r1 relaxivity of the used Gd contrast agent, we directed special 
interest to the high Gd concentration range (0.3-1.0 M Gd). We show here that an increasing 
intraliposomal Gd concentration (>0.3 M Gd) has a deteriorating effect on signal intensity, 
due to both a reduced r1 and increased r2 relaxivity. Internalization of the Gd-particles into 
liposomes creates an intraliposomal compartment with large r1 but small volume fraction and 
an extraliposomal compartment with large volume fraction but small r1. The final voxel signal 
intensity will thus be a combined result of the in- and efflux H2O rates, the H2O volume frac-
tions ratio of the compartments and R2 effects. Compartmentalization of Gd-liposomes in 
cells further compromises the maximum achievable signal intensity. 
Four main conclusions can be drawn.
Suspensions of Gd-liposomes with a lower intraliposomal [Gd] benefit from a higher vl /ve 
ratio (liposomal /extraliposomal H2O volume fraction), a lower relaxographic ‘shutter-speed’ | 
R1l – R1e| and a lower R2 effect resulting in less signal quenching. Less is more. However, even 
for the less concentrated 0.3 M Gd-liposomes, the water exchange rate across the liposomal 
membrane is still not high enough to distribute this high relaxivity over the entire voxel, result-
ing in signal quenching compared to free Gd. 
Smaller liposomes gain higher r1 relaxivity and higher SI due to the larger surface-to-volume 
ratio, resulting in a larger efflux H2O rate (κle ). Consequently water exchange across the lipo-
somal membrane is more efficient leading to a reduced quenching effect.
Concentrated liposome suspensions, i.e. containing high number of liposomes, are character-
ised by large R2 effects and reduced R1 effects, resulting in more signal quenching.
Compared to free Gd, compartmentalized Gd (in liposomes or cells) suffers from a decreased 
R1 and increased R2 effect, inducing signal loss and thus significantly contributing to the 
quenching effect. Especially in cell labeling studies where efforts are undertaken to augment 
Gd sensitivity, this effect needs to be taken into account. On the other hand, the versatility 
of contrast generation by encapsulated Gd can serve as a tool for read-out of functional cell 
status, since viable and lysed cells generate different contrast (10).
Understanding the underlying principles which lead to the observed results (i.e. the interplay 
between intra- and extraliposomal water fractions, the difference between the intra- and ex-
traliposomal relaxation rates and the increased R2 effect as a result of compartmentalization) 
allows one to tailor the optimal liposomal Gadolinium concentration according to the desired 
goal. 
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Assessment of transplanted cell viability by MRI
Abstract 
In cell therapy, noninvasive monitoring of in vivo cell fate is challenging. In this study we 
investigated possible differences in R1, R2 or R2* relaxation rate as a measure of overall cell 
viability of mesenchymal stem cells labeled with Gd-liposomes (Gd-MSCs) or iron oxide 
nanoparticles (SPIO-MSCs). Cells were also transduced with a luciferase vector, facilitating 
a correlation between MRI findings and cell viability using bioluminescence imaging (BLI). 
Viable Gd-MSCs were clearly distinguishable from nonviable Gd-MSCs under both in vitro 
and in vivo conditions, clearly differing quantitatively (ΔR1 and ΔR2) as well as by visual 
appearance (hypo- or hyperintense contrast). Immediately post-injection, viable Gd-MSCs 
caused a substantially larger ΔR2 and lower ΔR1 effect compared to nonviable MSCs. With 
time, the ΔR1 and ΔR2 relaxation rate showed a good negative correlation with increasing cell 
number following proliferation. 
Upon injection, no substantial quantitative or visual differences between viable and non-viable 
SPIO-MSCs were detected. Moreover, non-viable SPIO-MSCs caused a persisting signal void 
in vivo, compromising the specificity of this contrast agent. In vivo persistence of SPIO par-
ticles was confirmed by histological staining.
A large difference was found between SPIO- and Gd-labeled cells in the accuracy of MR 
relaxometry in assessing the cell viability status. Gd-liposomes provide a more accurate and 
specific assessment of cell viability than SPIO particles. Viable Gd-cells can be differentiated 
from nonviable Gd-cells even by visual interpretation. These findings clearly indicate Gd to be 
the favourable contrast agent in qualitative and quantitative evaluation of labeled cell fate in 
future cell therapy experiments.
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Introduction
In recent years, cell transplantation has evolved into a promising treatment option for a variety 
of diseases and disorders such as cancer, cardiovascular disease, neurodegenerative diseases, 
and musculoskeletal disorders. This field has clearly benefited from the technological advance-
ments in imaging sciences as the majority of clinical trials have involved the use of one or more 
imaging modalities to evaluate therapeutic efficacy of stem cell transplants (1-4). Molecular 
imaging techniques enable a complete assessment of the implanted stem cells (viability, prolif-
eration, migration, differentiation) and contribute to important insights into the mechanism 
of action of stem cells (5-6). However, not all preclinical visualization tools can be easily 
translated to clinical applications. One of the critical issues to address in cell transplantation 
is the noninvasive assessment of cell engraftment and survival in the long term. In pre-clinical 
research, investigation of cell viability usually requires the use of laborious ex vivo histological 
techniques. As histology provides only a snap-shot at a certain time point, an intra-individual 
longitudinal assessment of stem cell fate needs a different approach. The ability to noninva-
sively deduce basic functional information from cell transplants, would provide a powerful 
tool for evaluating therapy effect and initiate progress towards translational research.
MRI is a favourable imaging modality owing to its high spatial resolution, lack of use of ion-
izing radiation, excellent soft tissue visualization and functional information. Visualization of 
transplanted cells with MRI can be relatively easily accomplished by labeling the cells with 
MRI contrast agents (7). Until now, iron-oxide-based T2 contrast agents (CAs) (8-11) were 
considered the CA of choice, mainly given their high sensitivity. However, their use carries 
some serious limitations. Iron particles released from apoptotic cells will undergo re-uptake by 
locally attracted macrophages (12-18), causing a false-positive MRI signal. This is a relevant 
issue in imaging of cell transplants. For example, in cell grafting for repair of myocardial 
infarction, over 90% cell death occurs in the first 24 hours post-transplantation (19-21). Fur-
thermore, once iron particles have been cleared by macrophages, the magnetic label can be 
transferred to other cells of the monocyte/macrophage system and presumably also to many 
other cell types (22). This further complicates the iron clearance pathway, deteriorating the 
specificity of the MRI signal even more and clearly illustrating the difficulties in unambiguous 
identification of transplanted SPIO labeled cells. 
The use of the T1 CA Gd-DTPA might overcome these limitations. As macrophage endocy-
tosis is mainly size-dependent (13), it is hypothesized that the low molecular weight (500Da) 
Gd-DTPA molecule can escape macrophage re-uptake. Following labeled cell death, the swift 
diffusion of Gd will therefore increase the specificity of MRI signal read-out. Previously, it was 
shown that labeling with Gd-liposomes produces excellent MR visibility of mesenchymal stem 
cells (23). Remarkably, several studies reported a reduced longitudinal relaxivity following cel-
lular internalization of Gd in vitro (24-27). This ‘quenching’ is mainly caused by the decreased 
accessibility of H2O to compartmentalized Gd (28-29). To our knowledge, the ‘quenching’ of 
Gd hasn’t been studied in vivo up to now. We hypothesize that cell death, and the subsequent 
release and decompartmentalization of Gd will result in an increased T1 shortening in vivo.
The aim of this study was to assess whether the contrast characteristics of Gd- or SPIO-labeled 
cells can be used to extract information on overall cell transplant viability in vivo. For valida-
tion of MRI findings cells transduced with the luciferase gene were used for additional bio-
luminescence imaging (BLI) as well. As the activity of the luciferase enzyme is dependent on 
Mg2+, ATP and O2, it will be active in viable cells only, thus providing an excellent validation 
tool for cell viability assessment (30). 
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Material and Methods
preparation and characterization of liposomes
Gd-DTPA was incorporated in cationic liposomes using the lipid-film hydration technique, 
as described before (23). Briefly, a 100 μmol mixture of 1,2-dipalmitoyl-sn-glycero-3-phos-
phocholine (DPPC) (Lipoid GmbH, Ludwigshafen, Germany), cholesterol (Sigma-Aldrich, 
St. Louis, MO, USA), 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) (DOTAP) 
(Avanti Polar lipids, Alabaster, AL, USA) and rhodamine-PE (Avanti Polar lipids) in the mo-
lar ratio 47:33:20:0.1 was dissolved in chloroform-methanol, evaporated and hydrated in 
Gd-DTPA (Magnevist) (Bayer Schering Pharma AG, Berlin, Germany). Following extrusion 
through 200 and 100 nm filters and ultracentrifugation to separate nonencapsulated from 
encapsulated Gd, the liposome pellet was resuspended in 2 ml HEPES. 
Liposomal size was determined by dynamic light scattering (DLS) using a Zetasizer Nano 
(Malvern Instruments, Worcestershire, UK). The mean resultant size of Gd-DTPA liposomes 
was 101 nm with a polydispersity index (PDI) of 0.07. The zeta potential was 43±7.0 mV.
Liposomal phosphate content was assessed by spectrophotometric analysis according to Rouser 
(50). Relative Gd content was determined by inductively coupled plasma-optical emission 
spectroscopy (ICP-OES; Optima 4300DV, Perkin Elmer, Norwalk, CT, USA) operating at a 
wavelength of 342 nm) and was 66 ± 4 μg Gd/μmol total lipid.
Virus construction and production 
A self-inactivating lentivirus was prepared by transient transfection of HEK293T cells in 6 x 
19 cm dishes. Briefly, pND-Cag-Luc (60 μg per dish) was cotransfected into HEK293T cells 
with a mixture of pMDLg/pRRE (30 μg per dish), pMD2.G (15 mg per dish) and pRSV-Rev 
(15 μg per dish) packaging plasmids using polyethylemine.
Lentiviral supernatant was collected at 48 h and 72 h, filtered (0.45 mm) and concentrated by 
ultracentrifugation with a Beckman 45Ti rotor at 20K (4 ºC, 2 h). The pellet was then resus-
pended in 1ml phosphate-buffered saline (PBS). Mesenchymal stem cells (Millipore, Billerica, 
MA, USA) were grown to 50% confluency in a 24 well plate in DMEM/F10, 10% Fetal Calf 
Serum (FCS), penicillin/streptomycin (P/S) and infected with 50 μl lenti-viral stock, resulting 
in luciferase-expressing MSCs.
Cell Labeling and preparation
Fluc-MSCs of passage 2 or 3 were used for all experiments at 70% subconfluency. MSCs 
were cultured in Dulbecco's modified Eagle medium (Invitrogen; Carlsbad, CA, USA) supple-
mented with 2% FBS (Lonza; Basel, Switzerland), 2% penicillin-streptomycin (Invitrogen), 
2% L-glutamine (Invitrogen), 1% Modified Eagle Medium (MEM) essential vitamin mixture 
(Lonza), 1% Nonessential amino acids (NEAA) (Sigma-Aldrich; St. Louis, MO, USA) and 
0.5% glutamax (Invitrogen). 
Following two washing steps with PBS (Invitrogen, Breda, The Netherlands), the culture me-
dium was replaced by Optimem (Invitrogen). Cells were then labeled for 24 h with SPIO 
(Endorem™; Guerbet S.A., Paris, France) containing 100 μg Fe ml-1 culture medium (51) or 
with 125 μM Gd-liposomes for 4h (23). Labeling with 125 μM Gd-liposomes for 4h yields an 
intracellular Gd content of 30 ± 2.5 pg/cell, as reported before (23). Following labeling, cells 
were harvested by trypsinization, washed 3 times in PBS and centrifuged at 300 g for 5 min to 
discard of unincorporated contrast agent. 
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After centrifugation, cells were equally divided over two separate tubes and further processed 
to use as either viable cells or dead cells. Nonviable cells were obtained by repeated freeze thaw-
ing of one final suspension in liquid nitrogen. Cell death was assessed by Trypane Blue assay. 
For in vitro experiments, cell pellets were each suspended in Ficoll solution with a density of 
1.07 g mL-1, to prevent cell sedimentation during imaging (52). For in vivo experiments, the 
cell pellet was suspended in PBS. 
MRI and BLI phantom studies
From the same stock of cells serial dilutions containing live or dead cells were suspended in 50 
μl Ficoll and transferred to a 96-well plate (BLI phantom). Surrounding wells were filled with 
water to prevent susceptibility artifacts owing to air and/or very concentrated samples. 
MRI data were acquired by using a 3 T clinical scanner (Signa Excite; GE Medical Systems, 
Milwaukee, WI, USA) with unmodified gradients and custom made surface coils (inner diam-
eter of 5 cm). Spin echo (SE) sequences with multiple TR (100 - 2800 ms; echo time (TE) 10 
ms) and multiple TE (10-100 ms; TR 600 ms) were used to obtain T1 longitudinal relaxation 
times and T2 transverse relaxation times, respectively. T2* transverse relaxation times were ob-
tained with a 3D gradient echo sequence (GRE) (matrix = 234 x 234, slice thickness = 0.7 mm 
and number of excitations (NEX) = 2, using lower TEs (3-36 ms). Sequences were acquired 
with a field of view (FOV) = 5.0 x 5.0 cm2, matrix = 160 x 160, slice thickness = 1.4 mm and 
NEX = 2. To calculate T1, T2 and T2* times, we used two independent methods: An in-house 
developed algorithm script for Matlab (version R2007b) and an Image J plugin (MRI analysis 
calculator by Karl Schmidt). The MRI analysis calculator has been used previously by other 
authors (53,54). Relaxation times were calculated as follows:
refx
x TT
R
1
1
1
11 -=Δ [1]
In which T1cells, represents the T1 of the cell cluster (both in vitro and in vivo) and T1ref the T1 
of the surrounding wells containing Ficoll (in vitro) or of normal muscle (in vivo). The same 
equation was applied to derive the ΔR2 and ΔR2* using T2 and T2*, respectively. T1ref and 
T2ref in vitro were assessed to be 3100 ± 120 ms and 167 ± 18 ms respectively. T1ref and 
T2ref in vivo were assessed to be 1500 ± 91 ms and 36 ± 7.0 ms respectively. A voxel-by-voxel 
linear least squares fit of the natural logarithm of the signal amplitude versus at least 6 echo 
times (TE) was performed to construct R2 and R2* maps. For R1 maps at least 6 repetition 
times (TR) were used. 
For BLI phantoms, luciferase activity of Fluc-MSCs was measured by using the Xenogen IVIS 
Spectrum (Caliper LS, Hopkington, MA, USA) 10 min after the addition of D-luciferine at a 
final concentration of 50 μg μl-1 (integration time 10, 20, 30, 40, 50, and 60 s; f/stop 1; bin-
ning medium; field of view B). Optical intensity is reported as photons/second/area/steradian 
(p/s/cm2/sr). Data were analyzed with the software Living Image version 3.2 (Caliper LS). 
Cell Transplantation and In Vivo imaging
All animal experiments were conducted in compliance with dutch law and with the approval 
of the Institutional Animal Welfare Committee. Animals were provided with food and water 
ad libitum. All animal procedures were performed under anesthesia by inhalation of 2% iso-
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flurane (Baxter Healthcare, Deerfield, IL, USA)-oxygen mixture. Wistar rats (4-6 weeks) were 
obtained from Harlan (Horst, the Netherlands) and were allowed to acclimatize at the Eras-
mus MC vivarium for 1 week prior to cell injection.
Viable or dead Fluc-MSCs (5 x 106) labeled with Gd-liposome or SPIO were administered 
in the lower back by intramuscular injection (50 μl). The location of injection was properly 
marked on the skin.
In vivo studies
For T1, T2 and T2* mapping purposes the same sequences were used as in vitro. Formula (1) 
was applied, except that T1, T2 and T2* values from healthy spinal muscle were used as refer-
ence instead of Ficoll. BLI was performed from 5 min after intraperitoneal (i.p.) injection of 
D-luciferine (Promega) for 1h. Animals were scanned repeatedly over a two-week period at days 
0, 2, 5, 10 and 15. 
Immunohistochemistry
At end of follow up, muscular tissue at the injection site was carefully resected. Injection sites 
were identified by the markings on the skin. BLI imaging and macroscopic visual examination 
were further used to confirm the site of injection. Briefly, tissue was transferred to 4% para-
formaldehyde, transferred to 30% sucrose for 1 day, followed by immersion in OCT (Tissue-
TEK). Tissue was cryo-sectioned to obtain 10 mm-thick samples. Sections were stained for 
iron using Perl’s iron stain (Klinipath BVBA, Duiven, the Netherlands) and counterstained 
with hematoxylin (Sigma-Aldrich). 
Gd and SpIO In Vitro and ex Vivo Measurements
The total amount of cellular internalized SPIO or Gd content was measured by ICP-OES in 
three 20 μl aliquots of a SPIO- and Gd-labeled MSC stock solution, respectively. Aliquots 
were suspended in 4 ml. Triton X-100 2% (St. Louis, MO, USA), heated up at 55 °C and 
mixed for 30 min at 6 g to induce cellular and liposomal lysis. Cellular content of the CA was 
calculated as:
cells
pellet
cellular N
CA
CA = [2]
To measure the amount of retained Gd in the injected muscle, ICP was performed on the 
ipsi- and contralateral muscle as well. For this purpose, muscle was dissected in small pieces, 
and crushed in a microdismembrator. Crushed tissue was resuspended in 1% Triton/PBS, 
lyophilized and finally digested using HNO3 and H2O2 at 110 °C. 
Data analysis
All values are presented as mean±SD from at least triplicate samples and expressed in relation 
to unlabeled cells. For correlation assessment Spearman r coefficient was determined (Graph-
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pad InStat 3.06; Graphpad Software Inc., San Diego, CA, USA). The degree of significance is 
given when appropriate (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
Results
In vitro contrast behavior
A Trypan Blue exclusion test showed the actual death rate of cells, rendered non-viable by 
repeated freeze thawing, to be 99% (Fig. 1). Non-viable cells remained largely intact. In addi-
tion, to confirm the specificity of BLI for viable cells, photon emission by dead cells was shown 
to be absent (Fig. 2a,b). Linear regression analysis showed the amount of emitted photons and 
the number of viable cells to be linearly proportional (Fig. 2b). These findings supported the 
use of BLI as a validation tool for our MR results.
Heavily concentrated samples of viable Gd-MSCs (mesenchymal stem cells) generated a signal 
void (hypointensity) on MR images, an effect which is known as ‘quenching’ (Fig. 3a). In con-
trast, similar concentrations of nonviable Gd-MSCs generated a bright signal (hyperintensity) 
allowing them to be visually distinguished from viable Gd-MSCs. 
The ΔR1 (Fig. 4a) and ΔR2 (Fig. 4b) relaxation rate were found to be linearly proportional to 
the Gd-labeled cell amount across the entire range of cell numbers studied, thus allowing the 
Fig. 1 Light microscopy 
image showing Trypan Blue 
exclusion test on Gd-lipo-
some labeled MSCs prior 
to transplantation. Viable 
Gd-MSCs (a) exclude the 
Trypane Blue dye, whereas 
nonviable MSCs (b) stain 
blue due to membrane dis-
integrity.
Fig. 2 Bioluminescence imaging of a 1:1 serial dilution of a stock of 5*105 unlabeled Fluc-MSCs. BLI image showing 
signal from viable MSCs (rectangular box) and the absence of signal from non-viable MSCs (dashed rectangular box) (a). 
Total amount of captured photons was linearly proportional to MSC concentration (b).
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Fig. 3 MR-imaging of in vitro serial dilution series of viable (undashed boxes) vs non-viable (dashed boxes) labeled 
MSCs at 3.0T. T1-weighted image of Gd-liposomes labeled MSCs, varying in concentration from left to right 1.65*105, 
8.3*104, 4.1*104, 2.1*104, 1.0*104 and 5.1*103 MSCs μl-1 Ficoll (a) and T2-weighted image of SPIO-labeled MSCS 
varying in concentration from left to right 1.65*105, 8.3*104, 4.1*104, 2.1*104 and 1.0*104 MSCs μl-1 Ficoll (b). Scale 
bar represents 10 mm and applies to both (a) and (b). 
Fig. 4 ΔR1 (a), ΔR2 (b,c) and R2* (d) as a function of Gd or SPIO labeled cell density. The longitudinal r1 (a) and trans-
verse cellular r2 relaxivity (b,c) were obtained by a linear fit of the data. Data are presented as mean ± SD (n=3 different 
samples, SD refers to intersample SD).
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Fig. 5 Dual modality longitudinal imaging of MSCs transplanted in the lower back muscle. Imaging of SPIO-MSCs (a) 
and Gd-MSCs (b) on T2-weighted FSE (TE 120 ms, TR 3000, NEX 4) T1-weighted SE (TE 10 ms, TR 1200 ms) and 
T2*-weighted GRE (TE 8 ms, TR 50 ms, α 16º) images. BLI shows considerable viable cell proliferation, visible on MRI 
as a gradual decrease (Gd-MSCs) and increase (SPIO-MSCs) in signal intensity.
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measurement of the relaxivity per cell. The r1 and r2 cellular relaxivities (r1Ø respectively r2Ø) 
were determined from the slopes of the regression lines of the R1 and R2 relaxation rates against 
cell number. For viable Gd cells this yielded an r1Ø of 2 x 10-7 s-1 cell-1 and r2Ø of 4 x 10-6 s-1 cell-1. 
For non-viable Gd-cells r1Ø and r2Ø were 5 x 10-7 s-1 cell-1 and 1 x 10-6 s-1 cell-1, respectively.
As both viable and nonviable SPIO-MSCs (Fig. 3b) generated a signal void, a viability assess-
ment based on mere visual distinction was not possible. Moreover, T2 and T2* measurements 
showed no substantial difference in the ΔR2 (Fig. 4c) or ΔR2* (Fig. 4d) relaxation rate between 
viable and nonviable SPIO-MSCs. For both viable and non-viable SPIO-MSCs r2Ø was assessed 
to be 2 x 10-4 s-1 cell-1. The r2* Ø relaxivity for viable SPIO-MSCs was 9 x 10-6 s-1 cell-1 and for 
nonviable cells it was 0.1 x 10-6 s-1 cell-1.
Longitudinal in vivo contrast behavior
As expected, nonviable MSCs from both groups did not generate bioluminescent signal in vivo 
(Fig. 5a, b). All injected cell grafts were clearly visualized on MRI following injection (Fig. 5a, b). 
Optimized T1, T2 and T2*-weighted sequences were used to cover the entire range of cell visibil-
ity during the follow-up time and cell division. SPIO-MSCs caused a signal void (hypointensity), 
regardless of the cell viability (Fig. 5a). In the acute post-transplantation stage, no substantial 
differences in visual appearance or R2 and R2* values were detected between viable and non-
viable SPIO-MSCs (Fig. 7a,b). Over time, the number of detected photons increased at the site 
of viable cells injection (Fig. 5). In parallel, a substantial drop in ΔR2 relaxation rate from viable 
SPIO-MSCs (23 ± 11 s-1) occurred from day 5 onwards (Fig. 7a), whereas ΔR2 from nonviable 
cells was virtually unchanged (65 ± 7 s-1 at day 14 vs 78 ± 8 s-1 at day 0; Fig. 7b). Signal void 
from viable SPIO-MSCs was barely visible on T2-weighted scans at day 15, except for a small 
hypointense core on both T2 and T2*-weighted scans (Fig. 5a). This increase in signal intensity 
was accompanied by an increased bioluminescence signal.
Viable Gd-MSCs showed a different dynamic signal behavior. Immediately post-transplantation, 
 they were consistently detected as a hypointense area on T1-weighted scans (‘quenched signal 
intensity’), whereas a similar density of nonviable Gd-MSCs resulted in increased signal inten-
sity (hyperintensity) at the injection site (Fig. 5b). In contrast to SPIO-MSCs, hyperintense 
Fig. 6 In vivo measurement of the ΔR2 and ΔR2* relaxation rate of SPIO-MSCs. The ΔR2 effect from viable SPIO-
MSCs gradually decreased over time, accompanied by an increasing BLI signal. Non-viable cells displayed a marginal 
decrease in ΔR2 over time. Data are presented as mean ± SD (n=6 rats, SD refers to inter animal SD).
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signal from nonviable Gd-MSCs had already resolved already after 2 h post-transplantation 
(data not shown). In addition, substantial differences in R1 and R2 relaxation rates between 
viable and nonviable Gd-MSCs (Fig. 6) were measured as well. At day 0, the ΔR1 effect (0.5 
± 0.2 s-1; Fig. 7a) of viable Gd-MSCs was nearly half of the ΔR1 from non-viable MSCs (0.9 
± 0.3 s-1; Fig. 6b), while causing a substantially larger ΔR2 effect (66±26 s-1;Fig. 6c) compared 
with nonviable MSCs (0.6 ± 2.9 s-1; Fig. 6d). Both the ΔR1 and ΔR2 relaxation rate correlated 
very well with the increasing cell number following proliferation (Spearman r correlation coef-
ficient 0.89 and 0.90, respectively; p < 0.05). T1ref and T2ref (the T1 respectively T2 of normal 
muscle tissue) were assessed to be 1500 ± 91 ms and 36 ± 7.0 ms respectively.
Retention of Contrast Agent Gd 
The retrieved amount of Gd from viable cells was 84 ± 10% of the injected amount. Of the ini-
tially injected Gd amount 9 ± 2% was retrieved at sites of transplanted nonviable cells (Table 1). 
Red fluorescent signal from Gd-liposomes was not detectable at sites where non-viable Gd-MSCs 
Fig. 7 In vivo measurement of R1 and R2 relaxation rate of Gd-MSCs. Upon injection, viable Gd-MSCs cause a sub-
stantially larger ΔR2 but smaller ΔR1 effect than non-viable Gd-MSCs. ΔR1 and ΔR2 relaxation rate correlated well with 
the increasing cell number (Spearman r correlation coefficient 0.89 and 0.90 respectively, p<0.05). Data are presented as 
mean ± SD (n=6 rats, SD refers to inter animal SD).
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had been injected. Viable transplanted Gd-MSCs were clearly identified at the site of transplan-
tation at day 15 by the blue Hoechst dye and the perinuclear red dye from liposomes (Fig. 8).
At sites of injection with nonviable SPIO-MSCs, iron was shown to be still present (Fig. 9), in 
close proximity to post-injection hemorrhages.
Discussion
Molecular imaging has rapidly become a necessary tool for the validation and optimization of 
stem cell engrafting strategies in preclinical and clinical studies. One of the most critical and 
unresolved issues is the noninvasive assessment of the survival and proliferation of cells after 
implantation. Several available approaches using reporter genes allow the in vivo monitoring 
of cell survival, monitored by either MRI (31,32), bioluminescence (30) or nuclear techniques 
such as PET/SPECT (33,34). The reporter gene technique however, being quite invasive, can-
not be easily translated to the clinical arena. Therefore we sought to investigate a minimally 
invasive labeling technique that reflects the actual viability of labeled cells, and validated it by 
BLI. 
A future translation of MRI-based cell tracking to clinical medicine will require an excellent 
sensitivity and specificity of the contrast probe or an acceptable trade-off between these two 
requirements, depending on the application. High sensitivity might be essential to investigate 
Fig. 8 Histological detection of cells labeled with rho-
damine containing Gd-liposomes, in skeletal muscle 
tissue (day 15 post-transplantation). Red fluorescence 
from the rhodamine-liposomes is clearly visible as is the 
blue nuclear dye Hoechst, add-ed to the cells in culture 
prior to injection. Inset shows a 10x magnification of the 
area indicated by the rectangle.
Fig. 9 Histological detection of skeletal muscle tissue 
(day 15 post-transplantation), priorly transplanted 
with non-viable SPIO-MSCs. Perl’s iron stain shows 
iron (black  arrows) to be still present, in close proxim-
ity of erythrocytes (white arrows).
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the long-term fate of implanted stem cells, since probe dilution upon cell proliferation reduces 
the detection capabilities. Alternatively, a high specificity is demanded by applications such as 
cellular transplantation, to detect cell graft rejection at an early stage. 
In the current study we have shown Gd to be more specific than SPIO nanoparticles. Irrel-
evant signal from non-viable Gd-MSCs resolved already 2 h post-transplantation (data not 
shown) while at the original injection site of nonviable SPIO-MSCs hypointense MRI signal 
persisted for at least 15 days. In a recent study by Baligand et al., it was reported that even 95 
days post-transplantation, false-positive SPIO signal was still detectable in immunorejected 
grafts (35). Terrovitis et al. concluded that MRI of iron oxide-labeled stem cells is not a reliable 
technique for quantifying engraftment in the heart because of the considerable residual signals 
generated by the persistence of iron-laden tissue macrophages after cell death (17). Reuptake 
by macrophages of previously released SPIO seems to play a major role in this phenomenon 
(12-16). Specificity is a very important issue, especially in direct injections, involving high 
cell mortality rates; it would lead to massive release SPIO followed by macrophage uptake, 
thereby severely increasing the amount of false positives (decreased specificity). In contrast, as 
a result of its biological short half-life and low molecular weight (36,37), the vast majority of 
extracellular complexed Gd will diffuse out rapidly to end up intravascularly, followed by renal 
excretion (38). Theoretically it is thus less likely that complexed Gd released by injected dead 
cells undergoes reuptake by surrounding phagocytic cells. This is in line with our observations 
that only a fraction of the initially injected Gd quantity, contained in nonviable MSCs, was 
retrieved at the site of injection at day 15 (Table 1).
The intrinsic lower sensitivity of Gd, in comparison with SPIO, has been one of the main rea-
sons for its limited use for cell tracking purposes (39). However, we observed that viable Gd-
MSCs still generated sufficient hyperintense contrast up to at least 10 days post-transplantation. 
At day 10 viable SPIO-MSCs no longer caused a pronounced signal loss. A small hypointense 
core remained though, which contributed to a still significant ΔR2 value of the whole cell clus-
ter area. Loss of hypointensity (increase in signal intensity) is known to be caused by dilution 
owing to cell proliferation, which was confirmed by our bioluminescence and MRI data, show-
ing a substantial cell number increase. An additional disadvantage of SPIO was reported in a 
study by Walczak et al. (40), stating that accelerated SPIO dilution occurs in highly proliferat-
ing cells as a result of iron metabolism in the physiological cellular pathways (41). This effect 
has very likely played a role in the current study as well. The fact that Gd is not metabolized in-
tracellularly can therefore be a major incentive to use Gd instead of SPIO, especially for highly 
proliferating cells. Baligand et al. reported the detection of Gd-myoblasts up to 2 weeks (35). 
In that study, however, the amount of Gd retained intramuscularly was not reported and no 
correlation was made with cell death or cell proliferation. Hence it was not clear whether Gd 
signal decay was due to either the effective elimination of released Gd from dying cells (high 
specificity) or proliferation-induced Gd-dilution (low sensitivity) or a combination of both. 
The cell proliferation, as perceived by the increased mass effect of viable cells on MRI, the con-
secutive contrast dilutions and concurrent bioluminescence data, indicates towards a tumoral-
like behavior of the cells used in this study. It is unclear as to why this happened, but the intro-
duction of the luciferase construct may have contributed to this effect. For our study purposes, 
this proliferation was surely not a detrimental effect, as it allowed us to study the effect of fast 
proliferation on MRI contrast appearance. However, for a future translation to clinical stem 
cell therapy, it is undebatable that this tumor-like behavior is a major drawback. Luciferase-
transfected cells will certainly not be used in the clinical practice, probably eliminating already 
one of the risk factors for tumor transformation. Nonetheless, before proceding to the clinical 
stage, the malignant potential of any cell to be used for cell transplantation has to be ruled out. 
Several reports exist on the quantitative differentiation of cell-bound SPIO from free SPIO 
(as may occur after cell death), making use of either the R2 and/or R2* transverse relaxation 
rate. According to Kuhlpeter et al. compartmentalized, cell-bound SPIO causes a larger R2* 
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than free SPIO (42). The opposite effect was described in a recent study by Henning et al. 
(43), reporting a statistically significant difference in T2 transverse relaxation time between 
viable and nonviable lysed cells, but not in T2*. In the latter study, however, differences were 
reported only in vitro and could not be reproduced in vivo in arthritic joints. These differences 
in quantification results can be attributed to the somewhat complex nature of SPIO quanti-
fication. Quantification of SPIO-labeled cells is not straightforward. R2 relaxation rate is not 
only dominated by the iron content but also by the distribution of iron within a voxel (44-46). 
Quantification of the R2* relaxation rate on the other hand can be hindered by macroscopic 
susceptibility artifacts arising from air-tissue interfaces (47). Supposing that free SPIO can 
indeed be differentiated quantitatively from intracellular incorporated SPIO, this feature will 
be useless to distinguish between viable and nonviable cells as soon as bystander macrophages 
enter the transplantation site to engulf the free SPIO particles, released by non-viable cells. In 
the current study, our T2 measurements showed no substantial difference in the ΔR2 relax-
ation rate between viable and nonviable SPIO-MSCs. This was not unexpected as changes in 
T2 are governed for a large part by decompartmentalization of SPIO particles. Although cells 
had been freeze-thawed multiple times, they remained relatively intact. As SPIO particles are 
significantly larger than low molecular weight Gd, it seems unlikely that early in the cell death 
process SPIO particles will diffuse out. In later stages of cell death with concurrent cell frag-
mentation, SPIO particle decompartmentalization will start to affect R2 and/or R2*. 
  In this study we showed that Gd-MSCs exhibit a distinct relaxivity as a direct result of the cell 
viability both in vitro and in vivo, nonviable Gd-MSCs having a virtually absent R1 and R2 re-
laxation rate. Recalling that Gd-MSCs ΔR1 and ΔR2 relaxation rate correlated very well with 
the increasing cell number following proliferation (r 0.89 and 0.90, respectively; p < 0.05), Gd 
labeling of MSCs can thus very well be used as a tool to track cell fate in vivo. 
Of interest, viable Gd-MSCs showed a concentration dependent signal intensity be-
havior (Fig 3a); It is a known phenomenon that at higher Gd concentrations (irrespec-
tive of compartmentalization) Gd produces a substantial T2 effect (T2 time shortening) 
(48). This shortened T2 time subsequently produces a decreased signal intensity (‘sig-
nal quenching’), as can be derived from the Bloch equation SI= Mz(1-e
-TR/T1)e-TE/T2 (48). 
Again, this signal quenching was observed with viable Gd-MSCs directly post-transplantation. 
This allowed for a clear visual distinction of viable from nonviable cells, making this a valuable 
qualitative tool for fast read-out of cell fate. This quenching occurred in vitro as well, but at 
a higher cell density. This is believed to be due in part to differences in water availability, dif-
fusivity and concentration effects in vivo. Even when cells are being transplanted at a similar 
concentration as in vitro, the density of grafted cells in vivo will increase because of tissue pres-
sure, resistance and liquid resorption, resulting in an increased Gd load per voxel. Proliferation 
will inevitably result in cellular Gd dilution and thus a decreased Gd load per voxel, referred to 
as ‘dequenching’. In the current study this was observed as a hypointense quenched cell graft 
core, with peripheral hyperintensity. As for the striking contrast difference between viable and 
nonviable Gd-MSCs a plausible explanation is the following. Gd exerts its T1-shortening effect 
(i.e. R1 increase) by interacting with surrounding water molecules. It can thus be understood 
that it will be challenging for water to reach Gd that resides in endosomes inside viable cells 
with an intact membrane. Furthermore, efflux of Gd from viable cells will be highly unlikely. 
This ‘quenching’ effect  as a result of cellular Gd compartmentalization was reported previously 
by Terreno et al. (27). Similarly, in another study by Biancone et al. (49) an initial increase 
in signal intensity of endosomally contained Gd-HPDO3A was reported. This was explained 
to occur as a result of intracellular redistribution after endosomal degradation. We mimicked 
the compartmentalization effects in vitro (Fig. 4), comparing viable intact cells with nonviable 
leaky cells. Interestingly, our measurements confirmed that both ΔR1 (decrease; Fig. 4a) and 
ΔR2 (increase; Fig. 4b) are affected by compartmentalization, causing the typical Gd signal 
‘quenching’ in viable cells. ‘Quenching’ by viable Gd-cells can thus be explained by a decrease 
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in the ΔR1/ΔR2 ratio. Nonviable cells however, allowing both an efflux of Gd and/or influx of 
water molecules more easily, will exhibit an increased ΔR1/ΔR2 ratio. Quantification methods 
based on T1 or T2 may provide a valuable but laborious and time-consuming tool, both on the 
data acquisition side as well as on the data processing side. Clearly, this is not a relevant disad-
vantage for research applications. However, for a successful translation to clinical practice, where 
time-efficiency is of utmost importance, a qualitative, fast and visually interpretable tool is key. 
In this paper, we made use of Gd to allow for a nonambiguous distinction between cell death 
and viability. A combined interpretation of the quantitative (ΔR2/ΔR1) and qualitative find-
ings (contrast changes) may present an important noninvasive tool to track the actual cell 
fate of transplanted cells in real time, using mere MRI. In fact, visual evaluation of contrast 
changes from Gd-cells, allows us to assess overall cell viability of a transplanted cell graft. Sum-
marizing, to make statements on the overall cell viability and fate of a transplanted cell cluster, 
this means that a visible hypointense signal reflects viable cells; ‘dequenching’ (hypointense 
to hyperintense contrast) indicates cell proliferation; the persistent visibility of hyperintense 
signal indicates the ongoing presence of viable cells; quick appearance of hyperintense signal 
followed by consecutive quick disappearance indicates cell death; slow decrease in hyperin-
tense signal indicates ongoing cell proliferation. These may be considered as rough rules of 
thumb. Most important, as long as contrast is seen on T1W images, there is still a substantial 
overall cell viability of the cell cluster. For a more detailed cell fate evaluation a correlation to 
R1 and R2 values remains essential. Nevertheless, as a result of the high specificity, these rules 
of thumbs may prove beneficial in a clinical setting, for example, when immediate monitor-
ing of cell graft rejection is needed. To our knowledge, our study is the first to report the Gd 
quenching effect as an easy to interpret qualitative tool for cell viability assessment.
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Cell tracking in cardiac repair (review)
Abstract 
Stem cell therapies hold the great promise and interest for cardiac regeneration among scien-
tists, clinicians and patients. However, advancement and distillation of a standard treatment 
regimen are not yet finalised. Into this breach step recent developments in the imaging biosci-
ences. Thus far, these technical and protocol refinements have played a critical role not only 
in the evaluation of the recovery of cardiac function but also in providing important insights 
into the mechanism of action of stem cells. Molecular imaging, in its many forms, has rapidly 
become a necessary tool for the validation and optimisation of stem cell engrafting strategies 
in preclinical studies. These include a suite of radionuclide, magnetic resonance and optical 
imaging strategies to evaluate non-invasively the fate of transplanted cells. In this review, we 
highlight the state-of-the-art of the various imaging techniques for cardiac stem cell tracking 
presenting the strengths and limitations of each approach, with a particular focus on clinical 
applicability.
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Introduction
In the last decade a great amount of research and clinical interest has been directed at stem 
cells (SC) for their potential to regenerate otherwise permanently damaged tissues. Work with 
these pluripotent cells has begun to be broadly explored, giving new hope for regenerative ap-
proaches in the therapy of myocardial infarction (MI).
Early success in preclinical studies demonstrated that stem cell-based therapy holds the po-
tential to limit the functional degradation of cardiac function after MI (1). This instigated 
clinical translation at a rapid pace (Table 1). Since the first study in 2002 which showed safety 
and effectiveness on intracoronary transplantation of autologous SC (2), several randomised, 
controlled clinical trials have been performed. Due to the absence of standardised protocols 
(cell number, timing and route of injection, baseline patient characteristics and techniques 
of evaluating cardiac function), results have been mixed. However, recent metaanalyses have 
shown that improvement in ejection fraction (EF), ventricular dimension and infarct area, 
despite being modest, are statistically significant (3-5).
This field clearly benefited from the advancements in imaging sciences as almost all clinical 
trials involved the use of one or more imaging techniques to evaluate the therapeutic efficacy 
of stem cell transplantion. Clinically established techniques allow for the evaluation of myo-
cardial contractility, viability and perfusion, but do not provide the direct visualisation of 
transplanted stem cells, therefore their effective presence and viability can be only presumed. 
Ideally, transplanted cells in the infarcted myocardium are expected to survive engraftment, be 
self-renewing and differentiate into cardiac cells (cardiomyocytes, endothelial cells or smooth 
muscle cells) forming electromechanical junctions with adjacent viable tissues. However, the 
longterm improvement appears to be most closely related to paracrine effects rather than trans-
differentiation of the cell transplant and heart muscle regeneration (6).
Great strides in imaging techniques and technologies have been made that enable the cellular 
and molecular imaging of transplanted stem cells, their short and long term fate and in some 
instances their viability and differentiation status.
Stem cells for cardiac repair
Currently adult stem cells, embryonic stem cells (ESC) and induced pluripotent stem cells 
(iPS) can be used to regenerate heart tissue. Adult stem cells comprise skeletal myoblasts (SM), 
mesenchymal stem cells (MSC), bone marrow-derived stem cells (BMC), endothelial (EPC) 
and cardiac progenitor (CPC) cells. SM were the first option to be used in stem cell transplant 
as they are available from an autologous source (therefore lacking ethical or immunogenicity 
issues), and have been demonstrated to provide functional benefit after myocardial infarction 
in animals (7). However, in a recent clinical trial no sustained benefit in the global EF was 
observed and increased number of early postoperative arrhythmic events was reported (8).
BMC transplantation has been shown to improve heart function in animal models (1,9). How-
ever, others have identified that most of the cells injected adopted a mature haematopoietic 
transformation and only a small number of cardiomyocytes expressed the genetic markers of 
the transplanted cells (10,11). Mesenchymal stem cells (MSC) constitute the stromal compart-
ment of bone marrow and, importantly, are not hematopoietic. These are able to differentiate 
into a variety of cell types (12) and improvement in whole heart function has been described 
in a swine model of myocardial infarction (13). Visceral and subcutaneous adipose tissue have 
been shown to contain vascular/adipocyte progenitor cells and adult multipotent mesenchy-
mal cells (adipose tissue-derived stromal cells ( 14)). ASC have been reported to improve left 
ventricular function in animal models of myocardial infarction (15). The circulating endothe-
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lial progenitor cells (EPC) represent a more accessible source of autologous SC and have been 
used in clinical trials (16]. The existence of a subpopulation of resident cardiac SC (RCSC) has 
been reported that is self-renewing, clonogenic and multipotent, capable of differentiating in 
myocytes, smooth muscle and endothelial cells (17). Promising results have been reported in 
preclinical studies (18), and results of phase I clinical trials, started in 2009, are awaited with 
interest.
To date, ESC-derived cardiomyocytes (19) and ESC-derived endothelial cells (20) have been 
successfully used to treat heart disease in animal models. However several problems are related 
to their use, including immunological incompatibility with the host (21), the tendency to 
form teratomas (22) and ethical controversies. Several studies have been performed to ma-
nipulate the expression of transcription factors with the goal of transforming somatic cells 
(derived from an autologous source, such as keratinocytes and fat stromal cells) into induced 
pluripotent stem cells (iPS) (23). These cells possess the same advantages as ESC, without the 
associated immunological and ethical complications. Cardiomyocytes have been successfully 
obtained from iPS in vitro (24) and their transplantation in animal models of infarction re-
sulted in improved myocardial function (25).
To summarise, ESC and iPS have the greater potential for cardiomyogenesis, while the for-
mation of new cardiomyocytes by transdifferentiation of SM and BMC has so far not been 
supported with convincing evidence. It should be noted that several studies have reported 
moderate improvements in whole cardiac function after transplantation of SM and BMC 
(7,26). It has been demonstrated that SCs are responsible for paracrine effects, consisting of 
the release of various cytokines or growth factors (eg. VEGF, bFGF) that increase collateral 
perfusion and neoangiogenesis and influence the contractile characteristics of chronically fail-
ing myocardium (26).
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Cell tracking in cardiac repair (review)
Imaging of stem cell
The ability to image and monitor the biodistribution, viability and possibly the differentia-
tion status of implanted SCs is of massive clinical and research benefit. All of the preclinical 
and clinical imaging techniques have been leveraged towards this goal; each providing unique 
advantages and limitations. Figure 1 illustrates the major paradigms for the labeling of SC for 
detection by the various imaging approaches. Table  2 reports the most important preclinical 
studies in the field. Table  3 summarises the most relevant features of each imaging technique.
 
MRI
Magnetic resonance imaging (MRI) is a widely established technique for the evaluation of 
cardiac anatomy and function, often through the addition of paramagnetic contrast material 
(27). Taking advantage of its excellent spatial (10–100 μm [small animal MRI]); 500–1500 
μm [clinical]) and temporal resolution SC labeled with superparamagnetic and paramagnetic 
agents can be visualised (28,29). Multispectral non-1H MR imaging (specifically 19F) has also 
been exploited to enable tracking of transplanted cells.
 
Superparamagnetic iron oxide nanoparticles
Superparamagnetic iron oxide (SPIO) nanoparticles provide labeled cells with a large magnetic 
moment and are detectable by MR imaging devices or benchtop relaxometers. SPIO func-
tions by acting as magnetic inhomogeneities, locally disturbing the magnetic field. This leads 
to enhanced dephasing of protons, resulting in decreased signal intensity on T2-weighted 
and T2*-weighted images (Figs. 2 and 3). These nanoparticles often consist of a core of iron 
oxide (magnetite and/or maghemite) with a polymeric or polysaccharide coating. They are 
widely viewed to be biocompatible, have a limited effect on cell function and can be synthe-
sized to be biodegradable. According to their size (diameter), these are classified as ultrasmall 
paramagnetic iron oxide (USPIO, <10 nm), monocrystalline iron oxide particles (MION, or 
crosslinked CLIO; 10–30 nm), standard superparamagnetic iron oxide (SPIO; 60–150 nm) 
and micronsized iron oxide particles (MPIO, 0.7–1.6 μm). Of note, ferucarbotran (Resovist®; 
Bayer Schering Pharma, Berlin, Germany) and ferumoxides (Feridex I.V.®, Advanced Magnetic 
Industries, Cambridge, Maryland, USA; Endorem®, Guerbet, Gorinchem, the Netherlands) 
have been approved by the FDA for contrast enhanced-MRI imaging of liver tumors (30) and 
metastatic involvement of lymph nodes (31).
Cell uptake is mediated through the size and electrostatic charge conditions of the SPIO (32), 
schematically illustrated in Fig. 1a. Further, loading can be augmented through the addition 
of cell penetrating peptides, electroporation or transfection agents (33).
Studies reported that SPIOs do not affect cell viability, proliferation, differentiation or mi-
gration (34-38). However, recent work has raised several concerns, such as decreased MSC 
migration and colony-formation ability (39), and interference with cell function (40,41). A 
major issue beyond potential cellular effects is the question of contrast specificity to the pres-
ence of cells. Namely, the hypointense signal is maintained at a site regardless of cell viability 
and SPIO are present not necessarily within implanted SC at longer time points (42), but 
rather in phagocytosing monocytes following SC death (43). Recently, Winter et al. reported 
the absence of any discrimination between healthy successfully engrafted SC and dead SC 
phagocytosed by macrophages within the heart. In particular, no differences in signal voids up 
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Fig. 2 Anatomical and functional MR evaluation after transplantion of adipose-derived stem cell (ASC) and relative 
controls: cell culture medium (CCM), and untreated hearts. The CCM-treated and untreated hearts showed evident 
thinning in the anterior wall of the left ventricle. From Wang, L. et al. Am J Physiol Heart Circ Physiol 297: H1020-
H1031 2009 (15) (with permission)
Fig. 3 Longitudinal BLI and MRI of H9c2 cells after transplantation. BLI shows a robust distinct heart signal on day 1 
(red arrow), compared to no discernable signal in a representative control rat having received non-labeled cells (top panel, 
left). The signal increases slightly on day 3 but decreases rapidly to near background levels by day 6. MRI imaging of a 
representative rat injected with the same amount of cells labeled with Feridex shows a large hypointense signal (red arrow) 
in the anterolateral wall of the myocardium. The size of the signal decreases slightly over time, and the signal persists for 
at least 80 days post cell injection. No signal is observed in control rat that received non-labeled cells (bottom panel, left) 
Chen, I. Y et al. Mol Imaging Biol. 2009 May-Jun;11:178–87. (42) (with permission)
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to more than 40 days were observed with dead and viable cells recipient with respect to size, 
number and localisation (44). Similarly, it has been demonstrated that MRI overestimates the 
SPIO labeled SC survival after transplantation in the heart (45). Furthermore, SPIO-induced 
hypointensity can sometimes be difficult to interpret because it may be obscured by the pres-
ence of endogenous blood derivates, such as hemosiderin (46). The clinical translation of SPIO 
for cell tracking is further reduced now that ferumoxides (Feridex® or Endorem®) are no longer 
available in the USA and Europe. However, the use of iron oxides approaches should not be 
discouraged as they provide very high sensitivities. New compounds with improved tissue 
clearance properties (therefore higher specificities) are awaited from material sciences research. 
 
Paramagnetic ions
Cell labeling with “positive contrast” such as gadolinium (Gd) chelates and manganese (Mn) 
chloride compounds allow the visualisation of SC as hyperintense signal on T1-weighted im-
ages. Internalization of Gd can be accomplished by exposure of cells to Gd chelates or through 
the use of liposomal formulations (33). MRI sensitivity in the detection of Gd-labeled cells is 
lower compared to SPIO-labeled cells and is dependent upon contrast behaviour and relaxivity 
in the cellular compartment (endosomes) in which they are localised (47,48). This is a result 
of the reduced water accessibility to chelated ions following intracellular concentration, result-
ing in decreased relaxivity. To overcome these issues several approaches have been considered 
to drive the endosomal escape of paramagnetic compounds (49). Furthermore, safety issues 
might be related to the rapid dechelation of compounds at the low pH of lysosomes and endo-
somes raising concerns related to free Gd3+ ions (50).
Sub-millimolar concentrations of Mn chloride (MnCl2) have been sufficient to enable SC 
labeling and detection for both in vitro and in vivo MR, with no detectable toxicity. Also in 
the same study the potential of MnCl2 labeling in the assessment of SC viability by T1 and T2 
mapping was investigated in in vitro studies (51). Mn-oxide nanoparticles have recently been 
used to label and track implanted glioma cells. Of considerable interest, the feasibility of suc-
cessfully tracking two cell populations simultaneously has been suggested, where one is labeled 
with Mn-Oxide and the other with SPIOs (52). These and other paramagnetic ion techniques 
offer the hope that positive contrast approaches will enable sensitive MR tracking of SC in 
vivo. Novel nanotechnology approaches are becoming available for stem cell tracking such as 
gadolinium-containing carbon nanocapsules (Gadonanotubes), whose T1 relaxivity is greater 
than that of any known material to date (outperforming clinically available Gd-based contrast 
agents by 40-fold) (53). They will definitely play a role in the future of imaging sciences as 
soon as their toxicity profiles, currently under investigation, have been clarified.
19F MR
Similar to the imaging of relaxation of 1H from water, 19F can be used as the basis of the 
signal for MR spectroscopy and image formation. While this technique is not implemented 
widely in the clinic, there are unique advantages to fluorine-MR that make it an attractive 
option for SC tracking in myocardial applications. 19F is not present naturally in soft tissues 
therefore its signal is exclusively derived from the exogenous contrast agent applied, be it a 
perfluorocarbon particle or fluorinated nucleosides (54). 19F MRI can be used with existing 
1H imaging hardware since 19F and 1H gyromagnetic ratios differ by only 6%.
Importantly, 19F signal can be overlaid on 1H-MR anatomical images for a highly selective, 
high-resolution map of cell transplantation. This technique allows for quantitative determi-
nation of the cell population (55). A perfluorocarbon particle loaded cell scheme has been 
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used to show the unequivocal and unique signature for SC, enabling spatial cell localization 
via19F-MRI and quantitation via 19F-spectroscopy (56). Perfluorocarbons have been exten-
sively studied and used as blood substitutes, therefore their toxicity profiles are known. 19F 
cell tracking has attracted interest, but is still at an early stage of development. It should be 
noted that this method does suffer from the drawback of lower sensitivity requiring longer 
imaging times. Efforts are underway to address these deficits including imaging hardware, 
imaging sequences, and label improvement and 19F MR imaging is expected to play a role in 
cell tracking in the future (54).
 
Radionuclide imaging
Imaging of SC has also taken advantage of the high sensitivity (10-10−10-12 mol/L vs 10-3–10-5 
mol/L of MRI) and quantitative (acute cell retention as a percentage of the net injected dose 
per weight, [%ID/g]) characteristics of radionuclide imaging (57). However, PET and par-
ticularly SPECT have inferior spatial resolution (1–2 mm) compared with MRI. Moreover, 
radionuclide-labeled cells can only be visualised as long as the radioactivity is still detectable 
(e.g. 18F: 110 min; 111In: 2.8 days; 99mTc: 6 h). This sets an appreciable limitation on the radio-
isotopes direct labeling value for medium- and long-term SC transplant monitoring. SPECT 
has been largely used to investigate the short-term fate of transplanted cells labeled with ra-
dioactive compounds such as 111In-oxine (58-63), 99mTc-hexamethylprophylene amine oxine 
(HMPAO) (64) or 111In-tropolone (65,66). A persistent limitation for deployment of SPECT 
is that in order to generate useful (quantitative) images within a reasonable time frame, the 
administration of relatively large doses of radioactivity are required. This poses the concern 
of inherent radiation damage (reduced viability and proliferation). In the case of 111In, Auger 
electrons are also emitted leading to adverse biological effects in very short distances (from the 
nm to μm range). Brenner et al., demonstrated that despite the homing of progenitor cells into 
the infarction area, cell labeling with 111In-oxine impairs significantly the viability, prolifera-
tion and differentiation at 48 h after implantation (63). Similar results were observed after 
exposure of murine haematopoietic progenitor cells at even much lower levels of radioactivity 
(67). The use of other compounds, such as 111In-tropolone, inhibited cell proliferation 3 days 
after labeling (68). To abrogate these effects, it has been suggested that only a fraction of the 
SC population be labeled (69). Regardless of the method used, very few studies have reported 
the absence of any cell function impairment (58,62). These studies underline the need for fur-
ther in vitro studies considering different SC, exposed 
to different activities and importantly following the 
same labeling protocol.
Positron emission tomography (PET) has been re-
garded as having higher sensitivity (2 to 3 orders of 
magnitude) and better spatial and temporal resolu-
tion than SPECT (70). 18F-Fluorodeoxyglucose 
(18F-FDG) has been used for cell labeling and short 
term imaging in preclinical (71) and clinical settings 
Fig. 4 PET/CT images of a patient with history of anterior wall 
infarction. After percutaneous intervention 18 F-FDG labeled cells 
were implanted via intracoronary catheter and images obtained at 
2 hrs after the procedure. Total amount of SC at the injection site 
was measured (2.1% of injected dose). From Kang et al. J Nucl Med 
2006; 47:1295–1301. (73) (with permission)
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(Fig. 4) (72,73). After intracoronary injection all stem cells showed poor engraftment regard-
less of cell type and number of implanted cells (61,72,73). In all cases intravenous injection of 
SC did not show detectable homing of cells to the myocardium (72,73).
Augmenting the higher sensitivity, the wider availability of hybrid PET-CT systems allows 
for a combination of anatomical non-invasive coronary angiography and cell tracking. This 
multimodal imaging capability and clinical availability are tempered somewhat by the the 
short half-life of 18F. Isotopes with longer half-life, such as 64Cu (12.7 h) have been suggested 
(74). However, with radionuclide based techniques pursued so far, only the immediate fate of 
transplanted stem cells can be interrogated.
 
Reporter genes
Reporter gene approaches have significant potential to reveal insights into the mechanisms and 
fate of SC therapies. The reporter gene paradigm requires often the appropriate combination 
of reporter transgene and a reporter probe, such that the reporter gene product has to interact 
with an imaging probe (optical, nuclear, magnetic) and when this event occurs the signal may 
be detected and quantified with the corresponding imaging technique (Fig. 1c). 
Several advantages of reporter gene approaches have been described (75). Namely, this system 
identifies with exquisite specificity only viable cells (which actively contain the gene product) 
and allows long term tracking of transduced SC (circumventing issues of probe dilution with 
cellular proliferation). Reporter genes can be designed as “constitutive” whose signal is “always 
turned on” (suitable for the evaluation of transplantation, migration and proliferation of sta-
bly transduced SC) or “inducible” reporter gene which is activated and regulated by specific 
endogenous transcription factors and promoters (75,76) providing a non-invasive readout of 
information regarding SC differentiation.
The most widely used reporter gene for radiotracer based imaging is HSV1-tk (Herpes sim-
plex virus type 1 thymidine kinase) and its mutant, the HSV1-sr39tk. Unlike mammalian 
TK1, this enzyme efficiently phosphorylates purine and pyrimidine analogues which results 
in trapping and accumulation of these ligands. It has been successfully used in association 
with 18F or 124I -2′-deoxy-2′-fluoro-5-iodo-1-[β]-D-arabinofuranosyluracil (18F-FIAU and 
124I-FIAU), 18F 2′-fluoro-5-ethyl-1-[β]-D-arabinofuranosyluracil (18F-FEAU), and 9-(4-
[18F]fluoro-3-hydroxymethylbutyl) guanine (18F-FHBG) (75,77). Wu et al., pioneered the 
reporter gene approach in the heart by imaging in vivo transplanted cells (expressing lucifer-
ase or HSV1-sr39tk) up to 2 weeks by 18F-FHBG PET imaging or BLI (78). Furthermore, 
Cao et al., reported survival and proliferation (through increasing signal up to 4 weeks) of 
murine ES stably transduced with a triple fusion reporter gene, enabling simultaneous PET, 
bioluminescence and fluorescence imaging (79). Despite the advantage of signal amplification 
(through probe phosphorylation and accumulation within cells) of HSV-tk based approaches, 
its immunogenicity might limit use in humans (80). To overcome this limitation, the human 
mitochondrial thymidine kinase type 2 (hTK2) have been proposed (81). An alternative is 
the sodium iodide symporter (51) as a PET and SPECT reporter gene used in conjunction 
with 124I or 99mTc (pertechnetate), respectively (75,82). Here, despite the lack of probe/signal 
amplification observed in receptor- and transporter-based techniques (as 124I or 99mTc are free 
to diffuse out of the cells), hNIS is not immunogenic (since it is expressed in the thyroid, 
stomach salivary gland, choroid plexus but not in the heart) and does not require complex 
radiosynthesis of the probes. Nevertheless, in reporter gene approach for the imaging of SC-
based cardiac therapy several important issues remain. First, the non-physiological expression 
of reporter gene proteins may perturb the critical SC cellular and therapeutic functions. To 
be fully reliable, this system has to guarantee the long term expression of the reporter gene in 
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the proliferating population. Adenoviral transfection is hampered by episomal gene expression 
(the reporter gene is not integrated in the chromatin, and because they are not replicating, they 
become diluted with cell proliferation) and by immunogenicity (leakiness of immunogenic 
adenoviral proteins that can lead to an immune response) (83). On the other hand, lentiviral 
vectors accomplish the integration of the reporter gene in the host cell chromatin allowing 
stable expression in dividing cells (84) and circumventing immunogenicity (85). Even when 
lentiviral vectors are used however, transgene expression can be silenced by DNA methyla-
tion especially when strong promoters, such as CMV, are used to drive the expression of the 
reporter gene (86). The integration of the reporter gene within the genome has raised concerns 
about the risk of mutagenesis and potential oncogenicity (87).
The imaging of differentiation in vivo was recently investigated by Kammili et al., by employ-
ing a novel dual-reporter mouse embryonic SC line. Here, enhanced yellow fluorescent protein 
(EYFP) was used as a “constitutive reporter”, and the firefly luciferase reporter as an “inducible 
reporter”. This latter gene was under the control of the cardiac sodium-calcium exchanger 1 
(Ncx1) promoter which showed increased activity upon differentiation of SC into beating 
cardiomyocytes (76).
Several candidates have been proposed as MRI reporter genes such as β-galactosidase, trans-
ferrin receptor, ferritin, MagA and lysine-rich proteins (88,89). Recently, SM engineered to 
express ferritin have been transplanted in infarcted heart and detected (as decreased signal up 
to 25%) up to 3 weeks (90). Several studies have been reported with the application of MR 
reporters, however, none of these strategies have led to a significant number of follow-up stud-
ies. This is due to the low sensitivity of MRI for imaging of gene activity in vivo.
 
Optical imaging
BLI
In contrast to the immediate clinical impact of magnetic and nuclear tomographic imaging, opti-
cal imaging techniques such as bioluminescence, planar and fluorescence-mediated tomography 
have been largely restricted to use in preclinical models. Bioluminescence imaging is commonly 
used for cell tracking in SC transplantation studies (78,79,91) (Figs. 3 and 5). SC are transduced 
with a luciferase gene and implanted in the recipient animal. Following injection, the probe (D-
Luciferin) is oxidized only in the cells expressing luciferase in presence of ATP, O2 and Mg2+ 
resulting in light photons being emitted (which can be detected by ultrasensitive charge-coupled 
device [CCD] cameras). BLI has many advantages: it is highly sensitive, quantitative, simple and 
inexpensive. However, the barrier to clinical translation lies in the inherent limitations imposed 
by poor tissue penetration (1–2 cm) (allowing only surface imaging), high rates of scattering of 
visible wavelength photons on the human scale and low resolution (3–5 mm) (which hamper the 
exact evaluation of the exact location of the cells) (57).
 
Fluorescence
Direct labeling of SC with fluorescent probes for visualisation in vitro and in vivo has been 
fueled by the availability of near infrared (NIR) probes, as their spectral properties are matched 
to lower tissue attenuation in the so-called NIR-window. This provides greater signal pen-
etration of tissue through reduced light absorption and tissue scattering. Therefore they have 
clinical potential, however limited to near-surface or intraoperative imaging stem cell tracking.
Near infrared imaging provides high sensitivity as well as tomographic capabilities and there is 
no evidence at present that dyes released after cell death are taken up by macrophages. Intra-
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coronary delivery of MSC labeled with the NIR dye IR-786 has been successfully tracked in 
a swine model of myocardial infarction and sensitivity of 10.000 cells has been reported (92).
Quantum dots (QD) are a class of inorganic, fluorescent nanoparticles that have been success-
fully used to label SC. Biocompatibility of QD at low concentrations has been demonstrated 
in vitro in MSC cultures (93) and the absence of adverse effects on cell viability, proliferation 
or differentiation reported (94). One of the most attractive qualities of these nanoparticles is 
their capacity for multiplexed imaging. The tracking of different cell populations is concur-
rently achieved by labeling cells with different QDs. Multiplex optical imaging of QD-labeled 
embryonic stem cells have been reported up to 14 days from injection in mice (94). Moreover, 
it has been shown that single QD-MSC can be detected in histological sections for at least 8 
weeks after delivery (95). The long-term effects on SC functionality are still unknown, however 
Fig. 5 Bioluminescence imaging of CD34+ cells expressing the TGL gene (HSV1-tk, e-GFP, f-luc) and implanted in the 
heart of a SCID mouse. Systemically administered luciferin is activated (oxidized by luciferase) in the injected cells. Here 
we see follow- up of implanted cells up to 52 weeks post-implantation. Measurement of emitted light in CD34+ implants 
is higher than in controls (PBS injection). From Wang, J. et al. Circ Res 2010;106:1904–1911. (91) (with permission)
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concerns are related to their metallic core include its exposure 
or dissolution which may result in toxicity, particularly from 
heavy metals such as Pb, Cd and Se (96,97).
 
Multimodal imaging
The possibility of complementing the sensitivity of radio-nu-
clide or optical techniques with the high-resolution anatomi-
cal information from MRI is a key player in the clinical and 
research future of SC tracking. To date, the most interesting 
approach has been to develop transgenic cells that carry an 
optical/nuclear imaging reporter together with passive label-
ing with MRI contrast agents before administration. Qiao et al. assessed the survival and 
proliferation of SPIO-labeled murine ESC transduced with HSV1-sr39tk longitudinally (4 
weeks) following injection into the healthy or infarcted myocardium. ESCs grafted and un-
derwent proliferation, as shown by increasing up-
take of 18F-FHBG in PET (Fig. 6) and decreas-
ing the size of MR hypointense areas due to SPIO 
dilution. Interestingly at week 4 the majority of 
SPIO labels (released upon cell death) were phago-
cytized and contained in infiltrating macrophages 
rather than the ESC. Despite teratoma formation, 
a slight increase in left ventricular ejection fraction 
in ESC-treated animals was observed, mainly as a 
result of paracrine effects, as cardiac differentiation 
of implanted ESC was less than 0.5% (98). In a 
similar study human EPC derived from CD34+ 
Fig. 7 A MRI (upper row), 124I-PET (middle row), and fusion 
images 13 N-NH3 (gray scale)/ 124I (colour scale) (bottom row) 
of rat heart 1 day after injection of EPC labeled with iron (left), 
NIS only (middle), or both iron and NIS (right). Signal void 
of iron-labeled HEPCs is observed by MRI whereas HEPCs ex-
pressing NIS showed focal 124I accumulation by PET. B Consec-
utive myocardial sections showing the presence of transplanted 
cells: autoradiography for 124I uptake mediated by NIS reporter 
(left), X-galactosidase staining for LacZ gene expression of graft 
cells (middle), and Prussian blue staining for iron particle detec-
tion (right). C Mean±SD time–activity curves after 124I admin-
istration of transplanted cell and left ventricular blood measured 
by PET. From Higuchi T et al. J Nucl Med, 50:1088– 1094. (99) 
(with permission)
Fig. 6 Co-registration of MRI A and 18 F-FHBG PET B of murine ESC trans-
duced with HSV1-sr39tk and passively labeled with SPIO. Images depict the 
presence and tracking of SC 14 days after transplantation. This hybrid imaging 
C approach leverages the advantages of each technique; the fine anatomical 
resolution of MR and the specificity of nuclear imaging. From Qiao et al. 
Radiology 250:3, 821–829. (98) (with permission) 
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mononuclear cells of umbilical cord blood were transduced with NIS reporter gene and la-
beled with SPIOs. Rapid loss of viable grafted cells was observed, as 124I PET accumulation 
decreased below detection limit at 3 days after transplant. However, MRI signal void resulting 
from SPIO persisted, corresponding to retention of SPIOs within macrophages after graft 
cells’ death (Fig. 7) (99). Triple fusion reporter gene have been widely applied for multimodal-
ity fluorescence, bioluminescence and nuclear imaging approaches (100). Recently, in a quad-
modal optical, PET, CT and MRI coregistration approach CD34+ cells were transduced with 
a triple fusion reporter gene (e-GFP, f-Luc and HSV1-tk). Bioluminescence imaging revealed 
that cells persisted in the heart up to 12 months and MRI studies reported improvement in the 
left ventricular ejection fraction was preserved up to 6 months (Fig. 5) (91).
 
Conclusion
Many of the approaches to image stem cells are promising but further work is required before 
a wide clinical translation becomes reality. Beyond the unresolved safety and ethical issues, 
crucial questions: “What is the best route for cell delivery?” “What kind and how many cells?” 
and “When to inject?” remain.
It has become clear that there is no single ‘best method’ in cell tracking. Rather there is an array 
of high sensitivity, high spatial resolution and functional techniques that work best in combi-
nation. The persistent trends in molecular imaging are: to focus on the development of novel 
MR-compatible probes able to monitor and track with sufficient sensitivity and specificity the 
fate of transplanted cells, new PET/SPECT reporter genes with lessened immunogenicity and 
oncogenicity issues, and the application of related radioprobes with better pharmacokinetic 
profiles.
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Abstract
Background: In various stem cell therapy approaches poor cell survival has been recognized as 
an important factor limiting therapeutic efficacy. Therefore noninvasive monitoring of cell fate 
is warranted for developing clinically effective stem cell therapy. In this study we investigated 
the feasibility of the use of voxel-based R2 mapping as a tool to monitor the in vivo stem cell 
fate in myocardium when the cells are labeled with iron oxide particles (SPIO).
Materials and methods: Single cardiac phase with cardiac triggered double inversion black 
blood 2D fast Spin echo (BBFSE) images were acquired on the short axis of hearts. Repro-
ducibility studies were performed in normal rats (n=4) imaged in different sessions. A double 
cell labeling approach was used in which mesenchymal stem cells were transduced with the 
luciferase gene and subsequently labeled with ferumoxide particles (SPIO). Living labeled cells 
were injected in the myocardium of healthy Wistar rats (n=9). For control purposes animals 
were also injected with dead, labeled cells (n=5) or saline (n=3). Cell fate was monitored over a 
period of 8 weeks by bioluminescence imaging following injection of D-Luciferine and quan-
titative magnetic resonance imaging, using a black blood FSE sequence with multiple echo 
times (between 4.4 and 26.4 ms).
Results: Bioluminescence imaging revealed a significant increase of cell number during the 
first week (peak day 7) with a steep decrease of cell numbers to undetectable levels during the 
second week. MR imaging showed a sharp increase of R2 values shortly after injection at the 
injection site (peak day 5), followed by a very gradual decrease of R2 over a period of 15 days. 
No difference in appearance on T2-weighted images or in R2-values was observed between liv-
ing and dead cells over the entire time period studied.
Conclusion: No significant correlation between the bioluminescence optical data and R2 val-
ues were observed. Quantitative MR imaging by means of R2-mapping is not suitable for the 
in vivo assessment of stem cell fate in rat myocardium as validated by bioluminescence imag-
ing. These results do not follow previous in vitro reports where it was proposed that based on 
the difference in r2 relaxivity between intra-cellular and extra-cellular SPIO, living cells may 
be distinguished from death cells based on their R2 profile. Cell proliferation, cell migration, 
cell death, extracellular SPIO dispersion or aggregation exhibit different relaxivities. In vivo 
these processes happen simultaneously, making quantification very complex, if not impossible.
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Introduction
Regenerative approaches in the treatment of myocardial infarction have been widely investi-
gated in the past few years fuelling new hopes for patients and scientists. Preclinical evidence 
that stem-cell-based-therapy has the potential to limit the degradation of cardiac function after 
myocardial infarction, led to the rapid development of several clinical trials (1). Recent meta-
analyses reported a modest, but statistically significant improvement in the ejection fraction, 
ventricular dimension and infarct area (2, 3). One or more imaging techniques were greatly 
exploited in these clinical trials, however only indirect indications of the efficacy of stem cell 
transplantation was provided by the evaluation of  myocardial contractility, viability and per-
fusion. While these results depict a promising picture of the stem cell-based therapy, questions 
have been raised regarding actual grafting, transformation and proliferation of stem cells in 
the host tissue (therefore recovery of the physiological functions of the organ) or whether or 
not the transplanted cells simply exert paracrine effects (which can induce the recovery of the 
host tissue) (4). 
Molecular imaging (MI) techniques allow the direct visualization of stem cells, their short 
and long term fate and eventually their viability (5). Two cell labelling approaches are gener-
ally used for these purposes: reporter genes or chemical-based contrast agents (5). The former 
requires the introduction of a reporter gene into the cells of interest, through viral or non-
viral-vectors. The reporter gene encodes for a protein (enzymes, receptor, transporter) able to 
interact with a correspondent reporter probe which is activated or concentrated only in the 
cells expressing the reporter gene. Probe accumulation is proportional to the expression level 
of the reporter gene therefore the number of living cells or the induction of a specific reporter 
gene can be quantified. Passive loading of cells with radioactive agents (18F-FDG, 111In-Oxine, 
etc.) for positron emission tomography (PET)/single photon emission (SPECT) or contrast 
agents (iron oxides, Gadolinium, Manganese, 19F) for Magnetic resonance imaging  (MRI) is 
another approach commonly used for cell tracking (5, 6). 
Labelling with superparamagnetic iron oxide (SPIO) nanoparticles has been extensively stud-
ied as they act as magnetic inhomogeneities, locally disturbing the magnetic field, inducing a 
significant decrease of T2- and T2*-relaxation rates (hypointense signal). Studies reported that 
SPIOs do not affect cell viability, proliferation, differentiation or migration (7-10). However, 
a major drawback is related to the persistence of the hypointense signal at the site of transplant 
regardless of labelled cell viability. In fact, at longer time points SPIO-induced signal loss is not 
necessarily associated with implanted cells but rather with phagocytosing monocytes (11, 12). 
Intriguingly, SPIO induced relaxivities have been shown to be dependent on their location; 
i.e. the relaxivities are different when SPIOs are compartmentalized within the intracellular 
space or dispersed in the extracellular space (13, 14). Indeed, decreased T2 values have been 
reported in lysed versus viable SPIO-labelled cells, this effect is related to limited SPIO-proton 
interaction in the intracellular compartment compared to unlimited proton interactions of 
SPIO released from disrupted cells (15, 16).  
The majority of cell tracking studies in the heart have focused on the potential of SPIO la-
belling and MRI longitudinal follow-up of implanted cells, relying on a semi-quantitative 
approach based on signal intensity (signal-to-noise measurements). A quantitative approach, 
has already been used for the evaluation of SPIO labelled cells in vivo (17), but it has never 
been exploited to assess SPIO labelled cells implanted in the heart. In this work, we aimed: 
1) to perform quantitative R2 mapping of the heart at 7T; 2) to assess reproducibility and 
robustness of the technique; 3) to assess longitudinally in vivo the R2 changes related to cell 
proliferation and cell death as evaluated by bioluminescence of double-labelled mesenchymal 
stem cells (MSCs).
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Materials and Methods
Rat mesenchymal stem cells expressing firefly luciferase
The plasmid pND-Cag-Fluc was co-transfected into 293T cells with a mixture of Endofree 
Maxi-kit (Quiagen, Hilden Germany), VSVG (45mg/dish), pMD and pRev using polyeth-
ylenimine (Sigma Aldrich, St Louis, MO, USA). Lentivirus supernatant was collected at 48 
h and 72 h, filtered (0.45mm) and concentrated by sediment centrifugation. The pellet was 
then resuspended in 1 ml phospate buffered saline (PBS). Rat mesenchymal stem cells (rMSC; 
Millipore, Billerica, MA, USA) were grown to 50% confluency in a 24 well plate in Dul-
becco's modified Eagle medium (DMEM) /F10 (Invitrogen; Carlsbad, CA, USA), 10% fetal 
calf serum (FCS) and infected with 50 μl lenti-viral stock. Viral titer was assessed on concen-
trated supernatant by HIV-p24 ELISA (Dupont, Wilmington, DE, USA). Transduced rMSC 
(rMSC-Fluc) were expanded and plated at low densities. The expression of Fluc was evaluated 
by using a luminometer and clones with the highest expression of Fluc were selected and ex-
panded.
Cell labelling with SpIO
rMSC-Fluc were cultured in DMEM supplemented with 2% FBS (Lonza; Basel, Switzerland), 
1% MEM essential vitamin mixture (Lonza), 1% NEAA (Sigma-Aldrich; St. Louis, MO) 
2% v/v penicillin/streptomycin, 2% v/v L-glutamine, and 0.5% v/v glutamax (Invitrogen). 
Cells were grown at 80% confluency and incubated with a mixture of ferumoxide-protamine 
sulfate. Cells were labelled as previously described (18, 19). Briefly, ferumoxides (Endorem, 
Guerbet S.A., Paris, France; hydrodynamic diameter of 120-180 nm) were diluted in serum 
free DMEM to a final concentration of 100ug/ml; protamine sulfate was added to a final con-
centration of 5 ug/ml. After 5 minutes of intermitted shaking the solution was added to the 
cells. 24 hours later cells were washed three times with 10U/ml heparinized PBS, harvested by 
trypsinization, put through a 40 mm cell-strainer and counted. Non-viable cells were obtained 
by repeated freeze/thawing and brief sonication of the injection solution. 
Inductively coupled plasma Optical Emission Spectroscopy (ICP-OES; Optima 4300DV, Per-
kin Elmer, Norwalk, CT) was used to quantify the intracellular uptake of iron. 
Viability assessment of labelled cells
To assess any potential effect of cell labelling on cell viability or proliferation we labelled cells 
(wild type and expressing luciferase) with SPIO (triplicate samples), harvested cells at differ-
ent days, and counted the number of cells on an automatic cell counter. Doubling time was 
estimated assuming a exponential growth model: At=Ao2
t/td (At, cell number at time t; A0, cell 
number at time 0; t time; td, doubling time) (20). 
Cell transplantation and in vivo imaging
All animal experiments were conducted in compliance with the independent Institutional 
Animal Welfare Committee. For assessing the reproducibility of R2 mapping by MR Imaging 
techniques, rats (Wistar; Harlan; Horst, the Netherlands) (n=4) underwent anesthesia and 
MRI for a total of 4 sessions each (different days). 
For experiments regarding tracking of implanted cells by MRI, rats (Wistar; Harlan; Horst, 
the Netherlands) received intra-myocardial injections. Briefly, animals were induced with 2% 
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isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen mixture, and kept under anesthesia by the 
intraperitoneal administration of a combination of Fentanyl (300 ug/kg) and Medetomidine 
(300 ug/kg). Animals were ventilated by orotracheal intubation, followed by left thoracotomy. 
After intra-myocardial injection, the chest was closed, pneumothorax reduced and buprenor-
fine (0.1 mg/kg) administered subcutaneously.  Group 1 (n=9) received 1.5 x106 viable rMSC 
SPIO-labelled cells; group 2 (n=5) received 1.5 x106 non-viable SPIO-labelled cells; group 3 
(n=3) received PBS injection (sham experiment). 
Imaging studies
Bioluminescence
Optical bioluminescence was performed by using the charged coupled camera device Xenogen 
IVIS Spectrum (Caliper Life Sciences, Hopkington, MA, USA), 5 minutes after intraperito-
neal administration of 150 mg/Kg of D-Luciferine (Promega). Each rat was imaged up to 30 
minutes (integration time, 30, 60, 120 s and 180s; f/stop,1; binning, medium; field of view, 
B) to follow the pharmacokinetic profile of luciferin activation. Optical intensity was quanti-
fied in units of photons/second/cm2/steradian. Regions of interest were used to calculate the 
optical peak value at the level of the implanted cells in the heat. Data were analyzed with the 
software Living Image 2.6 (Caliper LS, Perkin Elmer).
Magnetic resonance imaging
MRI data were acquired by using a 7T scanner (Agilent-GE Discovery MR901 scanner, Mil-
waukee IL, USA) with 300 mT/m max gradient. A 150mm diameter quadrature coil was used 
for transmit and 4ch Rx surface coil array for receive purposes (Rapid Biomedical. Würzburg, 
Germany). 
All animals underwent longitudinal MRI. Every exam started with routine cine sequences 
(2-chamber view and 4-chamber view) to allow the proper positioning on the heart axial plane 
and the selection of the most representative section. The overall time required for slice posi-
tioning and scanning was 20 min.
Single cardiac phase with cardiac triggered double inversion black blood 2D fast Spin echo 
(BBFSE) images were acquired on the short axis of hearts. The effective echo times of the sepa-
rate scans were TE= 4.4, 8.8, 13.2, 17.6, 22, 26.4 ms, the repetition time was ~ TR= 600 ms. 
The resolution of images was: FOV= 50x50 mm, matrix= 256x256, slice thickness 1.8 mm. 
The scan time for all TE images was ~ 5 minutes. The triggering was provided by peripheral 
pulse oxygenation level monitoring on the hind leg of the rats (SA Instruments, Stony Brook, 
NY, USA). The echo train length was 8, the echo spacing was 4.2 ms, optimized to achieve the 
required span of available TE values, and yet making sure that the echo train does not extend 
beyond the cardiac resting phase.
Image processing
For reproducibility experiments, the inner and outer boundary of the myocardium were man-
ually drawn on the short axis image with the shortest TE, which has the highest signal-to-noise 
ratio (SNR). To correct for motion artifacts the image set was registered to the images with the 
shortest TE using a two-step approach. Five anatomical landmarks of the myocardium were 
manually selected to enable a point based rigid registration, which was used as an initialization 
for an intensity based mutual information based rigid registration. The myocardium region 
was divided into standard sectors (21) and the 6 mid-ventricular regions were considered. The 
mean T2 and the standard deviation were calculated for each region and each day.
For the quantification of SPIO-labelled rMSC, a region-of-interest (ROI) was manualy drawn 
on the short axis image at the level of the signal void (site of injection).
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A T2 map was then generated using a Maximum Likelihood (ML) estimator approach which 
takes the Rician noise distribution of the magnitude MR images into account. This ML for-
mulation also yields the Cramer-Rao Lower Bounds (CRLB) on the precision of the fits. The 
square root of the CRLB (srCRLB) is a lower bound on the standard deviation of the T2 and 
can therefore be used as an error estimate in ms. 
Histology
For histological evaluation,  hearts were harvested at 2 days and 15 days after injection, 
washed in ice-cold PBS, and fixed for 24 h in 4% paraformaldehyde, embedded in Tissue-
TEK OCT compound (Sakura, Finetek U.S.A Inc.), frozen at −80 °C, and cryosectioned to 
obtain 10-mm-thick samples. Slides were stained for iron by using the Accustain kit (Iron 
stain; Sigma-Aldrich) and imaged by light microscopy.
Statistics
Statistical data were evaluated using Graphpad Prism 5.0 (Graphpad Software). Statistical 
comparisons between two experimental groups were performed using t- tests (unpaired com-
parisons); comparison of multiple groups was performed with two-way ANOVA using Bonfer-
roni’s multiple comparison post hoc analysis. All statistical comparisons were two-sided, and 
the level of statistical significance was set at P < 0.05. Unless differently specified, all values 
were reported as Mean ± SEM.
Results
Viability assessment
Analysis of iron content by ICP measurements revealed 7.58 ± 0.09 iron pg/cell (rMSC) and 
7.67 ± 0.14 iron pg/cell (rMSC-Fluc) after the labelling procedure. The difference was not 
statistically significant. In order to assess whether the cell manipulation (Fluc transduction) or 
cell labelling could affect cell viability, cell proliferation studies were performed (Figure 1). The 
presence of the Fluc gene in these cells reduced proliferation rate compared to the wild type 
as lower cell counts were observed in the MSC-Fluc compared to the MSC at all time points 
(P<0.05). Lower cell counts were observed with MSC-SPIO labelled cells compared to control 
cells, only on day 7 (P<0.05). SPIO labelling of rMSC-Fluc cells did not have any statisti-
cally significant effect on cell proliferation compared to unlabelled control. Doubling times 
(expressed in days) were calculated to be: 1.85 (MSC unlabelled), 1.86 (MSC labelled with 
Fig. 1 Effect of cell labeling on growth profile. MSC and 
MSC-Fluc were labeled with SPIO, cultured up to 7 
days and cells were counted at different time points. A 
lower cell count was observed in the MSC-Fluc (dou-
bling time: 2.02 days) compared to the MSC (dou-
bling time: 1.85 days) at all time-points (P<0.05). A 
lower cell count was observed with MSC-SPIO labeled 
cells compared to control cells (MSC) only on day 7 
(P<0.05). SPIO labeling of rMSC-Fluc cell did not 
have any statistically significant effect on cell prolifera-
tion compared to unlabeled control.
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SPIO), 2.02 (MSC-Fluc unlabelled), 2.05 (MSC-Fluc labelled with SPIO). Doubling time of 
MSC-Fluc was statistically different from MSC at all time points (P<0.05).
Reproducibility study
Using a BBFSE-based mapping approach,  the robustness of the R2 value measurements was 
assessed . Figure 2 shows a representative axial slice of a healthy rat heart (no injection). The 
exponential of the signal decay was optimal and calculated errors were relatively small. The 
signal was quite homogenous with T2 values (22.47±1.92 ms) in the preferred area for cell 
injection (anterior and anterolateral segment). However, some regions such as the septal and 
the inferolateral region were more prone to movement artifacts (e.g. breathing) and were as-
sociated with a less reliable curve fitting.
Reproducibility studies were performed in 4 animals scanned 4 times each to assess the robust-
ness of the technique (Fig 3). Regarding repeated measures of T2/R2 in subsequent imaging 
sessions the following variability was observed: anterior, region 1 (21.72 ms ±1.49); antero-
septal, region 2 (22.68 ms ± 1.7), region 3 (26.17 ms ± 2.13), region 4 (22.62 ms ± 1.68), 
region 5 (25.99 ms ± 2.49), region 6 (21.54 ms ± 1.86) (Fig 3). 1-way ANOVA was used to 
test spatial variability of R2 and T2 values of the six different heart segments of 4 animals. We 
did not observe a statistically significant difference among the segments (P=0.67).
Fig. 2 R2 value variability in healthy  rat heart. Representative image depicting an axial slice of a healthy rat heart with 
super-imposed R2 values measured by using a BBFSE based mapping approach. The exponential curve of the signal de-
cay is optimal and calculated errors (mean ±SD) are reported. The signal is quite homogenous in the area corresponding 
to the preferred cell injection site in this paper (anterior and anterolateral segment). However some regions such as the 
septal region and the inferolateral region are affected by movement artifacts (breathing, blood flow) and are associated 
with not reliable curve fitting.
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Imaging cell fate
The viability and proliferation of implanted cells was assessed longitudinally in vivo by both 
bioluminescence imaging and MR imaging. We observed an increase in optical signal over 
days 3-7 (compared to day 3 a 3.21-fold and 15.37-fold increase at day 5 and 7 respectively) 
upon injection of viable cells, most probably related to cell proliferation in the implantation 
site. On day 10 the signal had declined substantially (0.7-fold reduction compared to highest 
peak at day 7) and reached background levels on day 15. 
In MR images, large areas of hypointensity, generated by iron labelled cells, were clearly visible 
in the MRI scans of the injected hearts. Importantly, no difference was observed in terms of 
size, number and distribution of these signal voids between live and non-viable cells. Longi-
tudinal MRI scans were performed to assess the changes in T2 relaxivity over time, related 
to SPIO dilution or potential decompartimentalization upon cell proliferation or cell death 
rspectively. Quantification of the signal revealed a 2-fold significant increase (P<0.05) in R2 
between day 3 and 5 after injection (Fig 4). This was probably related to the early reabsorption 
of the injection volume with re-distribution of the cells in the implantation site. From day 5 
onwards, R2 values decreased. In sham injected animals, no changes in the R2 values over time 
were observed at the site of the presumed injection.
No statistical correlation with the proliferation or viability profile monitored by biolumines-
cence was observed (P=0.1). 
We investigated whether the relaxivity changes associated with the decompartmentalization of 
iron oxides might be quantified by MRI. We injected a solution of SPIO labelled MSC-Fluc 
no longer viable (as an effect of repeated freeze/thawing cycles and brief sonication), therefore 
containing the same amount of SPIO of viable cells but dispersed in the extracellular compart-
ment. No difference was observed in terms of size, number and distribution of the generated 
signal voids between live and non-viable cells on weighted images. Higher R2 values were 
Fig. 3 Reproducibility study. This figure shows a representative BBFSE image with super-imposed R2 mapping values, of 
an animal imaged in 4 separate sessions (a). Schematic drawing of the region distribution. Region 1: anterior; Region 
2: antero-septal; Region 3: inferoseptal; Region 4: inferior; region 5: inferolateral; region 6: anterolateral (b). The graph 
illustrates the variability of R2 values (mean ± SEM) observed in the different heart regions of 4 animals in 4 different 
imaging sessions. (c)
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Fig. 4 Longitudinal imaging of cell fate by Bioluminescence and MRI. A. Representative images showing the evolution 
over time of bioluminescent signal (according to the colorscale provided) emitted by intra-myocardially injected rMSC-
Luc-SPIO cells, B. Representative images showing evolution of R2 values (according to the colorscale provided) super-
imposed on a BBFSE image of a short axis slice of a rat heart at the level of injection with rMSC-Luc-SPIO cells. Bottom 
right image represents data observed in sham-operated animals. C. Graph showing evolution of bioluminescent signal 
values and R2 values of rat hearts following intra-myocardial injection of rMSC-Luc-SPIO cells (mean ±SEM).
Fig. 5 R2 MRI mapping in viable and non-viable cells. A. Representative images showing evolution of R2 values super-
imposed on a BBFSE image of a short axis slice of a rat heart at the level of injection with non-viable rMSC-Luc-SPIO 
cells intra-myocardially, over time according to the colorscale provided. B. Graph showing evolution of R2 values of rat 
hearts at the site of injection of living and dead rMSC-Luc-SPIO cells. SPIO labeled MSC-Fluc no longer viable (as 
an effect of repeated freeze/thawing cycles and brief sonication), containing the same amount of iron of viable cells but 
decompartmentalized were injected in the heart (a). As an effect of decompartmentalization of SPIO, the implantation 
of non-viable cells is associated with higher R2 values compared to viable cells. However, this difference is statistically 
significant only at day 3 after implantation. In the following days despite a trend is clearly visible the difference is not 
statistically significant and it is probably related to the changes related to free SPIO in the extracellular matrix (uptake 
from endogenous cells). 
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associated with dead compared to the viable ones, however the difference was statistically sig-
nificant only on day 3. The dead cells showed a similar trend to viable cells, consisting in an 
increase in R2 on day 5 followed by a decrease
Histological analysis of cryo-sections of hearts revealed that injections with non-viable SPIO-
labelled cells were associated with a more puntiform appearance of the iron stain (due to the 
extracellular release of SPIO in the injection solution). Conversely the iron staining of viable 
SPIO-labelled cells depicted larger aggregates (Fig 6).
Discussion
The ability to monitor the localisation, viability, proliferation and possibly the differentiation 
status of implanted stem cells provides massive benefit in regenerative medicine approaches. 
All of the pre-clinical and clinical imaging techniques have been leveraged towards this goal; 
each providing unique advantages and limitations (5). MRI is a widely established technique 
for the evaluation of cardiac anatomy and function. Taking advantage of its excellent spatial 
resolution (10–100 μm [preclinical]); 500–1500 μm [clinical]), stem cells labelled with su-
perparamagnetic and paramagnetic agents can be visualised (22, 23). The choice of a proper 
labeling marker is however a crucial aspect in cell tracking by MRI. High sensitivity allows 
the long term evaluation of implanted stem cells, since probe dilution upon cell proliferation 
reduces the detection capabilities. Also, high specificity is demanded to investigate potential 
cell graft rejection at an early stage. 
In this study, luciferase expressing MSC labelled with SPIO were implanted in the heart and 
longitudinally monitored by quantitative MRI (T2 mapping) and bioluminescence imaging. 
A vast amount of work has been performed on longitudinal imaging of implanted cells in the 
heart by MRI; SPIO-labelling and assessment of cell fate by means of (loss of ) signal intensities 
on T2-weighted images being the most used approach. The detection of low signal intensity 
areas proves to be an insufficient method as it is associated with some limitations such as: a) 
inhomogeneity in the coil sensitivity (phased-array coils determine regional myocardial signal 
variations that may give an inaccurate interpretation); b) artefacts due to motion and flow; c) 
the inherent qualitative aspect of this approach, whose evaluation relies on regional differences 
in signal intensity, which strongly depend on the parameters of the sequences used (TR, TE, 
slice thickness, etc) (24).
To overcome these limitations, the alternative approach consists of the direct quantification of 
the T2 values of the myocardium. This allows the detection of subtle T2 differences in tissues, 
reducing the subjective interpretation of signal voids (and their dependence from parameters) 
Fig. 6 Representative histological sections of rat hearts 
injected with viable (upper panel) and non-viable 
(lower panel) SPIO-labeled cells harvested at 2 days 
(A, C) and 15 days (B, D) after injection. Iron staining 
(blue) depicts  the presence of  iron which is associated 
with larger aggregates in the viable cells (black arrow) 
compared to non-viable cells, which present a more 
puntiform appearance (white arrow) due to extracel-
lular release of SPIO in the injection solution. 
C
ha
pt
er
 6
135
and minimizing flow or motion dependent artefacts (24). Many in vivo studies on T2 mapping 
of the heart have been performed in humans in the last two decades, mainly based on spin echo 
acquisitions. Novel approaches based on T2 prepared steady-state free precession (24), hybrid 
sequences (25), bright blood approaches (26) or additional adiabatic prepulses (27) have also 
been suggested recently. It is an area of active investigation for quantitative assessment of myo-
cardial edema and iron overload. However, the use of quantitative mapping for quantification 
of SPIO-labelled cells implanted in the heart has been quite limited. 
A few studies suggested R2 (1/T2) and R2* (1/T2*) parametric mapping as a reliable and 
reproducible quantification method of SPIO or SPIO labelled cells per voxel (14, 28, 29). 
Importantly, variation of R2 and R2* according to SPIO compartmentalization have been 
described. Phantom studies demonstrated that with identical iron concentration, cell bound 
SPIO show higher R2* values compared to free SPIO. Conversely, R2 measurements are high-
er for free iron than for intra-cellular iron (13, 14).  
We sought to use R2 mapping as a means to detect, in vivo, changes associated with probe 
dilution and potential decompartmentalization of SPIO as a result of cell proliferation and cell 
death, respectively. We employed a double inversion recovery BBFSE sequence and tested its 
robustness in a reproducibility experiment. The signal was quite homogenous in the preferred 
regions for cell injection in these experiments such as the anterior and anterolateral segments 
with T2 values of 22.47±1.92 ms and 21.54±1.86 ms (prior to injection), respectively (Fig 2 
and Fig 3). As expected, regions associated with higher cardiac motion such as the septal and 
the inferolateral segment) corresponded on R2 maps to unreliable curve fitting. However, this 
limitation did not interfere with the longitudinal assessment of the relaxivity of the injected 
cells. Overall, the difference in R2 and T2 values among the six different segments was not 
statistically significant. 
In the longitudinal assessment of implanted cells, bioluminescence showed an initial increase 
of the optical signal (peak on day 7), most probably related to cell proliferation, followed by 
a decrease in signal strength. Limited persistence of bioluminescent signal has been observed 
previously (30) and the explanation of the signal decrease is not univocal. Cell manipulation 
impairs cell proliferative ability (Fig 1) and may induce further phenotypical changes that may 
lead to an immunogenic response by the host. Chen et al. reported from in vivo studies with 
bioluminescence, a half-life of Fluc labelled cells of 2.65 days, with an optical signal showing 
an increase within the first 3 days and further decrease with background levels on day 6. Our 
observations are in agreement with these and other findings, in which the majority (more than 
70%) of cells implanted in the heart were reported to die within the first week of injection in 
immunocompetent animals (30-32). The decreasing signal might also result from epigenetic 
silencing of reporter gene expression which complicates the overall quantification (33). This 
phenomenon does not seem likely in our study, since identically generated rMSC-Luc-SPIO 
cells were also injected in other anatomical locations in rats within our group, without a cor-
responding quick loss of  bioluminescent signal (34).
By using MRI to monitor cell proliferation, we and others previously reported that under in 
vitro conditions, cell proliferation/division is associated with a R2 decrease (T2 increase) (13, 
16). On MRI, we observed a 2-fold significant R2 increase from day 3 to 5 after injection, 
which corresponded to the increasing optical bioluminescence signal (cell proliferation) (Fig 
4). 
Conversely, when cells die and spread their content to the extracellular matrix an increase of 
the R2 of SPIO labelled cells has been investigated reported only in in vitro studies and results 
have been consistent and reproducible. In fact, Simon et al. reported a statistically significant 
difference in R2 relaxation times between viable and non-viable lysed cells (15). Similarly, 
Nedopil et al. reported on ferumoxides-labelled human mesenchymal stem cells implanted in 
ex vivo joints and showed on T2-w images a markedly lower signal (thus shorter T2) of apop-
totic compared to viable cells (35).  To our knowledge, this is the first attempt to investigate 
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the quantitative approach of SPIO-labelled cell fate in an in vivo setting. We observed observed 
a 2-fold significant R2 increase from day 3 to 5 after injection, which corresponded to the 
increasing optical bioluminescence signal (cell proliferation) (Fig 4). From day 5 onwards, R2 
values already decrease from day 5 onwards, while bioluminescence data still suggested ongoing 
proliferation.. Overall we found no significant correlation between bioluminescent signal profiles 
and MRI signal evolution (P=0.1). Moreover, we mimicked the release of SPIO content in the 
injection solution by inducing the death of SPIO-labelled MSC before implantion in the heart. 
As expected, higher R2 values were associated with the injection of non-viable versus viable cells. 
However, the difference was statistically significant only on day 3 (Fig 5 and Fig 6).
We argued that the processes happening in vivo (such as cell redistribution in the injection site 
or the re-absorption of the injection medium with further changes in the interactions of the 
SPIO particles) might obscure the detection of potential changes associated with probe dilu-
tion and cell death, making the overall quantitative assessment complicated. 
In addition to the above mentioned physiological processes, endogenous cells (e.g. macro-
phages) might be involved in the potential re-uptake of the SPIO released in the extracellular 
matrix or phagocytosis of dead cells may intervene in the later days after injection hampering 
the detection of the difference in the later days. Chen et al. reported a change in the histologi-
cal pattern of ferumoxides injected in the myocardium, from dispersed (day 2) to focal (day 
9), suggesting the involvement of macrophages in scavenging and concentrating SPIO (30). 
This is a common issue in the use of SPIO as a labelling marker, Winter et al. reported (by 
means of signal intensity of the hypointensity) the absence of any discrimination between 
healthy successfully engrafted and dead SPIO labelled cells phagocytosed by macrophages 
within the heart. Particularly, no differences in signal voids up to more than 40 days were ob-
served between dead and viable cells recipients with respect to size, number and localisation. 
Therefore, just signal loss in T2-w MR Images overestimates SPIO-labelled stem cells survival 
after transplantation in the heart (12). Similarly, by performing quantitative MRI mapping we 
were able to depict a slow decrease of the R2 values of the injected cells which remained higher 
than the relaxivity values of the normal myocardium for the length of our investigation. These 
findings confirmed for the first time by MRI mapping that SPIO is not a suitable probe for the 
longitudinal follow-up of the in vivo fate of implanted cells. 
It is worth to observe that one limitation of this study was related to a quantitative MRI ap-
proach based only on R2 and not also R2* measurements. First, because R2* values are more 
sensitive to changes from the intracellular to the extracellular space (decrease) and second 
because a calculated R2’ (R2*-R2) would probably have been more sensitive in depicting 
subtle changes. R2* measurements have been attempted, however we found this approach 
not possible to achieve at 7T, since the MR signal saturates at very short echo time, making 
impractical R2* curve fitting. 
Cell proliferation, cell migration, cell death, extracellular SPIO dispersion or aggregation ex-
hibit different relaxivities. Unless, there is only one well defined  process happening in a re-
stricted volume of interest in vivo quantification is very complex, as previously investigated in 
vitro by our previous study (13).
In conclusion, many of the techniques to image stem cells are promising but further work 
is required before a wide clinical translation becomes reality. From the review of the current 
literature it seems that there is “no single best method”, rather an array of different techniques, 
each one with specific advantages in terms of spatial resolution, sensitivity and specificity. 
Reporter gene imaging, considered as the most reliable approach in the quantitative short and 
long term evaluation of engraftment and survival, is still associated with unsolved issues such 
as gene silencing, immunogenicity and debated safety. MRI offers great spatial resolution and 
quantitative capabilities; however currently available probes are sub-optimal. The development 
of hybrid techniques (MRI/PET) together with improved reporter genes would certainly play 
a role in the quantitative assessment of cell transplantation in longitudinal studies.
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CINE T1 Mapping in the rat myocardium
Abstract
Purpose: To evaluate the reproducibility and sensitivity of the modified CINE inversion re-
covery (mCINE-IR) acquisition on rats for measuring the myocardial T1 at 7T.
Materials and Methods: The recently published mCINE-IR acquisition on humans was ap-
plied on rats for the first time, enabling the possibility of translational studies with an identical 
sequence. Simulations were used to study signal evolution and heart rate dependency. Gado-
linium phantoms, a heart specimen and a healthy rat were used to study reproducibility. Two 
cryo-infarcted rats were scanned to measure delayed enhancement (DE).
Results: In the phantom reproducibility studies the T1 measurements had a maximum co-
efficient of variation (COV) of 1.3%. For the in vivo reproducibility the COV was below 
4.8% in the anterior cardiac segments. In simulations, phantoms and specimens a heart rate 
dependency of approximately 0.5 ms/bpm was present. The T1 maps of the cryo-infarcted rats 
showed a clear lowering of T1 in de DE region.
Conclusion: The results show that mCINE-IR is highly reproducible and that the sensitivity 
allows detecting T1 changes in the rat myocardium.
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Introduction
Estimating the T1 relaxation parameter of tissues is a promising MRI technique which can be 
used for detecting and characterizing different types of pathology in vivo. T1 estimation has 
drawn an increasing amount of attention in the past few years, as the quantitative measure-
ments have the potential to be less vendor and scanner dependent than the conventional T1-
weighted images (1), which are not normalized and are characterized by signal intensities and 
contrasts dependent on specific pulse sequences. 
In clinical MRI, T1 mapping has been increasingly applied for the study of ischemic heart 
disease, adding valuable information to the more established technique of delayed contrast en-
hancement (DE) (2,3,4). With DE the relative signal difference between healthy and infarcted 
myocardium is used to assess tissue viability (5,6,7,8), but there is no calibrated quantification 
and it also does not identify diffuse interstitial myocardial fibrosis. Recent work has shown that 
T1 mapping can differentiate between viable and necrotic tissues after contrast administration 
(4,9,10,11) and that it can be used to identify diffuse myocardial fibrosis (3,12). In preclinical 
research, myocardial T1 mapping has already proved capable of detecting the presence of edema 
in the myocardium (10,13). Another interesting preclinical application of T1 mapping would 
be to enable the visualization and quantification of injected labeled stem cells (14,15). 
Several methods and sequences have been introduced to measure the T1 in the cardiovascular 
system. The most common approaches include the Modified Look-Locker inversion recovery 
method (MOLLI), the variable flip angle method and the CINE Inversion recovery method. 
The use of MOLLI sequences is frequently reported in human (9,16,17) and also applied in small 
animals (18). It is a single-slice technique that acquires data during a number of consecutive 
inversion recoveries and merges that into one image set. In humans the images are acquired in a 
single-shot balanced SSFP acquisition with an acquisition window of about 190 ms during the 
end diastolic phase when the myocardium is relatively stable. However, in small animals where 
the RR interval is only 100-200 ms this approach is not possible. A segmented acquisition can be 
performed but that leads to long scan times up to 43 minutes to create one T1 map (18). A recent 
work (19) used temporal undersampling and radial acquisition to reduce scan time. This led to 
reproducible cardiac T1 estimations but with an in-plane resolution of 0.60x0.60 mm. As the rat 
myocardium is approximately 1.5-2 cm it is desirable to achieve a higher resolution. The MOLLI 
method has been reported to show a heart rate dependency of the estimated T1 values in humans 
(20,21). In most other works the relation of the estimated T1 with heart rate is not investigated. 
A three dimensional variable flip angle method has been implemented in small animals (22), 
and has shown reproducible results on mouse myocardium where it was able to detect regional 
differences in mice with induced infarction. The drawbacks of this method are the long scan 
duration up to 50 minutes to acquire 5 different flip angles and the sensitivity to B1 imper-
fections. The CINE inversion recovery method (CINE-IR) sequence was first developed for 
human studies. That implementation consists of an inversion pulse played out after a cardiac 
trigger, followed by data acquisition in a segmented multi-phase fashion (CINE) (23). A second 
heart cycle can be left unperturbed to allow the longitudinal magnetization to recover (24,25). 
This approach could potentially cause problems for small animal imaging, since the T1 values 
found in the heart can be in the range of 1000 ms, while the RR interval is around 150-180 
ms. This implies that when the acquisitions are performed in one RR interval there is only a 
partial recovery of longitudinal magnetization and only a small part of the inversion recovery 
curve can be measured.
In the processing, one of the frequently reported options to estimate T1 by fitting the MRI 
data to the signal model is to make use of a Least Squares (LS) method (26,27,28). While this 
approach is accurate for a normal noise distribution, in MR magnitude images the noise dis-
tribution is Rician and the results of LS estimation are no longer accurate (29). Furthermore, 
in literature usually no uncertainty measure is reported for T1 estimations (4,16,22).
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To deal with the fast heart rate of small animals, our study employs a modified version of the 
CINE inversion recovery (mCINE-IR) that has recently been applied for the estimation of 
myocardial T1 in humans (2). With respect to the original version of the CINE-IR sequence, 
in mCINE-IR the number of acquired cardiac phases is variable to allow sampling of a suffi-
cient part of the relaxation curve. Since the sequence is applicable both on high and low heart 
beat rates and at various resolutions without modification, it facilitates translational studies 
from small animal to human models. 
The contribution of this work is that it evaluates this novel T1 mapping protocol for the first 
time on small animals in terms of reproducibility and sensitivity. Two sources of potential er-
ror are studied in more detail. The first is that the excitation could be heterogeneous due to 
the pulse profile and out of plane motion as mCINE-IR is a single-slice technique. This effect 
could lead to heterogeneous relaxation behavior. The second is the effect of different heart 
rates on the estimated T1 values, which change sequence timings and could therefore affect 
the acquisition. The effect of these two sources of error on the reproducibility and sensitivity of 
the T1 estimations are investigated. To do this a novel estimation method based on maximum 
likelihood estimation is deployed, which is more accurate than a LS method, includes estima-
tion of the noise level and shows the uncertainty of the estimated T1. Simulations are used to 
investigate the propagation of the errors introduced by the heterogeneous relaxation behavior, 
heart rate changes and noise to the estimations and therefore the accuracy and precision of 
the estimated T1 values. Additionally, phantom and in vitro MRI studies with mCINE-IR are 
Figure 1: The mCINE-IR pulse sequence. A FSPGR, RF = 5°, CINE acquisition is performed between adiabatic inver-
sion pulses. The number of cardiac cycles between two inversions, NRR, can be chosen freely to achieve sufficient longitu-
dinal regrowth of magnetization. In this example the magnetization of the tissue with T1 = 400 has reached equilibrium 
in the given time, but for the tissue with T1 = 1000 it could be beneficial to increase NRR to allow more regrowth of 
magnetization. The points on the T1 = 400 ms curve indicate the used points for the T1 estimation in the myocardium, 
taken during the diastolic phase.
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performed to investigate the precision and reproducibility of the estimations from real MR 
images. Finally, mCINE-IR is used for acquisitions on rats to investigate the reproducibility 
in vivo and to evaluate whether the accuracy and reproducibility of mCINE-IR is sufficiently 
high to detect T1 changes in the rat myocardium due to the delayed enhancement of a cryo-
infarcted region.
Materials and Methods
pulse Sequence
The modified CINE acquisition (Figure 1) is based on the original CINE Inversion Recovery 
sequence (23,24,25). It uses a non-selective adiabatic inversion pulse, applied immediately 
after a cardiac trigger. It is followed by a continuously applied Fast Spoiled Gradient Echo 
(FSPGR) acquisition. As demonstrated earlier this continuous application of small angle RF 
pulses will affect the longitudinal relaxation of magnetization and decrease the apparent T1 
(30). Unlike normal CINE sequences the acquisition is not limited to one or two RR intervals 
(24,25), but the number of heartbeats between two subsequent inversions can be chosen freely 
and optimized for the application. A viewsharing algorithm and linear retrospective interpola-
tion are performed on the recorded data to reconstruct the subscribed number of images of 
cardiac phases per RR interval (31). Each individual image experiences a different time delay 
after the inversion pulse and therefore has a different T1 weighting. 
 
Data acquisition
For the acquisitions a 7.0 T preclinical scanner (Discovery MR901TM, Agilent Technologies – 
GE Healthcare) was used with a 72 mm volume transmit coil and a 4 channel phased-array sur-
face receive coil. The acquisitions were performed using ECG triggering with a temporal reso-
lution of 1 ms. The T1 values measured in the rat myocardium were expected to be in the range 
of 700-1000 ms, and with a typical RR interval (TRR) of 165 ms, the number of heart cycles 
between two inversions (NRR) was chosen to be 15 such that the effective repetition time (TReff 
= TRR x NRR) ranges up to approximately 2500 ms providing enough time for a sufficient signal 
recovery. The number of views per segment was 6. Since images were reconstructed from each 
of the NRR cardiac cycles in a CINE fashion, also NRR points of the inversion recovery curve in 
the same cardiac phase are available. We selected images from the diastolic phase, which made 
it possible to register images with different inversion times fairly easy, which results in a more 
accurate T1 estimation. The resulting TI values depend on heart rate, starting from the first 
diastolic phase and increasing with steps of TRR. For a heart rate of 365 bpm this resulted in TI 
values from 91 ms up to 2380 ms. During TReff the selected slice is continuously excited and 
sampled by the FSPGR RF pulses with a constant repetition time to maintain the steady state. 
For the FSPGR acquisition the flip angle = 5 degree, the TR = 3.8 ms and the TE = 1.3 ms. 
An open source electronics board (ARDUINO, http://arduino.cc) was used, for recording real 
heart rates from rats and for gating the scanner with simulated ECG pulses. This hardware 
allows real time interruptions at high temporal resolution. We scaled the temporal resolution 
to 64 μs. For all in vitro scans the temperature was controlled at a constant value with a hot 
air blowing system and a MR compatible thermometer (SA Instruments, Stony Brook, NY).
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T1 estimation
For the T1 estimation a three parameter exponential signal model was fitted through the data. 
The signal model used for the modified CINE acquisition was (30):
[1.]
With parameter vector θ = {A, B, T1}. To obtain θ a Maximum Likelihood (ML) estimator was 
used which maximizes the joint probability of the measurements and takes the Rician noise 
distribution of the magnitude MR images into account. The probability density function of 
the Rician distributed signal y is:
[2.]
Where Sθ is the predicted noise free magnitude, σ the standard deviation of the noise in the 
complex MR data, I0 is the zeroth order Bessel function of the first kind and  the Heaviside 
function. To obtain the parameters in θ the logarithm of the joint likelihood for the measured 
points was maximized in a numerical optimization with a gradient descent type procedure us-
ing a trust region method, solving: 
[3.]
The noise level σ is also estimated during the optimization. To avoid that the estimator finds a 
local maximum the optimization was iteratively initialized with a range of different values for 
θ, after which the best fit was chosen.  When using a ML estimator and when the derivative 
of the signal model to θ is known the square root of the Cramér-Rao lower bounds (CRLBσ) 
(29) can be calculated, which gives a lower bound on the standard deviation of the estimated 
parameters and can therefore be used as an indication of the uncertainty of the estimated 
parameters.
Two types of estimations are used in our work. The first is a region-based estimation, in which 
all the voxels in a defined region are used for one single estimation. The second method is 
voxel-based, in which for each individual voxel within a region T1 estimation is performed. 
The whole estimation pipeline was implemented in an in-house written Matlab (The Math-
works, 2008) script. 
 
Simulation experiments
Bloch simulations of signal intensities were performed in Matlab. Signal evolution distorted 
with Rician noise was simulated with the parameters of the mCINE-IR sequence. The T1 was 
estimated by the same procedure as for the real MR data. Three experiments were performed. 
The first was a simulation of the magnetization components of three different homogenous 
tissues with T1 values of 450, 1150 and 2400 ms during an mCINE-IR acquisition at an heart 
rate of 365 bpm to see the signal evolution during the acquisition. Other simulation param-
eters were flip angle = 3.5 degree, TR = 3.8 ms, equilibrium magnetization = 1 and the σ of 
added Rician noise = 0.05. The second experiment consisted of 1000 T1 estimations with the 
same three tissues as in the first experiment. The T1 was estimated for 12 different heart rates 
between 265 and 485 bpm to investigate whether a heart rate dependency exists. The third 
experiment was designed to study the effect of heterogeneous relaxation behavior within a re-
gion of interest.  As mCINE-IR is a single-slice technique the excitation can be heterogeneous 
due to the pulse profile and out of plane motion. This could lead to heterogeneous relaxation 
behavior within a volume, with apparent different T1 values. Also the T1 values in biological 
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tissue are not likely to be completely homogenous, even in a small region. To investigate this, 
the second experiment was repeated but now with a signal that was a mix of the tissues with T1 
= 100 and 2100 ms in a ratio 1:3, thus simulating a region with a small compartment of short 
T1 tissue. To quantify the heart rate dependency a straight line was fitted through the means 
to obtain the slope with 95% confidence intervals.
 
phantom experiments
A phantom of different dilutions of the T1 modifying contrast agent Gadolinium (Magnevist, 
Bayer, Germany) was constructed to perform MRI experiments.  Six different water solutions 
were created in which the Magnevist was diluted 750, 1500, 2250, 3000, 3750 and 4500 times 
respectively. The acquisition was always performed during NRR = 15 cardiac cycles, leading to 
TReff values from respectively 1856 ms to 3396 ms depending on the simulated heart rate. 
The scan parameters for the phantom scans were matrix = 256x192, NEX = 6, FOV = 45x34 
mm, in-plane voxel size = 0.17x0.17 mm, slice thickness = 2 mm and scan time approximately 
6 minutes. To simulate a phantom with heterogeneous relaxation behavior, the signals of the 
750 and 4500 times diluted Gd solutions were mixed by using all voxels in a single region-
based fit. Since the protocol acquires 12 images per cardiac cycle, in total 12*NRR images were 
acquired. Although all of these could be used in the T1 estimation since there is no motion 
in the phantoms, only one from each cardiac cycle was used to mimic the procedure taken in 
vivo where only the images from the diastolic phase are selected. A region-based estimation 
was performed by drawing regions of interest in the tubes covering the whole tubes except the 
outer 1 mm to avoid boundary effects. In a first experiment to study the reproducibility of the 
results of T1 estimation with the mCINE-IR the phantoms were scanned seven times with a 
heart rate of 365 bpm. The mean and standard deviation were calculated. The second experi-
ment was to study the effect of different heart rates. The T1 of each individual phantom and 
of the mixed signal was estimated for 12 different heart rates between 265 bpm and 485 bpm 
with steps of 20 bpm. A line was fitted through the T1 values to obtain the slope with 95% 
confidence intervals.
ex vivo experiments
A rat heart was post mortem surgically removed from the body and fixated in agar gel. Scan 
parameters were acquisition matrix = 256x192, NEX = 6, FOV = 50x38 mm, in-plane 
voxel size = 0.20x0.20 mm, slice thickness = 2 mm, and scan time approximately 6 min-
utes.  A region of interest of approximately 5x5 mm was drawn in the myocardium and a 
region-based T1 estimation was performed. To evaluate the reproducibility the specimen 
was scanned five times with a constant heart rate of 365 bpm. To study the heart rate de-
pendency the specimen was scanned with the same heart rates as the phantoms, rang-
ing from 265 to 485 bpm, and the slope with 95% confidence intervals was estimated. 
In vivo experiments
All experiments with animals were performed with prior approval of the institutional animal 
care committee and according to Dutch law.
To study the characteristics of the heart rate of rats in vivo, 1000 RR intervals of two healthy rats 
and four infarcted rats were recorded during scanning. The duration of each RR interval was mea-
sured, and the mean and standard deviation were calculated.  For the imaging experiments the 
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heart rate of the scanned rat at the beginning of the examination was stored in the DICOM header. 
In a reproducibility experiment one healthy rat was scanned in four different scanning ses-
sions to test the reproducibility of the T1 estimations with mCINE-IR in vivo. Scan param-
eters were acquisition matrix = 256x192, NEX = 6, FOV = 60x45 mm, in-plane voxel size = 
0.23x0.23 mm, slice thickness = 2 mm, and scan time approximately 6 minutes.  The trig-
gering was provided by peripheral pulse oxygenation level monitoring on the hind leg of the 
rats (SA Instruments, Stony Brook, NY, USA). To define the region of interest, the inner and 
outer boundaries of the myocardium were manually drawn on the short axis image. Since the 
measurements were performed in separate scanning sessions, the positioning of the rat and 
the myocardium could be different for each case. Therefore a two-step image registration was 
applied to define corresponding regions of interest. In the first step five anatomical landmarks 
were selected, two points on the intersection of the ventricles and three points on a straight 
line through the apex and the centre of the right ventricle. These points were used for a rigid 
point based registration. The result of this registration was used as the initialization for the 
second step, which was intensity based rigid registration with a mutual information metric 
(32) using open source elastix software (33). The myocardium region was divided into six 
standardized regions (34) by using the selected landmarks. Then a voxel-based estimation was 
performed for all these segments. The voxels where the CRLBσ was less than 15% of the T1 
value were defined as successful fits. The mean T1 and the standard deviation of the successful 
fits within one segment were then calculated per segment. 
In two rats a cryo-infarct was created by exposing the heart through a thoracotomy and apply-
ing a cryoprobe for 14 seconds on the anterior LV wall. The rats were scanned at three time 
points with mCINE-IR: pre-contrast and at 5 and 16 minutes after administration of the 
gadobutrol (Gadovist, Gadovist, Bayer Schering Pharma AG, Berlin, Germany) with a con-
centration of 0.5 mmol/kg. Scan parameters were acquisition matrix = 256x192, NEX = 10, 
FOV = 50x38 mm, in-plane voxel size = 0.20x0.20 mm, slice thickness = 2 mm, and scan time 
approximately 10 minutes. A standard T1 weighted inversion recovery fast gradient echo se-
quence was used to show the presence of DE 3-5 minutes after injection. The scan parameters 
were matrix = 192x160, TE/TR = 1.2/3.4, NEX=40, flip angle = 14 degree, slice thickness = 
2 mm, inversion time 100 ms, and scan time 2 minutes. In the processing the myocardium 
was defined by drawing the inner and outer boundary on the image with the longest inversion 
time and therefore highest SNR. Voxel-based T1 maps were created for the three time points. 
 
Results
Simulation 
Figure 2 shows the results of the simulated signal evolution. The three different grayscales 
represent the three tissues. As can be seen the magnetization goes to a different equilibrium 
value for each tissue. For longer T1 values this equilibrium is lower, which is an effect of the 
constant application of RF pulses. The estimated T1 values are 369, 735 and 1101 ms, lower 
than the true values of 450, 1150 and 2400 ms. Figure 3a is the outcome of the simulations of 
1000 estimations per tissue and per heart rate for the three tissues. The scattered points are the 
outcomes of the estimations, 1000 for each heart rate and each tissue, and the gray box with 
the black line is the mean with 95% confidence intervals. The results show that for longer T1 
values there is a larger variation in the estimations. This is in line with the results in Figure 2, 
which shows that for longer T1 values the signal to noise ratio (SNR) is lower. Also a smaller 
part of the total recovery curve is sampled with longer T1 values. Higher heart rates also result 
in a larger variation of the estimations. However, there is no significant effect on the mean of 
the estimated T1 values. All means are close to each other and with a large margin within each 
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other’s 95% confidence intervals. There is no trend that the estimated T1 goes up or down 
with heart rate. 
In Figure 3b the result of the simulation 
with the mixed tissue is shown, which was 
an approximation of a region with a long 
and a short T1 component. The T1 esti-
mations show a significant slope, and a de-
crease of estimated T1 with an increasing 
heart rate occurs. With a linear fit through the means of the estimations it results that the slope 
of this line with 95% confidence interval is -0.51 (-0.54, -0.48) ms/bpm, meaning that the T1 
for this mixed tissue decreases with 1 ms per extra two beats per minute. 
phantom
The results of the reproducibility experiments are in Table 1 with the mean outcome per phan-
tom, the standard deviation of the seven experiments, the mean CRLBσ for the estimations and 
Figure 2: The simulated inversion recovery signal evo-
lutions of the three different T1 values. The estimated 
T1 values are 369, 735 and 1101 for three tissues. TR 
= 3.8 ms, equilibrium magnetization = 1 and the σ of 
the added Rician noise is 0.05. The figure shows that 
SNR decreases for higher T1 values.
Figure 3 Simulations of T1 estimations. Figure 3a are the estimations of the homogenous tissues; Figure 3b on the com-
bined tissue of the highest and lowest T1. There are 1000 estimations per tissue for each heart rate. The gray boxes behind 
the points show the mean and the 95% confidence interval of the mean. For the homogeneous tissues the uncertainty 
increases for higher heart rate and higher T1, but the means do not change with heart rate. The T1 estimations of the 
mixed signal decrease with heart rate with a slope of 0.51 ms/bpm.
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the COV.  The 3750x diluted phantom has a high T1 and was the farthest from the receiver 
coil, which resulted in a poor SNR of a maximum value 1.5 at the equilibrium, which resulted 
in a COV of 5.4%. For the other five phantoms the COV was within 1.3%.  The CRLBσ val-
ues are all in the same range, or a little lower than the standard deviations, as expected from 
lower bounds on the standard deviation. In Figure 4 the results of the experiment with the dif-
ferent heart rates are displayed. The 3750x diluted phantom was excluded from this figure for 
clarity as the error introduced by the low SNR exceeded the effect of the changing heart rate. 
The black lines are for the five phantoms. The gray points are for the fit on the mixed signal. 
Next to each curve the fitted slope is displayed with 95% confidence intervals. It shows that as 
the T1 increases the slope also slowly increases, going from -0.02 to -0.27 ms/bpm, which was 
not observed in the simulations. For the mixed signal the slope with 95% confidence intervals 
is -0.54 (-0.61, -0.48) ms/bpm, significantly steeper than for each of the phantoms separately, 
which is in agreement with the simulation results.
ex vivo
The reproducibility experiment resulted in a mean T1 of 643.2 ms of the region of interest in 
the myocardium with a standard deviation of 2.9 ms and a COV of 0.45%, showing a similar 
reproducibility as in the phantoms. The results of the heart rate dependency experiment are 
plotted with CRLBσ error bars in Figure 5. The slope of the line fitted through the points with 
95% confidence intervals is -0.50  (-0.60, -0.40) ms/bpm, which is in the same range as the 
mixed phantom and significantly steeper than the homogenous phantoms.
Figure 4 The outcome of the T1 estimations on the 
phantoms for 12 different heart rates. The black scat-
tered point are the estimated T1 values of the five 
phantoms. The gray points are the combination of the 
high and low dilution. The numbers printed on the 
right are the slopes of the dashed lines fitted through 
the measurements. The slope for the mixed signal is 
steeper than for each of the dilutions individually. 
Figure 5: The estimated T1 values for the myocardium 
specimen. The scattered points are T1 estimations at 
different heart rates. The error bars are calculated with 
the Cramér-Rao lower bounds. The dashed line is fit-
ted through the measurements and has a slope with 
95% confidence interval of 0.50 (0.40, 0.60) ms/bpm, 
displaying a heart rate dependency.
C
ha
pt
er
 7
151
In vivo
The heart rate measurements of the four infarcted and two healthy rats resulted in a mean RR 
interval and standard deviation for each rat. For the infarcted rats the average mean RR interval 
and the average standard deviation were 365 and 13 bpm and for the healthy rats 370 and 13 bpm. 
Figure 6 shows the reproducibility results for the six segments of the myocardium. The per-
centage of successful fits, which have a CRLBσ of less than 15% of the estimated T1 value, is 
displayed for each segment, as well as the mean T1 with standard deviations. The reproduc-
ibility and the percentage of successful fits are higher for the three anterior segments than for 
the three inferior segments. The COV of the mean T1 is below 4.8% for the anterior segments, 
while it is above 12% for the inferior segments. The mean heart rate was 355 bpm with a stan-
dard deviation of 10 bpm.
Dilution Mean T1 (ms) Std (ms) CRLBσ (ms) COV
750 188.9 1.9 1.7 1.0%
1500 314.0 3.9 3.4 1.2%
2250 493.2 5.5 3.4 1.1%
3000 633.7 5.5 5.6 0.8%
3750 723.7 39.0 22.1 5.4%
4500 749.6 9.8 6.8 1.3%
Table 1: Outcomes of the T1 estimations for the six different Gd dilutions. The measurement is repeated seven times and 
the mean, the standard deviation, the CRLBσ and the COV of these seven measurements are displayed.
Figure 6 The results of the reproducibility study on the six segments of the rat myocardium. Mean and standard deviation 
of are plotted for the four experiments. The mean T1 with standard deviation of the mean and the percentage of success-
ful fits are displayed as text. The range of the T1 values axis is different for the upper and the bottom row. The anterior 
segments show both a high fit success rate and a reproducible outcome with all COV values below 5%. The inferior seg-
ments have lower success rates and less reproducible outcomes, all with a COV above 12%.
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In Figure 7 the results for the DE experiments are displayed for both rats. On the left the pre-
contrast T1 map estimated from mCINE-IR is displayed as an overlay over the myocardium. 
There are no distinct regions with a different T1. After contrast administration the standard 
T1W IR was acquired to demonstrate the presence of DE, shown in the figure with an arrow. 
For both the rats a distinct region of bright signal is visible in the myocardium. These regions 
are also present, at the same location, in the post-contrast T1 maps. As can be seen from the 
overlay the T1 in the infarcted regions is clearly lower than the T1 of the healthy myocardium. 
The infarcted T1 is also similar in both the time points, 5-15 minutes and 16-26 minutes after 
administration, while the T1 of the healthy myocardium is already increasing in the second 
time point with respect to the first. 
Discussion
Our results have shown the reproducibility in vitro and in vivo of a T1 mapping technique 
based on the mCINE-IR sequence, applied on small animals. The dependency of the estimated 
T1 on heart rate for biological tissue is around 0.5 ms/bpm, as shown in Figure 4 and 5. The 
standard deviation of both the six recorded RR intervals and the heart rates of the reproduc-
ibility study was around 10 bpm, which would result in a T1 change of 5 ms. However, when 
the rats were under anesthesia it was sometimes observed that their heart rate slowly decreased 
during the scan, up to heart rate differences in the order of 50 bpm, corresponding with T1 
changes of 25 ms. This is still only a small error in comparison with the T1 difference between 
the infarcted and healthy myocardium, as shown in Figure 7. However, in research where the 
goal is to detect smaller T1 differences the heart rates of the animals should be monitored to 
have the option to correct the T1 if large heart rate differences occur. But from the clear dis-
tinction in the T1 maps between infarcted and healthy myocardium, together with the repro-
Figure 7 The results of the DE experiments for both rats. The pre-contrast T1 map shows no distinct regions with a dif-
ferent T1. In the T1W images the DE of the infarct is clearly visible and indicated with an arrow. The post-contrast T1 
maps show a substantial lowering of T1 in the infarcted region.
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ducibility results which show that the COV in vivo is below 5%, it is clear that mCINE-IR is 
a promising technique for measuring the T1 in the myocardium of small animals.
In our sequence, due to the continuous application of the small angle RF pulses the relaxation 
is characterized by an apparent time constant T1 (often referred as to T1*), which is shorter 
than the original T1. The relation between the observed T1* and T1 can be described with the 
following formula (35):
[4.]
with α flip angle in degrees and TR the repetition time of the small excitations. However, this 
correction is very sensitive to small changes in α and therefore α has to be known with a high 
precision. Although various B1 mapping methods exist (36,37), achieving such a precision a 
still a challenge. Another correction factor that is proposed and used in literature (30,35) is:
[5.]
where A and B are the two fitting constants from the signal model in equation 1. This correc-
tion factor can only be applied when the signal inversion recovery starts from the completely 
recovered equilibrium value. This is not the case since the magnetization has a smaller equilib-
rium value due to the constant RF pulse application. 
The simulation results show that for a mixture of long and short T1 values a heart rate depen-
dency is introduced that is not present in homogenous tissues. As the heart rate gets higher, 
TReff gets shorter and a shorter part of the recovery can be sampled, which affects the estima-
tion and causes the apparent T1 to be shorter. This is also shown by the results of the mixed 
phantom in Figure 4, which displayed a steeper heart rate dependency than each of the in-
dividual phantoms. However, the homogeneous solutions also show a mild heart rate depen-
dency. Possible explanations are B1 inhomogeneities or a RF pulse profile that is not constant 
over the entire slice. When the flip angle changes over the volume, equation 4 shows that the 
apparent T1 will be influenced which could introduce a mixture of T1 values within a voxel 
or a region.
To address the heart rate dependency caused by a mixed signal an approach could be bi- 
or multi-exponential fitting. Several other works have tried this with mixed results. In (38) 
mono- and bi- exponential fitting was evaluated for both T1 and T2 mapping in the human 
brain. For the T1 estimations all the cases scored better with a mono-exponential fit. A prob-
lem of multi-exponential fittings is that the extra degrees of freedom increase the uncertainty 
of the T1 values. An iterative approach, starting with mono-exponential and increasing the 
number of fitted exponentials could be a solution. Likelihood ratio tests (39) could be applied 
to test whether the addition of extra variables really improves the estimation.
Another way to deal with the heart rate dependency could be to change NRR  as demonstrated 
in (2). When the heart rate increases, TReff decreases. By adding extra cycles the effective repeti-
tion time could then be increased again. However, this method has some limitations. It is not 
desirable to change the acquisition protocol during a scan in which heart rate changes occur. 
Also, only steps of at least one RR interval, around 160 ms, can be added to or subtracted from 
the TReff. However, this corresponds with heart rate changes of approximately 22 bpm and 
since that corresponds with a T1 change of only 11 ms, this step size could be small enough 
and could be an effective way to reduce heart rate dependency effects. 
In the in vivo results, the fits were more successful on the anterior segments than on the in-
ferior segments. The inferior segments are at the heart-lung interface which is known to give 
susceptibility problems (40). This could be a cause of the difference in results. In our case 
another source of error could come from the use of a surface coil, as the inferior segments are 
farther from the coil than the anterior segments, which lowers the SNR.
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In conclusion, in this work the reproducibility of myocardial T1 mapping in small animals 
with mCINE-IR is evaluated and demonstrated to be good, and the capability to detect the 
T1 differences caused by DE is shown. It demonstrates that mCINE-IR is a promising new 
technique that could enable translational T1 mapping studies from small animal model to hu-
man with a single technique. 
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In the past decades an upcoming use of stem cells to repair incurable, diseased tissue occurred. 
This relatively new field of cell therapy in itself holds great promise for a variety of diseases and 
disorders such as cancer, cardiovascular disease, neurodegenerative diseases, and musculoskel-
etal disorders by providing unique opportunities for tissue regeneration and targeted therapy 
or drug delivery (1–4). In both pre-clinical and clinical studies, therapeutic benefit of cell 
therapy for all these aspects has been demonstrated (5–10). However, the understanding of the 
processes by which stem cell therapy results in therapeutic benefit are poorly understood. The 
exact role and fate of stem cells in host tissue after transplantation is the subject of ongoing 
exploration. Therefore, the ability to track the fate of transplanted cells in vivo, has been the 
focus of increasing numbers of research efforts. Molecular and cellular imaging techniques en-
able a complete assessment of the implanted stem cells with regard to viability, proliferation, 
migration, differentiation and contribute to important insights into the mechanism of action 
of stem cell transplantation (11,12). The basic concept in cell imaging consists of the labeling 
of suitable cells with a powerful contrast agent to enable visualization by imaging modalities 
such as MRI. In this route from cell culture to MRI scanning, many hurdles need to be taken 
resulting in many research questions: the contrast agent has to be designed in such a way to fa-
cilitate an efficient uptake by the cells in culture. (i) The optimal labeling concentration needs 
to be titrated, with regard to both labeling efficiency and cellular toxicity. (ii) Not only direct 
cellular toxicity, but also occult permanent damage to the cells’ genome needs to be established 
prior to cell transplantation. (iii) The contrast agent should not interfere with the cell’s func-
tionality, nor should it carry oncogenic potential. (iv) The contrast agent should be retained by 
the cell and not be transferrable to other cells in vivo (specificity). (v) The contrast agent should 
allow for a noninvasive assessment of cell engraftment and survival in the long term. (vi) The 
contrast agent should allow quantification using robust scanning sequences and sensitive coils. 
This thesis has addressed the above issues with regard to stem cell tracking using MRI, which 
will be discussed separately in the following sections.
Feasibility of cell labeling with Gd-liposomes
We demonstrated the feasibility of labeling MSCs with liposome encapsulated Gd. Liposomes 
appeared an efficient vehicle to deliver Gd inside the cell. The attained intracellular Gd con-
centration was considerably higher -up to nearly 100 times- than most intracellular Gd loads 
reported in other studies (see Table I, chapter 2). The liposome as a vehicle thus perfectly met 
our expectations: to yield high intracellular buildup. Even higher Gd loads were achieved with 
increasing Gd addition, owing to the abundant uptake of cationic liposomal lipids (DOTAP) 
through binding to anionic charges in the cell membrane. The advantages of electrochemi-
cal interaction in cell labeling have been demonstrated before (13). Exploiting the attracting 
forces of opposing electrochemical charges therefore seems a promising strategy. 
Gd-liposomes and their impact on cell function and viability 
With regard to toxicity, our results indicated a dose-dependent toxicity of Gd-liposomes. A 
slight toxic effect was observed, which was shown to be due to the lipid components rather 
than to Gd itself, in concordance with previous reports, indicating towards DOTAP as a cause 
of damage to cellular physiology (14).
Gd is toxic in its free, dechelated form, reported for the first time in 1992. Dechelated Gd 
is held responsible for the occurrence of the progressive, incurable and often crippling dis-
ease nephrogenic systemic fibrosis (NSF) in patients with renal failure. The awareness on this 
downside probably resulted in a collective reluctance to explore Gd-based formulations for 
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cellular labeling in the past decades, favoring T2 contrast agents like SPIO. This negative 
connotation of Gd was later on nuanced as being mainly a problem of the linear contrast 
agents. The macrocyclic Gadovist, as used in our thesis, is more resistant to dechelation and 
considered to be more stable (15) . Furthermore, NSF has only been identified to occur in pa-
tients with impaired renal function (16),  allowing selection of suitable patient groups for cell 
transplantation. Although the long-term biological effect of intracellular Gd was not assessed, 
the absence of fluorescent Gd-liposomes in the cell nucleus renders their interference with the 
cell’s DNA unlikely. Gd-liposome labeled MSCs maintained the multi-lineage differentiation 
capability, differentiating into both adipocytes and osteocytes. The absence of any Gd-related 
direct toxicity in our studies is therefore all the more important and offers opportunities to 
strengthen the future role for Gd as a cellular contrast agent. 
Quantification: the use of Gd-liposomes as a tool for functional read-out
In cell therapy, information on cell survival is of paramount importance since it is an absolute 
prerequisite of a favorable therapy outcome and because visualization of cell transplant viabil-
ity will contribute to our understanding of transplanted cell fate in vivo. Without cell survival, 
the migration, engraftment, differentiation and integration into tissue obviously is impossible. 
The reported high cell death rates post-transplantation (17–19) play a role here as well.  As 
histology provides only a snap-shot at a certain time point, an intra-individual longitudinal 
assessment of stem cell fate needs a different approach. The ability to noninvasively deduce 
basic functional information from cell transplants, would provide a powerful tool for evaluat-
ing therapy effect and initiate progress towards translational research. 
Quantification is a trending item in radiology. Comparing the MRI contrast behavior of viable 
to nonviable Gd-liposomes MSCs, a striking visually perceivable difference existed: whereas 
viable cells appeared hypointense (‘black’), nonviable Gd-liposome labeled cells appeared hy-
perintense (‘white’). Although the concept of a quick visual perception is and has been of 
tremendous importance in radiology, a field which traditionally has leaned on the subjective 
assessment of morphological changes quantification, the value and importance of quantifi-
cation is increasingly being recognized in radiology. To this end, we performed quantifica-
tion of the T1 and T2 relaxation times of both SPIO- and Gd-labeled cells in a longitudinal 
follow-up study, with regard to cell viability, sensitivity and specificity. Little was known on 
the quantification of Gd-labeled cells. With regard to the quantification of MSCs labeled 
with SPIOs however, we expected some challenges. Reportedly, the intravoxel distribution of 
the agent (20–22), the macroscopic susceptibility artifacts (23) and the relatively large size of 
SPIOs (causing false-positives due to engulfment by macrophages) (24) were shown to cloud 
quantification attempts. Indeed, we confirmed SPIO-labeled cells to be difficult candidates 
for quantification. The persistent signal void from both viable and nonviable SPIO-labeled 
MSCs revealed no significant distinction in R2 relaxation rate, during longitudinal follow-up 
for two weeks. In contradistinction, a significantly lower R1 and higher R2 relaxation rate was 
measured for viable Gd-liposome labeled MSCs compared with nonviable cells. A cell status 
dependent contrast behavior was shown for Gd-liposome labeled cells, dynamically changing 
from quenching (‘black signal’) to dequenching (‘white’ signal) with ongoing proliferation. 
Quantification: specificity of signal
To ensure that perceived contrast or measured signal indeed is attributed to the originally 
labeled cells, the contrast label needs to be labeled-cell specific, even after death of the labeled 
cell. Ideally, the contrast label should be non-transferrable to other cell types. Irrelevant sig-
162
Discussion
nal from non-viable Gd-MSCs resolved already at two hours post-transplantation, making 
Gd-liposomes a highly specific cell label. MRI signal from nonviable SPIO-MSCs however 
persisted for at least 15 days while at the original injection site. The superior performance of 
Gd-liposomes compared to SPIO was no surprise, realizing that SPIO reportedly produced 
false-positives up to 95 days post-transplantation (25), attributed to the persistence of SPIO-
laden tissue macrophages after cell death (26). A high specificity is indispensable to detect 
cell graft rejection at an early stage. In contrast, the vast majority of extracellular complexed 
Gd is expected to diffuse out rapidly to end up intravascularly (27) as a result of its biological 
short half-life and low molecular weight. This allows an effective escape from reuptake by sur-
rounding phagocytic cells. Indeed, only a tiny fraction of the initially injected Gd quantity, 
contained in nonviable MSCs, was retrieved at the site of injection at day 15.
Quantification: sensitivity of signal
For translational purposes to the clinical setting, sensitivity is at least as essential as specificity, 
to facilitate investigation of the long-term fate of implanted stem cells. The MSCs, which had 
the luciferase construct incorporated, exhibited a tumoral growth rate, which was considered 
a serendipitous advantage as it offered insight in dynamic contrast transformation as a result 
of proliferation. Accelerated SPIO dilution in highly proliferating cells is thought to occur 
as a result of iron metabolism in the physiological cellular pathways (28). It was therefore no 
surprise that MRI signal from Gd-liposomes labeled MSCs remained longer visible than the 
signal void of diluting SPIO labeled MSCs. An additional problem of SPIOs, of which the 
availability SPIOs has become problematic since the cessation of their manufacturing for eco-
nomic reasons (29), may have tipped the scales in cellular imaging in favor of Gd. 
Quenching effect
The ‘black’ (hypointense) signal generated by compartmentalized Gd is called “quenching” 
and is explained by the drop in r1 relaxivity caused by the decreased accessibility of H2O to 
compartmentalized (i.e. intracellular and/or intraliposomal) Gd (30,31). Our study was the 
first to show that the (de)quenching is related to cell viability and cell proliferation. Although 
the contrast range seems limited at first sight (black, white, or the grey in between), rules of 
thumb on the dynamic contrast behavior were defined, taking into account the pace at which 
contrast changes occur. To our belief, this is an important discovery, which can be added to 
the radiologist’s tools equipment, evading the use of laborious off-line retrospective (and some-
times expensive) quantification techniques. 
The quenching effect is dependent on several factors. Not only the compartmentalization state 
(viable vs non-viable state) is of influence, but also the availability of water in the proximity, 
the water exchange rate (dependent on the size of the liposomes), the Gd concentration per 
voxel and R2 effects play a role. These effects were all studied. For example, for equal voxel 
[Gd] less concentrated liposomes (0.3M Gd) yielded higher R1/R2 ratio because of the higher 
intraliposomal water fraction (vl). Regarding compartmentalization, less membrane barriers 
means a higher R1/R2 ratio, effectuated by both R1 and R2 effects. Understanding the un-
derlying principles allows one to tailor the optimal liposomal Gadolinium concentration ac-
cording to the desired goal. Labeling cells with compartmentalized Gd is not simply a case of 
loading the vehicle to the maximum. 
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pre-clinical evaluation 
To serve as a potential bridge towards a clinical translation we performed a preclinical evalua-
tion in a cardiac environment. The aim was to assess the feasibility of quantification techniques 
in a four-dimensional dynamic environment (a beating heart), per se. After successfully testing 
a double inversion recovery BBFSE sequence for its robustness and reproducibility, the signal 
from luciferase expressing SPIO-labelled MSCs implanted in the heart was measured. No 
significant correlation was apparent between bioluminescent signal profiles and MRI signal 
evolution. We argued that several different confounders occurring in parallel may contribute 
to the ambiguous signal behavior in vivo, such as cell redistribution in the injection site, re-
absorption of the injection medium, reuptake by bystander phagocytic cells or intracellular 
iron metabolism. Realizing that cell proliferation, cell migration, cell death, extracellular SPIO 
dispersion and aggregation all exhibit different relaxivities, we were able to demonstrate the 
difficulty to assess quantitatively in vivo, the properties of SPIO labeled cells by MRI. 
With regard to T1 quantification, we also tested the reproducibility and sensitivity of the mod-
ified CINE inversion recovery (mCINE-IR) acquisition on rats for measuring the myocardial 
T1 at 7T. The published mCINE-IR acquisition on humans was applied on rats for the first 
time, enabling the possibility of translational studies with an identical sequence. These results 
showed that mCINE-IR is highly reproducible and that the sensitivity allows detecting T1 
changes in the rat myocardium, offering new opportunities for Gd-labeled cell quantification.
These results emphasize the translational challenges for SPIO as a cell label. Surely, other cell 
labels might as well encounter (a selection of ) the mentioned issues, still making a swift clinical 
translation a major challenge. In general, small improvements in the field of sequence develop-
ment, coil development the optimization of contrast labels, together with a tight collaboration 
between radiologists, basic MR researchers and MR physicists, might eventually result in a 
giant leap towards clinical practice.  
Future perspectives: potential applications
Bearing in mind the ever ongoing shortage of donor organs, studies like these can be consid-
ered major breakthroughs and may ultimately turn out to be gamechangers in the field of cell 
therapy. We are convinced that, ever since the discovery of the ‘reprogammability’ of stem cells 
by Takahashi and Yamanaka in 2006 (32), more and more researchers will be attracted towards 
this field, demanding advanced methods to track their reprogrammed stem cells in vivo. 
Realizing that liposomes allow for a tremendous build-up of contrast agent, it is thinkable that 
the application of Gd-loaded liposomes might be further elevated to a higher level by other 
researchers, aiming to in vivo target cells, expressing certain ligands, rather than to label them 
in vitro. This was already shown to be a realistic and viable approach in a recent report (33), 
showing that macrophages could be targeted in vivo specifically using phosphatidylserine-con-
taining liposomes. The versatility of liposomes could finally be exploited to its fullest, combin-
ing a diagnostic contrast agent with a therapeutic agent (“theragnostics”). This fits very well in 
the currently emerging trend of personalized medicine, partially based on personal genomics 
(the personal genotyping of disease). Liposomes are to be seen as a potential important player 
in this new field of personalized medicine (34). 
Instead of serving merely as a contrast label for studying the fate of transplanted stem cells, 
the application of Gd-liposomes could be extended into other fields as well. For example, the 
lack of intracellular Gd metabolism might prove beneficial in oncology. Recently, evidence 
accumulated in the field of oncology on the existence of a tumor subpopulation with distinct 
characteristics resembling stem cells, coined as cancer stem cell (CSCs) (35). Eradication of 
the stem-cell compartment of a tumor is hypothesized to be the key to cure cancer (36). As 
isolation of these CSCs is possible, labeling of these highly proliferating CSCs in vitro is theo-
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retically possible. After implantation, this should allow to study the role of these CSCs by real 
time MR imaging in vivo, possibly offering new insights in cancer development in vivo. 
Another possible application to think of, is to image in vivo the extent of tumor heterogeneity. 
As known, many tumors exhibit different regions with different biological behavior and ex-
pression of different markers. Targeting these specific markers by liposomes in the blood-pool 
might depict specific regions of interest in the tumor. This might visualize highly aggressive 
subregions to be able to better tune the therapy and to assess the response to therapy. It might 
also obviate the need for a histological biopsy, avoiding the problems which arise with sample 
errors, e.g. after taking a biopsy of a less aggressive region.
Stem cell therapy in its early days was embraced as the long-awaited solution to incurable dis-
eases. Over the years, researchers in this field have had to acknowledge the complexity of stem 
cell therapy. Stem cell imaging has shown to be a strategic tool to elucidate some of the basic 
questions with regard to cell fate. This thesis contributed its parts by addressing several impor-
tant questions with regard to cell labeling. Cell labeling with either SPIOs or Gd-liposomes 
{Kim, 2010 #399}was shown to be a feasible technique thus earning its place in the repertoire 
of cell therapy monitoring tools. Especially Gd-liposomes appear to be a user-friendly cell la-
bel candidate, allowing a functional read-out of cells in vivo both visually and a relatively easy 
and straightforward quantification. The absolute highlight in this thesis was the discovery that 
using Gd-liposomes stem cell fate (i.e. cell viability and cell proliferation) can be made appar-
ent to the naked eye. In our opinion, this thesis adds a piece to the ‘stem cell therapy’ puzzle. 
Ongoing an upcoming collaborations across national and continental borders, bring new hope 
to further elucidate the ‘black box’ of stem cell fate in vivo.
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Summary
This thesis has addressed important issues with regard to stem cell tracking using MRI, which 
will be summarized separately in the following sections.
In chapter 2 cell labeling was performed with water soluble Gadolinium-DTPA containing 
liposomes, to allow for cell tracking by MRI. Liposomes were used to assure a highly con-
centrated intracellular buildup of Gd, aiming to overcome the relatively low MRI sensitivity 
of Gd (as compared to T2 contrast agents). Liposomes were positively charged (cationic) to 
facilitate uptake by binding to anionic charges in the cell membrane of bone marrow-derived 
mesenchymal stem cells (MSCs). We determined the cellular Gd load by variations in labeling 
time (1h, 4h and 24h) and liposome concentration (125, 250, 500, 1000 μM lipid), closely 
monitoring effects on cell viability, proliferation rate and differentiation ability. Labeling was 
both time- and dose-dependent. Labeling for 4h was most efficient regarding the combination 
of processing time and final cellular Gd uptake. Labeling for 4h with low-dose concentration 
(125 μM lipid, corresponding to 52±3 μM Gd) yielded an intracellular load of 30±2.5 pg Gd 
cell-1, without any effects on cell viability, proliferation and cell differentiation. Gd-liposomes, 
co-labeled with fluorescent dyes, exhibited a prolonged cellular retention, with an endosomal 
distribution pattern. In vitro assay over 20 days demonstrated a drop in the average Gd load 
per cell, as a result of mitosis. However, there was no significant change in the sum of the Gd 
load in all daughter cells at endpoint (20 d.), indicating an excellent cellular retention of Gd. 
MSCs labeled with Gd-liposomes were imaged with MRI at both 1.5T and 3.0T, resulting in 
excellent visualization both in vitro and in vivo. Prolonged in vivo imaging of 500,000 Gd-
labeled cells was possible for at least two weeks (3.0T).  
In chapter 3 the contribution of liposomal Gd concentration ([Gd]), size and compartmen-
talization state on relaxivity quenching were assessed. To this end, dependency of SI on intrali-
posomal [Gd] was assessed comparing three different intraliposomal [Gd] (0.3, 0.6 and 1.0M 
Gd) in both small (80nm) and large (120 nm) cationic liposomes. In addition, five compart-
mentalization states were compared: free Gd, intact Gd-liposomes, ruptured Gd-liposomes, 
Gd-liposomes in intact cells and Gd-liposomes in ruptured cells (simulating cell death). Gd 
also causes R2 effects, which is often overlooked. Therefore both R1 and R2 relaxation rate of a 
dilution range were measured by T1- and T2-mapping on a 7T scanner. As the unidirectional 
water efflux rate (outbound across the liposome membrane, κle) is proportional to the surface/
volume ratio, smaller liposomes yielded a consistently higher R1 than larger liposomes. For 
equal voxel [Gd] less concentrated liposomes (0.3M Gd) yielded higher R1/ R2 ratio because of 
the higher liposomal water fraction (vl).  Gd exhibits a dualistic behavior: from hypointensity 
to hyperintensity to hypointensity, with decreasing [Gd]. Regarding compartmentalization 
less membrane barriers means a higher R1/ R2 ratio. Gd-liposomes thus exhibit a versatile con-
trast behaviour, dependent on the compartmentalization state, liposomal size, intraliposomal 
[Gd] and liposome number. Both R1 and R2 effects contribute to this. The versatility allows 
one to tailor the optimal liposomal formulation to desired goals in cell labeling and tracking. 
In chapter 4 we investigated possible differences in R1, R2 or R2* relaxation rate as a measure 
of overall cell viability for mesenchymal stem cells labeled with Gd-liposomes (Gd-MSCs) or 
iron oxide nanoparticles (SPIO-MSCs). Cells were also transduced with a luciferase vector, 
facilitating a correlation between MRI findings and cell viability using bioluminescence im-
aging (BLI). Viable Gd-MSCs were clearly distinguishable from nonviable Gd-MSCs under 
both in vitro and in vivo conditions, clearly differing quantitatively (ΔR1 and ΔR2) as well as 
by visual appearance (hypo- or hyperintense contrast). Immediately post-injection, viable Gd-
MSCs caused a substantially larger ΔR2 and lower ΔR1 effect compared to
 nonviable MSCs. 
With time, the ΔR1 and ΔR2 relaxation rate showed a good negative correlation with increas-
ing cell number following proliferation. Upon injection, no substantial quantitative or visual 
differences between viable and non-viable SPIO-MSCs were detected. Moreover, non-viable 
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SPIO-MSCs caused a persisting signal void in vivo, compromising the specificity of this con-
trast agent. In vivo persistence of SPIO particles was confirmed by histological staining. A large 
difference was found between SPIO- and Gd-labeled cells in the accuracy of MR relaxometry 
in assessing the cell viability status. Gd-liposomes provide a more accurate and specific assess-
ment of cell viability than SPIO particles. Viable Gd-cells can be differentiated from nonviable 
Gd-cells even by visual interpretation. These findings clearly indicate Gd to be the favour-
able contrast agent in qualitative and quantitative evaluation of labeled cell fate in future cell 
therapy experiments. 
Chapter 5 presents an overview of the many facets of cell tracking in cardiac repair. Stem cell 
therapies hold the great promise and interest for cardiac regeneration among scientists, clini-
cians and patients. However, advancement and distillation of a standard treatment regimen are 
not yet finalised. Recent developments in the imaging biosciences offer promising opportuni-
ties. Thus far, these technical and protocol refinements have played a critical role not only in the 
evaluation of the recovery of cardiac function but also in providing important insights into the 
mechanism of action of stem cells. Molecular imaging, in its many forms, has rapidly become a 
necessary tool for the validation and optimisation of stem cell engrafting strategies in preclinical 
studies. These include a suite of radionuclide, magnetic resonance and optical imaging strategies 
to evaluate non-invasively the fate of transplanted cells. In this review, we highlight the state-of-
the-art of the various imaging techniques for cardiac stem cell tracking presenting the strengths 
and limitations of each approach, with a particular focus on clinical applicability.
Chapter 6 handles on the in vivo MRI mapping of iron oxide labeled stem cells transplanted 
in the heart.  In various stem cell therapy approaches poor cell survival has been recognized 
as an important factor limiting therapeutic efficacy. Therefore noninvasive monitoring of cell 
fate is warranted for developing clinically effective stem cell therapy. In this chapter we inves-
tigated the feasibility of the use of voxel-based R2 mapping as a tool to monitor the in vivo 
stem cell fate in myocardium when the cells are labeled with iron oxide particles (SPIO). To 
this end, single cardiac phase with cardiac triggered double inversion black blood 2D fast 
Spin echo (BBFSE) images were acquired on the short axis of hearts. Reproducibility studies 
were performed in normal rats imaged in different sessions. A double cell labeling approach 
was used in which mesenchymal stem cells were transduced with the luciferase gene and sub-
sequently labeled with ferumoxide particles (SPIO). Living labeled cells were injected in the 
myocardium of healthy Wistar rats. For control purposes animals were also injected with dead, 
labeled cells or saline. Cell fate was monitored over a period of 8 weeks by bioluminescence 
imaging following injection of D-Luciferine and quantitative magnetic resonance imaging, us-
ing a black blood FSE sequence with multiple echo times. Bioluminescence imaging revealed 
a significant increase of cell number during the first week (peak day 7) with a steep decrease 
of cell numbers to undetectable levels during the second week. MR imaging showed a sharp 
increase of R2 values shortly after injection at the injection site (peak day 5), followed by a very 
gradual decrease of R2 over a period of 15 days. No difference in appearance on T2-weighted 
images nor in R2-values was observed between living and dead cells over the entire time period 
studied. No significant correlation between the bioluminescence optical data and R2 values 
were observed. Quantitative MR imaging by means of R2-mapping is not suitable for the in 
vivo assessment of stem cell fate in rat myocardium as validated by bioluminescence imaging. 
These results do not follow previous in vitro reports where it was proposed that based on the 
difference in r2 relaxivity between intra-cellular and extra-cellular SPIO, living cells may be 
distinguished from death cells based on their R2 profile. Cell proliferation, cell migration, cell 
death, extracellular SPIO dispersion or aggregation exhibit different relaxivities. In vivo these 
processes happen simultaneously, making quantification very complex, if not impossible.
In chapter 7 we evaluated the reproducibility and sensitivity of the modified CINE inversion 
recovery (mCINE-IR) acquisition on rats for measuring the myocardial T1 at 7T. The priorly 
published mCINE-IR acquisition on humans was applied on rats for the first time, enabling 
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the possibility of translational studies with an identical sequence. Simulations were used to 
study signal evolution and heart rate dependency. Gadolinium phantoms, a heart specimen 
and a healthy rat were used to study reproducibility. Two cryo-infarcted rats were scanned to 
measure delayed enhancement (DE). In the phantom reproducibility studies the T1 measure-
ments had a maximum coefficient of variation (COV) of 1.3%. For the in vivo reproducibility 
the COV was below 4.8% in the anterior cardiac segments. In simulations, phantoms and 
specimens a heart rate dependency of approximately 0.5 ms/bpm was present. The T1 maps of 
the cryo-infarcted rats showed a clear lowering of T1 in de DE region. The results show that 
mCINE-IR is highly reproducible and that the sensitivity allows detecting T1 changes in the 
rat myocardium.
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In dit proefschrift worden enkele belangrijke kwesties behandeld met betrekking tot de beeld-
vorming van stamcellen met MRI. Hieronder zullen de afzonderlijke hoofdstukken achtereen-
volgens worden samengevat.
In hoofdstuk 2 werden stamcellen geladen met gadolinium(Gd)-DTPA bevattende lipo-
somen, om deze cellen vervolgens te kunnen visualiseren met MRI technieken. Om de relatief 
lage MRI sensitiviteit van Gd (vergeleken met T2 contrastmiddelen) trachten te overwinnen, 
werden liposomen als compacte en efficiënte contrastdragers gebruikt teneinde een  zeer gecon-
centreerde intracellulaire Gd concentratie te bereiken. Dankzij de positieve lading van de li-
posomen was een effectieve opname door binding aan anionische ladingen in de celmembraan 
van uit beenmerg afkomstige mesenchymale stamcellen (MSCs) goed mogelijk. Wij hebben 
de uiteindelijke intracellulaire Gd concentratie bepaald voor verschillende incubatietijden (1, 
4 en 24 uur) en verschillende intraliposomale Gd concentraties (125, 250, 500, 1000 μM 
lipiden), waarbij effecten op de levensvatbaarheid van de cellen, op de proliferatiesnelheid 
en het vermogen tot differentiatie nauwlettend werden bestudeerd. De uiteindelijke intracel-
lulaire Gd concentratie was zowel tijd- en dosis-afhankelijk. Een incubatietijd van 4 uur was 
het meest efficiënt met betrekking tot de combinatie van de doorlooptijd en de uiteindelijke 
intracellulaire Gd opname. Een incubatietijd van 4 uur met de laagste liposoom concentratie 
(125 μM lipiden, overeenkomend met 52 ± 3 μM Gd) leverde een intracellulaire Gd concen-
tratie op van 30 ± 2,5 pg Gd per cel, zonder enig effect op levensvatbaarheid van de cellen, 
proliferatie en cel differentiatie. Gd-liposomen, welke tevens waren uitgerust met fluorescente 
kleurstoffen, verdeelden zich in de cel over endosomen en vertoonden geen microscopisch 
waarneembare lekkage. In vitro studies  gedurende 20 dagen lieten een daling zien in de gemid-
delde Gd concentratie per cel als gevolg van mitose. Het feit dat de totale Gd hoeveelheid 
in alle cellen echter gelijk bleef, duidt op een goede intracellulaire retentie van het contrast. 
MSCs welke geladen waren met Gd-liposomen konden uitstekend afgebeeld worden met MRI 
bij een veldsterkte van 1.5T en 3.0T, zowel in vitro als in vivo. Een cluster van zeker 500.000 
met Gd-liposomen geladen cellen konden met MRI zichtbaar gemaakt worden voor ten min-
ste twee weken (bij 3.0T).
In hoofdstuk 3 werd de invloed van de intraliposomale Gd concentratie ([Gd]), de liposomale 
grootte en de compartimentalisatie op relaxiviteit ‘quenching’ bepaald. Daartoe werd bekeken 
in hoeverre variaties in intraliposomale [Gd] (0,3, 0,6 en 1,0 M Gd) en variaties in liposomale 
grootte (80 nm en 120 nm) kationische liposomen de signaalintensiteit (SI) beinvloeden. 
Daarnaast werd ook het effect van verschillende vormen van compartimentalisatie bestudeerd: 
vrij Gd, intacte Gd-liposomen, afgebroken Gd-liposomen, Gd-liposomen in intacte cellen 
en Gd-liposomen in geruptureerde cellen (celdood simulatie). Naast de bekende R1 effecten 
veroorzaakt Gd ook - vaak genegeerde - R2 effecten. Daarom werd zowel het R1 als het R2 
relaxatie tempo van een seriële verdunning gemeten door T1 en T2-mapping op een 7T scan-
ner. Aangezien de unidirectionele water efflux snelheid (uitgaand over het liposoommembraan, 
κle) evenredig is met de oppervlakte / volumeverhouding, leverden kleinere liposomen een 
consistent hogere R1 relaxatie tempo op dan grotere liposomen. Bij gelijkblijvende voxel [Gd] 
bleken de minst geconcentreerde liposomen (0,3 M Gd) de hoogste R1/R2 verhouding te heb-
ben, als gevolg van een grotere extraliposomale waterfractie (vl). Gd vertoont een dualistisch 
gedrag: van hypointensiteit tot hyperintensiteit en gradueel weer terug naar hypointensiteit, 
met afnemende [Gd]. Met betrekking tot compartimentalisatie kan gesteld worden dat minder 
membraanbarrières een hogere R1/R2 ratio betekent. Gd-liposomen worden dus gekenmerkt 
door een veelzijdig contrast gedrag, afhankelijk van de compartimentalisatie, de liposomale 
grootte, de intraliposomale [Gd] en het liposoom aantal. Zowel R1 en R2 effecten dragen 
hieraan bij. De veelzijdigheid maakt het mogelijk om de optimale liposomale formulering aan 
te passen aan de gewenste doelen in cel labeling en tracking.
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In hoofdstuk 4 onderzochten we mogelijke verschillen in R1, R2 of R2* relaxatie snelheid 
als maat voor cellulaire levensvatbaarheid voor mesenchymale stamcellen gelabeld met hetzij 
Gd-liposomen (Gd-MSC) hetzij ijzeroxide nanodeeltjes (SPIO-MSC's). De cellen werden ook 
genetisch gemodificeerd en uitgerust met een luciferase vector, om een correlatie tussen MRI 
bevindingen en de levensvatbaarheid van de cellen met behulp van bioluminescentie imaging 
(BLI) te faciliteren. Levende Gd-MSC's waren duidelijk te onderscheiden van dode Gd-MSCs 
onder zowel in vitro als in vivo omstandigheden, zowel kwantitatief (op basis van duidelijke 
verschillen in R1 en R2), alsook kwalitatief (hypo- of juist hyperintens contrast). Onmiddellijk 
na de injectie, veroorzaakten levende Gd-MSC's een aanzienlijk groter ΔR2 en lager ΔR1 effect 
in vergelijking met dode MSC's. Na verloop van tijd, lieten zowel de ΔR1 als de ΔR2 relaxatie 
snelheid een goede negatieve correlatie zien met toenemend aantal cellen na proliferatie. Na 
injectie werden geen substantiële kwantitatieve of visuele verschillen tussen levende en dode 
SPIO-MSC's gedetecteerd. Bovendien veroorzaakten dode SPIO-MSC's een aanhoudend 
signaalverlies in vivo, hetgeen ten koste gaat van de specificiteit. Persisterende aanwezigheid 
van SPIO deeltjes in vivo werd bevestigd door histologische kleuring. Met betrekking tot de 
beoordeling van de cel levensvatbaarheid blijkt er dus een groot verschil te bestaan tussen 
SPIO- en Gd-gelabelde cellen in de nauwkeurigheid van MR relaxometrie. Met Gd-liposomen 
is een meer accurate en specifieke beoordeling van de levensvatbaarheid van de cellen mogelijk 
dan met SPIO deeltjes. Levende Gd-gelabelde cellen kunnen worden onderscheiden van dode 
Gd-cellen, zelfs door visuele interpretatie. Deze resultaten wijzen in de richting van Gd(-
liposomen) als hèt contrastmiddel bij voorkeur in de kwalitatieve en kwantitatieve evaluatie 
van gelabelde cellen in toekomstige celtherapie experimenten.
Hoofdstuk 5 geeft een overzicht van de vele facetten van cel tracking in cardiale regeneratie. 
Stamceltherapie is een veelbelovende therapie welke de interesse heeft van vele wetenschap-
pers, artsen en patiënten. Zowel de voortschrijding als de vormgeving in een standaard behan-
delingsprotocol zijn echter nog verre van voltooid. Recente ontwikkelingen in de beeldvorm-
ingsbiowetenschappen zijn onmisbaar geworden. De technische en protocollaire verfijningen 
op dat vlak hebben een cruciale rol gespeeld bij de evaluatie van het herstel van de hartfunctie 
maar ook inzicht verschaft in het mechanisme van de werking van stamcellen. Moleculaire 
beeldvorming, in zijn vele vormen, is in korte tijd een noodzakelijk instrument voor de valida-
tie en optimalisatie van stamceltransplantatie in preklinische studies geworden. Deze omvatten 
een reeks van radionuclide, magnetische resonantie en optische beeldvorming strategieën om 
het lot van de getransplanteerde cellen op een niet-invasieve wijze te evalueren. In deze review 
is er aandacht voor de state-of-the-art van de verschillende beeldvormende technieken voor 
cardiale stamcel tracking, waarbij de sterke en zwakke punten van elke benadering de revue 
passeren, met een bijzondere aandacht voor de klinische toepasbaarheid.
Hoofdstuk 6 is een in vivo studie naar de mogelijkheid tot MRI kwantificatie van met ijzerox-
ide geladen stamcellen, welke getransplanteerd werden in het hart. In diverse stamceltherapie 
studies wordt de matig tot slechte overleving van de getransplanteerde cel erkend als een be-
langrijke limiterende factor voor de therapeutische werkzaamheid. Daarom kan niet-invasieve 
monitoring van het lot van de getransplanteerde cel een belangrijke bijdrage leveren aan het 
ontwikkelen van klinisch effectieve stamceltherapie. In dit hoofdstuk onderzochten we de uit-
voerbaarheid van het gebruik van voxel-gebaseerde R2 mapping als een instrument om in vivo 
het lot van stamcellen, geladen met ijzeroxidedeeltjes (SPIO), te kunnen monitoren in het 
myocardium. Daartoe werden met een speciale MRI sequentie (BBFSE) korte as beelden van 
het hart vervaardigd. De reproduceerbaarheid van de metingen met deze sequentie werden 
bepaald in gezonde ratten, welke gescand werden in verschillende sessies. De gebruikte cel-
len bevatten tevens het luciferasegen om de cellulaire levensvatbaarheid te kunnen valideren. 
Levende gelabelde cellen werden geïnjecteerd in het myocardium van gezonde Wistar ratten. 
Voor controledoeleinden werden de dieren ook geïnjecteerd met dode gelabelde cellen of zou-
toplossing. De geïnjecteerde cellen werden gevolgd over een periode van 8 weken met biolu-
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minescentie beeldvorming en kwantitatieve MRI. Bioluminescentie beeldvorming toonde een 
aanzienlijke toename van het aantal cellen tijdens de eerste week (piek dag 7) met een sterke af-
name van celaantallen tot onwaarneembare niveaus tijdens de tweede week. MRI kwantificatie 
toonde een sterk verhoogde R2 relaxatiesnelheid kort na injectie op de injectieplaats (piek op 
dag 5), gevolgd door een geleidelijke afname van de R2 relaxatiesnelheid gedurende 15 dagen. 
Op de T2-gewogen beelden waren noch visuele noch kwantitatieve (R2 waarden) verschillen 
merkbaar tussen levende en dode cellen gedurende de gehele periode. Er werd geen signifi-
cante correlatie tussen de bioluminescentie waarden enerzijds en de R2 waarden anderzijds 
waargenomen. Dankzij de validatie middels bioluminescentie is dus gebleken dat SPIO niet 
geschikt is om in vivo het lot van stamcellen in het myocardium te bepalen middels kwantita-
tieve MR beeldvorminng (R2-mapping). Deze resultaten staan in schril contrast met eerdere in 
vitro studies waarin werd voorgesteld dat levende cellen van dode cellen onderscheiden konden 
worden op basis van het verschil in r2 relaxiviteit tussen intracellulair en extracellulair SPIO. 
Celproliferatie, celmigratie, celdood, extracellulaire SPIO dispersie of aggregatie vertonen ver-
schillende r2 relaxiviteit. In vivo kunnen deze processen gelijktijdig gebeuren, waardoor kwan-
tificatie zeer complex, zo niet onmogelijk is.
In hoofdstuk 7 evalueerden we de reproduceerbaarheid en de gevoeligheid van een gemodi-
ficeerde CINE inversie sequentie (mCINE-IR) op ratten voor het meten van de myocardiale 
longitudinale relaxatietijd (T1) bij 7T. De reeds eerder gepubliceerde mCINE IR-acquisitie 
op mensen werd toegepast op ratten voor de eerste keer, met het oog op toekomstige transla-
tionele studies. Simulaties werden gebruikt om de signaal evolutie en hartslag afhankelijkheid 
te bestuderen. Gadolinium fantomen, een monster van het hart (specimens) en een gezonde 
rat werden gebruikt om de reproduceerbaarheid te bestuderen. Twee ratten, waarbij een cryo-
infarct geïnduceerd was, werden gescand om de vertraagde aankleuring van het myocard (de-
layed enhancement, DE) te meten. In de fantoom reproduceerbaarheid studies hadden de T1 
metingen een maximale variatiecoëfficiënt (COV) van 1,3%. Voor de in vivo reproduceerbaar-
heid was de COV minder dan 4,8% in de voorste cardiale segmenten. In simulaties, fantomen 
en specimens was een hartslag afhankelijkheid van ongeveer 0,5 ms / bpm aanwezig. De T1 
metingen van de cryo-infarct ratten toonden een duidelijke verlaging van de T1 in de DE-
regio. De resultaten tonen dat mCINE-IR een zeer reproduceerbare en gevoelige techniek is 
die het mogelijk maakt om T1 veranderingen in een rat myocardium te detecteren.
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Curriculum Vitae
Personal Information
Name Jamal Guenoun
Nationality Dutch, Moroccan
Place, DOB The Hague, 22 January 1982
Education/Diplomas
2016 European Diploma in Radiology (EDiR)
2007 Medicine
 Erasmus University Rotterdam, Rotterdam, the Netherlands
2000 Gymnasium (cum Laude)
 Gymnasium Haganum, ‘s-Gravenhage
Professional Experience
2016 – 2017 Fellowship Musculoskeletal Radiology 
 Erasmus Medical Center, Rotterdam, the Netherlands
2015 Visiting internship musculoskeletal radiology (prof. dr. J. Gielen) 
 University Hospital Antwerpen (UZA), Belgium
2012 – 2016 Resident Radiology, sub-specialization musculoskeletal radiology
 Erasmus Medical Center, Rotterdam, the Netherlands
2008 – 2012 PhD research
 Molecular Imaging Group, Dept. of Radiology
 Erasmus Medical Center, Rotterdam, the Netherlands
2007 – 2008 Resident Radiology
 Erasmus Medical Center, Rotterdam, the Netherlands
Honours and Awards
2015 Invest in the Youth Award For abstract ’Distinguishing viable from dead  
 transplanted stem cells by Gadolinium-nanoparticles’ 
 European Congress of Radiology (ECR), Vienna, Austria
2015 Award for best oral presentation ’Distinguishing viable from  
 dead transplanted stem cells by Gadolinium-nanoparticles’  
 European Congress of Radiology (ECR), Vienna, Austria
2009 Young Investigator Travel Stipend Award For abstract “Quantification  
 of r1 and r2 relaxivity of rat mesenchymal stem cells labelled with Gd-DTPA 
 liposomes for cell tracking at 3,0T” 
 World Molecular Imaging Congress, Montreal, Canada
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PhD portfolio
Portfolio
Oral communications at meetings 
Date Title Institution/Event Location ECTS
March 
4-8 2015
Making use of the intrinsic 
Gadolinium quenching 
effect for cellular imaging, a 
bimodal approach with BLI 
validation
European 
Congress of 
Radiology (ECR) 
Vienna, Austria 1
March 
7-11 2013
Can MRI distinguish viable 
from dead stem cells?
European 
Congress of 
Radiology (ECR) 
Vienna, Austria 1
Sept 30 
2011
Cellular imaging: In vivo 
assessment of Gd- or SPIO-
labeled cell graft viability, 
combining MRI and 
bioluminescence imaging
Radiologendagen ‘s- 
Hertogenbosch
1
May 7-8 
2009
Gd-liposomes for cell 
tracking
ENCITE 
meeting
Prague, Czech 
republic
1
Sept 30-
Oct 4 
2009
Contrast behavior of Gd-
liposome labeled MSCs 
reflects functional cell status 
in vivo
ESMRMB 
(European 
Society for 
Magnetic 
Resonance in 
Medicine and 
Biology)
Antalya, 
Turkey
1
Nov 30-
Dec 4 
2009
Visualizing in vivo cellular 
viability on MRI using Gd-
DTPA liposome labeled 
MSCs
Radiological 
Society of North 
America (RSNA)
Chicago, USA 1
Nov 26 
2009
Using Gd-DTPA liposome 
labeled mesenchymal stem 
cells in rat skeletal muscle 
as a tool for functional cell 
status in vivo
Imagination Nijmegen, the 
Netherlands
1
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C
ha
pt
er
 9
181
poster presentations at meetings
Date Title Institution/Event Location ECTS
Nov 27-
Dec 02 
2011
In vivo R2 mapping 
of SPIO-labeled MSC 
viability in the rat heart 
with bioluminescence 
validation
Radiological 
Society of 
North America 
(RSNA)
Chicago, USA 1
Nov 27-
Dec 02 
2011
In vivo assessment of 
Gd- or SPIO-labeled cell 
graft viability: a bimodal 
approach combining MRI 
and bioluminescence 
imaging
Radiological 
Society of 
North America 
(RSNA)
Chicago, USA 1
Nov 27-
Dec 02 
2011
Quantification of viable 
Gd-liposome labeled cells 
in vivo with MRI mapping 
with bioluminescence 
validation
Radiological 
Society of 
North America 
(RSNA)
Chicago, USA 1
June 19-
21 2011
Optimizing the cell labeling 
strategy with cationic Gd-
liposomes: Longitudinal 
in vivo follow up of Gd-
labeled MSCs
European 
Society for 
Molecular 
Imaging 
(ESMI)
Leiden, the 
Netherlands
1
June 19-
21 2011
In vivo R2 mapping 
of SPIO-labeled MSC 
viability in the rat heart 
with bioluminescence 
validation
European 
Society for 
Molecular 
Imaging 
(ESMI)
Leiden, the 
Netherlands
1
June 19-
21 2011
Quantification of Gd-
liposome-labeled cell 
number in vivo using T1 
and T2 MRI mapping 
techniques, validated by 
BLI
European 
Society for 
Molecular 
Imaging 
(ESMI)
Leiden, the 
Netherlands
1
May 27-
31 2009
Using Gd-DTPA liposome 
labeled mesenchymal stem 
cells in rat skeletal muscle 
as a tool for functional cell 
status in vivo 
European 
Society for 
Molecular 
Imaging 
(ESMI)
Barcelona, 
Spain,
1
Sep 22-26 
2009
MRI tracking of ultrasound 
guided intramyocardially 
injected stem cells
World 
Molecular 
Imaging 
Congress 
(WMIC)
Montreal, 
Canada
1
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Sep 22-26 
2009
Quantification of the 
r1 and r2 relaxivities of 
mesenchymal stem cells 
with Gd-DTPA liposomes 
at 1.5 and 3.0T
World 
Molecular 
Imaging 
Congress 
(WMIC)
Montreal, 
Canada
1
Sep 30-
Oct 4 
2009
Using Gd-DTPA liposome 
labeled mesenchymal stem 
cells in rat skeletal muscle 
as a tool for functional cell 
status in vivo
ESMRMB 
(European 
Society for 
Magnetic 
Resonance in 
Medicine and 
Biology)
Antalya, 
Turkey
1
Sept 30-
Oct 4 
2009
Quantification of the 
r1 and r2 relaxivities of 
mesenchymal stem cells 
with Gd-DTPA liposomes 
at 1.5 and 3.0T
ESMRMB 
(European 
Society for 
Magnetic 
Resonance in 
Medicine and 
Biology)
Antalya, 
Turkey
1
Nov 30-
Dec 4 
2009
Molecular imaging using 
lipid-based nanoparticles 
for MRI
Radiological 
Society of 
North America 
(RSNA)
Chicago, USA 1
Subtotal (ECTS): 12
Completed courses and skills
Date Title Institution/Event Location ECTS
2015 Workshop Hospital 
Management
Erasmus 
Desideriusschool
Rotterdam 0.4
2015 Workshop Medical Ethics Erasmus 
Desideriusschool
Rotterdam 0.4
2014 Workshop Communication Erasmus 
Desideriusschool
Rotterdam 0.4
2014 Workshop Health law Erasmus 
Desideriusschool
Rotterdam 1.0
2013-
2014
Imaging techniques (CT, 
MRI, US, fluoroscopy, 
conventional radiography)
Regional 
Teachings 
Residents 
Radiology, 
UMCU
Eindhoven 1.2
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2012 6th Animal Imaging 
Workshop
Applied 
Molecular 
Imaging Erasmus 
(AMIE)
Rotterdam 1.5
2012 Radiation Protection course 
for Radiologists, 3M
Boerhaave 
Instituut
Leiden 8
2011 Translational imaging 
workshop 
Applied 
Molecular 
Imaging Erasmus 
(AMIE)
Rotterdam 1.5
2010 4th Animal Imaging 
Workshop
Applied 
Molecular 
Imaging Erasmus 
(AMIE)
Rotterdam 1.5
2010 Biomedical English writing Molecular 
Medicine 
(MOLMED), 
Erasmus MC
Rotterdam 0.8
2010 Statistics: Introduction to 
SPSS
Molecular 
Medicine 
(MOLMED), 
Erasmus MC
Rotterdam 0.8
2009 3rd Animal Imaging 
Workshop
Applied 
Molecular 
Imaging Erasmus 
(AMIE)
Rotterdam 1.5
2009 Laboratory animal science 
(art. 9)
Erasmus MC Rotterdam 3
2009 Student supervising and 
mentoring
Molecular 
Imaging Group, 
Erasmus MC
Rotterdam 7
2008 Small animal molecular 
imaging
ESMRMB 
(European Society 
for Magnetic 
Resonance in 
Medicine and 
Biology)
Marseille, 
France
1
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2008 Cardiovascular applications 
of  Molecular imaging
DiMI/EMIL 
(Diagnostic 
in Molecular 
Imaging/
European 
Molecular 
Imaging 
Laboratories)
Munster, 
Germany
1
2008 Confocal laser scanning 
microscopy course
Erasmus MC Rotterdam
Subtotal (ECTS): 31.2
Total (ECTS): 50.2
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Publications
List of publications
Original articles
1 Karim AF, Verdijk RM, Guenoun J, van Hagen PM, van Laar JA.
 An inflammatory condition with different faces: immunoglobulin G4-related disease, 
Neth J Med. 2016 Mar;74(3):110-5. 
2 M.R. Bernsen, J. Guenoun, S.T. van Tiel, G.P. Krestin, Nanoparticles and clinically 
applicable cell tracking (review), Br J Radiol. 2015 Oct;88(1054):20150375.
3 A.F. Karim, L.E.H. Westenberg, R.M. Verdijk, J. Guenoun, A.D.A. Paridaens, P.M. 
van Hagen, J.A.M. van Laar, Infliximab for IgG4 related orbital disease, Ophthal Plast 
Reconstr Surg. 2016 Jan 18. [Epub ahead of print]
4 J. Guenoun, G.N. Doeswijk, G.P. Krestin, M.R. Bernsen, Compartmentalization of 
Gd-liposomes: The quenching effect explained, Contrast Media Mol Imaging. 2016 
Mar;11(2):106-14. doi: 10.1002/cmmi.1669
5 H. Smit, R.P. Guridi, J. Guenoun, D.H.J. Poot, G.N. Doeswijk, M. Milanesi, M.R. 
Bernsen, G.P. Krestin, S.Klein, G. Kotek, T1 Mapping in the rat myocardium at 7T 
using a modified CINE inversion recovery sequence, J Magn Reson Imaging. 2014 
Apr;39(4):901-10
6 J. Guenoun, A. Ruggiero, G.N. Doeswijk, R.C. Janssens, G.A. Koning, G. Kotek, G.P. 
Krestin, M.R. Bernsen, In vivo quantitative assessment of cell viability of Gadolinium 
or iron-labeled cells using MRI and bioluminescence imaging, Contrast Media Mol 
Imaging 2013 Mar-Apr;8(2):165-74
7 J. Guenoun, A. Ruggiero, H. Schmidt, G.N. Doeswijk, S. Klein, G.C. Houston, G.P. 
Krestin, G. Kotek, M.R. Bernsen, In vivo MRI mapping of iron oxide labeled stem cells 
transplanted in the heart, Contrast Media Mol Imaging 2013 Nov-Dec;8(6):487-94
8 J. Guenoun, G.A. Koning, G.N. Doeswijk, L. Bosman, P.A. Wielopolski, G.P. 
Krestin, M.R. Bernsen, Cationic Gd-DTPA liposomes for highly efficient labeling of 
mesenchymal stem cells and cell tracking with MRI, Cell Transplant 2012;21(1):191-
205
Review articles
9 Ruggiero, D.L.J. Thorek, J. Guenoun, G.P. Krestin, M.R. Bernsen, Cell tracking 
in cardiac repair: what to image and how to image (review), Eur Radiol 2012 
Jan;22(1):189-204
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Googling for ‘how to write an acknowledgements section in a thesis’ yields the paper by Hy-
land Graduates’ gratitude: the generic structure of dissertation acknowledgements. Let’s pretend I 
haven’t read the paper.
 It was during an appraisal interview somewhere in 2008, in my first year as a resident radiol-
ogy, that prof. dr. Gabriel Krestin encouraged me to consider to broaden my horizon by per-
forming research. During our conversation terms fell such as ‘molecular imaging’, ‘novel field 
in radiology’, ‘if you choose for this research project you get to attend the ‘World Molecular Imaging 
Congress’ in Nice (WMIC) and ‘I’ll sleep on it’. (I think. I don’t remember exactly, but that was 
about the moral of the story). Certainly, ‘Nice’ sounded nice, but that was not a sufficient 
incentive to agree to the proposition.
The proposition occurred to me as a giant leap sideways, fearing the significant interference 
with my training in becoming a radiologist. Numerous scenarios crossed my mind. Including 
the worst case scenario in which I would defend my thesis 9 years after starting research, shar-
ing though one common denominator: undoubtedly they would pose a tremendous personal 
challenge. As the common thread in my life is to seek challenges rather than avoiding them, I 
decided to throw myself diligently into this new chapter in life in May 2008. ‘Nice’ turned out 
to be quite cool actually. I finished this thesis on the 12th of February 2016 and defende dit on 
the 19th of January 2017. Worst case came true.
Prof. dr. Gabriel Krestin, dear Gabriel, I thank you for the inexhaustive trust you had in our 
research projects and for your unconditional support as my promotor. In spite of the novelty 
of ‘molecular imaging’ you were always up to date and able to keep a helicopterview. I admire 
your strategic insight when you suggested me to patent the discovery of Gd-liposomes and 
their ability to visualize cell viability. Still at this very day, I am deeply grateful for allowing 
me in 2007 as a resident in perhaps the most challenging radiology department in the Nether-
lands. Thanks for your valuable and thorough reviews of our papers.  
I thank dr. Monique Bernsen, dr. Nico Mollet and prof. Aad van der Lugt for giving me a clear 
and honest description of their research fields in 2008, while I was considering the choice 
between ‘molecular imaging’, ‘cardiac imaging’ and ‘carotid imaging', respectively. In 2008 the 
infrastructure of the molecular imaging group was at an embryonic stage of development (e.g. 
there was no laboratory of our own yet) and the specialized ‘Animal Imaging Facility’ (AIF) was 
yet to be finished. Monique was quite clear about this. ‘Molecular imaging’ or ‘cellular imaging’, 
at least at that time, was a relatively unexplored area. Although definitely offering challenges 
of their own kind, ‘cardiac imaging’ and ‘carotid imaging' were relatively mature research fields 
at that time. I got a room next to Monique. On the 23rd floor. Overlooking ‘de Maas’. I was 
literally in higher spirits. The sky was the limit.
Early in 2009, gradually becoming aware of the complexity of the field, I was back on both 
feet again. I needed to learn skills on animal handling, thoracotomy, anesthesia, small animal 
intubation, stem cell isolation from bone marrow, cell culture, cell labeling, liposome genera-
tion and MRI scanning.  
Fortunately research is performed in team-work. I am therefore much indebted to our lab 
technicians Sandra T. van Tiel and Gabriela N. Doeswijk for their clear instructions, their 
patience and their time while teaching me the basics of these skills. Without your kickstart, 
it probably would have taken me months of time to ‘DIY’ it. Gabriela, you deserve special 
attention. Working together intensively on several projects, you went above and beyond to 
assist wherever needed, including (but not limited to): MR scanning, cell and animal care, 
ICP measurements, histology, confocal fluorescence, liposome creation. Tal vez nunca lo dejé 
mostrar, pero su ayuda fue indispensable para mi investigación. Muchos gracias.
 Fortunately you, dr. Monique Bernsen, as my co-promotor, were able to motivate me through 
this maze. Your approachability and preparedness to exchange thoughts ‘stante pede’ are unpar-
C
ha
pt
er
 9
189
alleled. In spite of our different professional background - you rationalizing from a biological 
point of view and me from a medical point of view- owing to your creativity we were always 
able to forge a joint plan. Whenever you found me pondering on things too much, you used 
to encourage me to ‘just go out there and start’. Indeed, etymologically, research derives from 
the French word ‘recherche’, on its turn derived from Latin ‘cercar’, meaning ‘to go around’, 
‘to wander’. 
So I went out there and wandered, ending up at the 8th floor talking to Roel Janssens, an always 
cheerful technician in the laboratory of genetics. Roel, without hesitation you agreed to geneti-
cally modify our mesenchymal stem cells to contain the firefly luciferase gene. Needless to say 
that without your efforts, chapter 3 would have been useless with actual validation of stem cell 
viability. Thank you man!
Alessandro, I got to learn you as a tremendously dedicated, concentrated and mysteriously 
taciturn researcher. I remember trying to break the ice by playing Lady Gaga’s track ‘Alejandro’ 
loud in our room. Soon we started exchanging our experiences on molecular/cellular imaging 
and I discovered that we shared the same interest in nanoparticles. You were the best sparring 
partner I could imagine. We spent day and night at the AIF operating and scanning, where we 
laid the basis for chapter 3 and 6.
Dr. Gerben Koning, was king when it came to liposomes. You helped me out on several occa-
sions with my liposomes and truly taught me the subtleties of using the lipid-film hydration 
technique. I have yet to encounter a man with your serenity. You provided such a fantastic 
learning environment, helping me to keep things on track. May your gentle soul rest in peace. 
MRI stands for “Magnificent Research Investigator”. At least when Piotr Wielopolski is around. 
Hearing you talk about MRI still makes me feel a complete novice. As I’m never sure whether 
to speak English, Polish, Spanish or Dutch I’ll just tick to a mix of all four for simplicity’s sake. 
Thanks for teaching me the advanced MRI skills, especially in cardiac scanning. 
Gyula “the Quantifier” Kotek. ‘Seeing is believing’ is a lie. No quantification, no glory. I am 
much indebted for your assistance in the design, implementation and analysis of the MRI re-
laxation time mapping sequences. I haven’t quantified the amount of hours we spent together, 
I hope you’ll forgive me for that. Köszönöm szépen. Good luck with your company.
Li Li, Bilyana, Lilia: with you I shared frustrations, hints, tips and not to forget frustrations 
(and sometimes each other’s HEPES without notifying). I won’t forget the good laughs we 
had in the liposome lab. It really soothed the dull and repetitive process of creating liposomes. 
Many thanks to all the lab technicians in the liposome lab for their hospitality!
I am indebted to all the people in the lab of experimental cardiology, especially Marcel de Jong-
Popijus, for all your valuable tips on cell culturing, prof. dr. Dirk Jan Duncker, for your hospi-
tality, kindness and for making your lab available to us. Thank you Ewout van den Bos, for your 
time to show me the intricacies of performing cryo-infarctions on a 2 cm beating rat heart. 
Thank you Nicole Kops for your assistance in the differentiation assays.
Dr. Kristina Djanashvili, thank you for your enlightening discussion moments on the quench-
ing of carboxyfluorescin cationic liposomes.  
Dr. Ingrid Renes, special thanks to you for your kindness in providing access to the lab of 
pediatrics and for the tools to perform immunohistochemistry (antibodies and fluorescence 
microscope).
To my roommates Joost Haeck and our graphical designer Ton Everaers I can say that it was 
great to having surfed with you guys. Not on the internet, but on a real surfboard! There 
should be a sequel soon. Thanks Joost for the laughs we had as roommates and thanks Ton for 
your support in designing the abstract posters for each congress and for the design of “Het 
Boekie”. I think I was your easiest ‘customer’ of all times (“zwarte letters op wit papier is een 
briljant idee, nietje d’r doorheen, hoppa en weg ermee, geen hond die ‘t leest”).
Lizanne Bosman, it was an honor to supervise a bright student like you. Your dedication and 
creativity contributed significantly to chapter 2. 
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altijd vrij gelaten in mijn beslissingen en me daarin onvoorwaardelijk gesteund. Ik ben jullie 
daar heel dankbaar voor. 
Lieve Kaoutar, je hebt me steeds gestimuleerd om mijn promotie af te ronden en me daar ook 
altijd in gesteund. Je gaf me ruimte en tijd, ook al betekende dat nog minder tijd voor jou en 
de kinderen. Dank voor alles. De rest laat ik je weten in persoon.
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